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A prayer for the wild at heart, kept in cages. 
 xi
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS v 
LIST OF TABLES xv 
LIST OF FIGURES xvi 
   
LIST OF SYMBOLS AND ABBREVIATIONS xix 
SUMMARY xxi 
CHAPTER 
1 INTRODUCTION 1 
Motivation 1 
Goal and Central Hypothesis 5 
Specific Aims 6 
 Specific Aim I 6 
 Specific Aim II 8 
 Specific Aim III 9 
Significance 10 
2 LITERATURE REVIEW 12 
Bone Structure and Function 12 
Angiogenesis and Bone Formation and Repair 16 
Bone Trauma and Clinical Repair 19 
Bone Defect Models 22 
Experimental Treatments 25 
Growth Factor Selection 34 
 xii
Methods of Growth Factor Delivery 39 
3 QUANTITATIVE ASSESSMENT OF SCAFFOLD AND GROWTH FACTOR-




 Scaffold Production 47 
 Addition of Growth Factor to Scaffolds 48 
 Surgical Technique 48 
 X-ray and Micro-CT 51 
 Mechanical Testing 52 
 Vascular Perfusion 53 
 Histology 53 
 Statistics 54 
Results 54 
 Scaffold Characterization 54 
 X-ray Imaging 56 
 Micro-CT Analysis 58 
 Mechanical Testing 66 
 Histology 69 
Discussion 73 
4 DOSE-DEPENDENT AND INTERACTION EFFECTS OF DUAL 





 Scaffold Production 84 
 Addition of Growth Factor to Scaffolds 84 
 Surgical Procedure 85 
 X-ray and Micro-CT 86 
 Mechanical Testing 87 
 Histology 87 
 Statistics 88 
Results 88 
 X-ray Imaging 88 
 Micro-CT Analysis 92 
 Mechanical Testing 103 
 Histology 109 
Discussion 113 
5 EFFECTS OF ANGIOGENIC GROWTH FACTOR DELIVERY AND 





 Scaffold Production 124 
 Addition of Growth Factor to Scaffolds 124 
 Quantification of Growth Factor Release Kinetics 125 
 Study Designs 126 
 Surgical Procedure 127 
 X-ray and Micro-CT 128 
 Mechanical Testing 129 
 xiv
 Histology 129 
 Statistics 130 
Results 130 
 Quantification of Growth Factor Release Kinetics 130 
 X-ray Imaging 133 
 Micro-CT Analysis 137 
 Mechanical Testing 155 
 Histology 161 
Discussion 167 
6 CONCLUSIONS AND FUTURE DIRECTIONS 175 
 Segmental Defect Model and Analysis Techniques 175 
 Growth Factor Delivery and Release 177 
 Growth Factor Co-Delivery and Interaction 179 
 Potential Modifications to the Model 182 
 Conclusions 183 
APPENDIX A: EFFECTS OF VOXEL RESOLUTION ON MICRO-COMPUTED 
TOMOGRAPHYANALYSIS OF PERFUSED RAT HINDLIMB 
VASCULATURE 186 
APPENDIX B: FABRICATION OF POLY(L-LACTIDE-CO-D,L-LACTIDE) 
ORIENTED POLYMER SCAFFOLDS 192 
APPENDIX C: RAT SEGMENTAL DEFECT SURGERY PROTOCOL 199 
APPENDIX D: RAT VASCULAR PERFUSION PROTOCOL 205 
REFERENCES 210 
VITA  228 
 xv
LIST OF TABLES 
Page 
Table 1: Average bone volumes and mechanical properties 68 
Table 2: Micro-CT parameters at high and medium resolution for scaffold VOI 187 
Table 3: Micro-CT parameters at high and medium resolution for core VOI 188 
Table 4: Micro-CT parameters at high and medium resolution for periphery VOI 189 
 
 xvi
LIST OF FIGURES 
Page 
Figure 1: Rat femur with attached fixation plate assembly and 8 mm defect 50 
Figure 2: Micro-CT and electron microscopy images of PLDL scaffolds 55 
Figure 3: X-ray images of empty, PLDL, and growth factor treated defects 57 
Figure 4: Average in vivo bone volumes  59 
Figure 5: Post-mortem bone volumes for the total defect volume 61 
Figure 6: Micro-CT images of post-mortem samples  61 
Figure 7: Distribution of mineral through the core and periphery of the defect 62 
Figure 8: Peripheral and core spatial distribution of mineral through the defect 62 
Figure 9: Distribution of mineral over proximal and distal aspects of the defect 63 
Figure 10: Vascular Volumes for perfused empty and scaffold treated defects 65 
Figure 11: Micro-CT images of vasculature in perfused decalcified samples 65 
Figure 12: Average maximum torque for scaffold and growth factor treated defects 67 
Figure 13: Average stiffness for scaffold and growth factor treated defects 67 
Figure 14: Empty defect histology 70 
Figure 15: Scaffold-treated defect histology 71 
Figure 16: BMP-2 and TGF-β3 treated defect histology 72 
Figure 17: X-ray images of dose-dependent response to growth factor treatment 89 
Figure 18: X-ray images of individually and co-delivered growth factor treatments 91 
Figure 19: In vivo bone volumes for dose-dependent growth factor treatment 94 
Figure 20: Average post-mortem bone volumes for dose-dependent response 94 
Figure 21: Core vs. peripheral distribution of bone volume 95 
Figure 22: Core vs. peripheral distribution of bone volume fractions 95 
 xvii
Figure 23: Distal vs. proximal distribution of bone volume post-mortem 96 
Figure 24: Micro-CT images of the dose-dependent response to co-delivered protein 97 
Figure 25: Mature in vivo bone volumes for single vs. co-delivered growth factors 99 
Figure 26: Mature vs. immature in vivo bone volume measurements 99 
Figure 27: Mature vs. immature post-mortem bone volumes  100 
Figure 28: Proximal vs. distal bone volume distribution 100 
Figure 29: Core vs. peripheral bone volume distribution 101 
Figure 30: Core vs. peripheral bone volume fraction distribution 101 
Figure 31: Micro-CT images of the single vs. co-delivered growth factors 102 
Figure 32: Average stiffness values for dose-dependent growth factor response 104 
Figure 33: Average maximum torque values for dose-dependent response 104 
Figure 34: Average work values for dose-dependent growth factor response 105 
Figure 35: Average stiffness values for single vs. co-delivered growth factors 107 
Figure 36: Average maximum torque values for single, co-delivered growth factors 107 
Figure 37: Average work values for single vs. co-delivered growth factors 108 
Figure 38: Histology for RGD-alginate filled PLDL implant 110 
Figure 39: Histology for 200/20 dose BMP-2/TGF-β3 treated defect 111 
Figure 40: Histology for defect treated with 2000 ng BMP-2 112 
Figure 41: Cumulative release of soluble mature rhBMP-2 131 
Figure 42: Cumulative release of soluble active TGF-β3 131 
Figure 43: Cumulative release of soluble mature rrVEGF 132 
Figure 44: X-ray images of dose-response to VEGF delivery 135 
Figure 45: X-ray images of samples with modified scaffolds 135 
Figure 46: X-ray images of co-delivered angiogenic and osteogenic growth factors 136 
Figure 47: In vivo micro-CT quantification of bone volume for VEGF dose response 138 
 xviii
Figure 48: In vitro micro-CT assessment of VEGF dose response 138 
Figure 49: Core vs. periphery distribution of bone volume with VEGF dose  139 
Figure 50: Distal vs. proximal distribution of bone volumes with VEGF dose  139 
Figure 51: Micro-CT images of full defects from VEGF dose response study 140 
Figure 52: Micro-CT quantification of vascular volumes from VEGF dose response 141 
Figure 53: Micro-CT images of perfused decalcified samples from VEGF dose  142 
Figure 54: In vivo quantification of bone volume with scaffold modification 144 
Figure 55: In vitro quantification of bone volume with scaffold modification 144 
Figure 56: Core vs. periphery bone volume distribution with scaffold modification 145 
Figure 57: Distal vs. proximal bone volume distribution with scaffold modification 145 
Figure 58: Micro-CT images of samples treated with modified scaffolds 146 
Figure 59: Micro-CT quantification of vascular volume with scaffold modification 147 
Figure 60: Micro-CT images of perfused samples with scaffold modification 148 
Figure 61: In vivo bone volumes from angiogenic/osteogenic growth factor delivery 151 
Figure 62: In vitro bone volumes from angiogenic/osteogenic growth factor delivery 151 
Figure 63: Core vs. periphery distribution of bone volume with triple growth factors 152 
Figure 64: Distal vs. proximal bone volume distribution with triple growth factors 152 
Figure 65: Vascular volumes determined with triple growth factor co-delivery 153 
Figure 66: Micro-CT images of perfused samples with triple growth factors 154 
Figure 67: Average stiffness for VEGF dose-response 156 
Figure 68: Average maximum torque for VEGF dose-response 156 
Figure 69: Average stiffness with scaffold modification 158 
Figure 70: Average maximum torque with scaffold modification 158 
Figure 71: Average stiffness with triple growth factor delivery 160 
Figure 72: Average maximum torque with triple growth factor delivery 160 
 xix
Figure 73: Histology for traditional geometry PLDL/TCP implant 162 
Figure 74: Histology for cored PLDL/TCP implant 163 
Figure 75: Histology for cored implant with BMP-2, TGF-β3, and VEGF 164 
Figure 76: Histology showing cellular nature of newly formed bone 165 
Figure 77: Histology showing cells on surface of new bone 166 






LIST OF SYMBOLS AND ABBREVIATIONS 
 
2-D  two-dimensional  
3-D  three-dimensional 
α-MEM  α-modified eagle’s medium 
ACS  absorbable collagen sponge 
ALP  alkaline phosphatase 
BMP  bone morphogenetic protein 
BMP-2  bone morphogenetic protein-2 
BMP-4  bone morphogenetic protein-4 
BMP-7  bone morphogenetic protein-7 
BMP-9  bone morphogenetic protein-9 
BMSC  bone marrow stromal cell 
BV  bone volume 
BVF  bone volume fraction 
caALK2  constitutively active ALK2 
DBM  demineralized bone matrix 
DNA  deoxyribonucleic acid 
FDA  food and drug administration 
HA  hydroxyapatite 
hDBM  human demineralized bone matrix 
HIF-1α  hypoxia-inducible factor-1α 
micro-CT  micro-computed tomography 
MSC  mesenchymal stem cell 
PCL  polycaprolactone 
 xxi
PEG  polyethylene glycol 
PLDL  poly(L-lactide-co-D,L-lactide) 
PLGA  poly(lactic-co-glycolic acid) 
PRP  platelet-rich plasma 
RANKL  receptor activator of nuclear factor κB ligand 
TCP  tricalcium phosphate 
TGF-β1  transforming growth factor-β1 
TGF-b3  transforming growth factor-β3 
TGF-β3  transforming growth factor-β3 
VEGF  vascular endothelial growth factor 












The complex process of critically-sized load-bearing bone defect healing is poorly 
understood. The interplay between revascularization of the injured tissue and 
regeneration of a functional bone structure is critical to survival of the limb. The central 
goal for this dissertation is to establish a novel in vivo model of segmental bone defect 
repair and to assess the ability of tissue-engineered scaffolds using a growth factor co-
delivery strategy to heal these defects. 
Traditional assessment of large bone defect healing has relied entirely on 
radiography and histology/histomorphometry. The animal model designed in this thesis 
enables the investigator to use in vivo X-ray and quantitative micro-CT imaging of the 
defect to assess mineralized matrix deposition, and to easily free the defect from the 
stabilization device for mechanical testing of samples post-mortem. Additionally, a 
hindlimb vascular perfusion procedure was developed to facilitate micro-CT 
quantification of vascular structures within the defect. 
These methodologies were applied to assess functional bone repair resulting from 
co-delivery of osteogenic (BMP-2), chondrogenic (TGF-β3), and angiogenic (VEGF) 
growth factors. The dose-dependence effects of and interactions between these growth 
factors were assessed using micro-CT and mechanical testing methods. There was a dose-
dependent response to co-delivery of BMP-2/TGF-β3 in terms of mineralized matrix 
deposition and restoration of mechanical properties. An additive interaction was 
determined between the two growth factors.  
 xxiii
Delivery of VEGF alone did not result in a dose-dependent beneficial effect on 
bone formation or revascularization of the defect. Modification of the implanted porous 
polymer structural scaffolds to contain a macroscopic cored center and 10% ceramic 
component enhanced revascularization of the defects. Co-delivery of VEGF with 
ΒΜΠ−2/TGF−β3 did not incur any benefit over delivery of only BMP-2/TGF-β3. 
In conclusion, this work has yielded a novel, reproducible and robust small animal 
model of osseous nonunion and quantified the ability of low dose sustained release 








Localized bone loss due to trauma or disease is a significant cause for loss of 
patient quality of life and contributes to patient disability. In optimal situations, bone is 
recognized for its unique capability to regenerate without scar formation – given adequate 
vascularity, presence of vascular and osteoinductive growth factors, presence of 
osteoprogenitor cells, and mechanical stability. Of the roughly six million fractures that 
occur in the United States annually, 5-10% require clinical intervention in the form of a 
graft [BORRELLI 2003]. One must also account for other bone defects that require 
intervening therapy, such as those due to congenital malformations, disease, 
osteosarcoma, metabolic bone disorders, and soft tissue damage (spinal fusions).  
Although autografting (removal of morselized host tissue from a remote site – 
typically the iliac crest) is the gold standard treatment, this procedure is limited by lack of 
available donor material, an inability to obtain a structural graft, and considerable donor 
site morbidity. Thus, the allograft is the popular and facile solution to the problem of 
significant bone loss. Allografts are structural segments of bone that are removed from 
donor cadavers and then processed to devitalize the tissue and reduce the possibility for 
transfer of disease-causing agents. Despite their ready availability and ease of use, 
allografts are subject to a high rate of re-fracture within a relatively short time period (2 
years) post-engraftment [LUCARELLI 2005, WHEELER 2005, ITO 2005]. This re-
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fracture incidence is due in large part to a lack of graft integration into the remaining host 
bone [ENNEKING 2001, ITO 2005, WHEELER 2005]. Lack of porosity within the 
allograft inhibits revascularization and revitalization of the allograft tissue, resulting in a 
propensity to accumulate microdamage that may ultimately lead to catastrophic graft 
failure (25% clinical failure rate) or contribute to the 30-60% complication rate 
associated with allografts [LUCARELLI 2005, WHEELER 2005]. Complications 
frequently result in treatment of defect non-unions or delayed unions, often necessitating 
revision surgery and significantly impacting patient quality of life. 
In response to the shortcomings of the standard clinical treatments, a variety of 
experimental (tissue-engineered) strategies have been developed as potential treatments 
for large bone defects. In general, these strategies rely on a combination of a biological 
agent and a carrier for the agent. The biological agents are typically cells, bioactive 
extracellular matrix, growth factors, or gene delivery systems. The carrier materials may 
or may not have mechanical integrity, and may intrinsically carry bioactive factors, as is 
the case with active demineralized bone matrix (DBM). The driving hypothesis behind 
these treatment strategies is that augmenting the body’s natural healing processes will 
stimulate the surrounding tissue to produce viable bone within the framework of the 
defect.  
Three crucial factors in bone formation are the presence of osteoprogenitors, 
proper mechanical stimulation, and the availability of a proximal vascular supply. 
Osteoprogenitors may be delivered as part of the tissue engineering therapy or recruited 
from local reservoirs of these cells, such as the periosteum and bone marrow. Mechanical 
signals may take many forms. In osseous defect healing, the typical concern is provision 
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of adequate stability to the defect site to prevent atrophic nonunion. Although dynamic 
mechanical stimulation is known to be osteogenic at certain levels in healthy bone and at 
certain stages of bone development, too much mechanical freedom can be detrimental in 
cases of bone defect repair. Excessive micromotion in the fracture or defect site produces 
a situation in which healing does not progress beyond the formation of a soft tissue 
callus. This lack of mineralization may be partially due to disruption of vascular structure 
formation by micromotion. Bone formation is tightly linked to the availability of a 
vascular supply. Without close proximity to a blood supply (< 0.1 mm), osteocytes do not 
survive and new bone cannot form or existing bone remodel [SAADEH 2000]. Vascular 
invasion is critical for the conversion of cartilage to bone in endochondral ossification 
processes, including growth plate maturation and long bone healing, as well as for 
medullary fracture callus formation [CARLEVARO 2000, GERBER 1999]. Despite this 
knowledge of the critical relationship between the two tissue types, there are little data 
correlating the formation of mineralized tissue with the invasion or maturation of a 
vascular supply (angiogenesis and arteriogenesis, respectively) in fracture or defect 
models. 
One emerging strategy used in the treatment of bone defects is growth factor 
therapy. Use of BMP-2 on an absorbable collagen sponge has recently been approved by 
the FDA for use in spinal fusions. Further investigations are assessing the efficacy of this 
treatment in augmenting open tibial shaft fracture repair. The effects of growth factors on 
biological systems are varied, complex, and not completely characterized. However, the 
potency of growth factors such as BMP-2 and VEGF has inspired many pre-clinical 
investigations into their potential as agents for bone regeneration and targets for tumor 
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therapy. Although less widely known, TGF-β3 is under investigation as a treatment to 
reduce scarring in lacerations. Not only are the effects of growth factors important, but 
the delivery mechanism as well. Many of these proteins have a short active half-life, 
making the problem of sustained delivery difficult to address. Relying on a burst-release 
bolus dose of growth factors often requires that a large total amount of protein be 
delivered. This may be due to rapid diffusion of the protein away from the site of delivery 
and/or an inability to preserve the protein in its bioactive form. Delivery of growth factor 
that is exclusively tethered to the implant is not always beneficial, as there may be 
insufficient quantities of diffusible protein to stimulate adjacent cells to proliferate and 
migrate into the implant. In natural physiologic healing processes, a variety of 
biochemical cues act in concert. Exploiting natural interactions between two or more 
growth factors may more closely mimic the natural healing process and stimulate a 
greater response to the delivered bioactive molecules than independent delivery of any 
individual molecule would achieve. The effects of growth factor co-delivery, however, 
are largely unknown. One interesting potential application for growth factor co-delivery 
is the problem of regenerating vascularized bone in large osseous defects. 
 Characterization and modulation of vascular invasion and mineralized matrix 
formation has implications for the treatment of large or challenged osseous defects. 
Nonunion of bony defects may occur as a result of defect size, infection, micromotion, 
patient health, age, or co-morbidity with other diseases, and often results in loss of limb 
functionality. In these situations, clinical intervention is necessitated. Accelerating 
vascularized bony union using a tissue-engineering approach could provide a viable and 
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lasting treatment for a variety of bone defects, including challenged fractures, segmental 
defects, cranial-maxillofacial defects, and spinal fusions.  
 
1.2 Goal and Central Hypothesis 
The long-term goal of this work is to develop tissue engineering strategies to 
elevate and accelerate functional bone repair in patients with clinically challenging 
defects.  The overall objective of this thesis is to evaluate the effects of co-delivered 
growth factors on functional bone repair using a robust small animal bone defect model 
and quantitative evaluation of vascular ingrowth, bone formation, and functional 
integration. This objective will be addressed by establishing a critically-sized rat femoral 
defect model, quantifying mineralized tissues and vascular invasion within the defect 
sites, and examining the effects that delivery of scaffolds with osteogenic, 
chondroinductive, and angiogenic growth factors have on functional repair. The effects of 
scaffold macroarchitecture on mineralization and vascularization will be addressed as 
well.  
The central hypothesis is that by exploiting the interaction effects between growth 
factors, osseous repair tissue can be generated more quickly and with greater 
functionality than can be achieved using a single growth factor delivery at the same dose. 
Here, interactions between osteoinductive, chondroinductive, and angiogenic growth 





1.3 Specific Aims 
 The following three specific aims are outlined in order to test the central 
hypothesis: 
 
Specific Aim #1: Develop a critically-sized segmental femoral defect model in rats and 
test the ability of an oriented polymer scaffold to promote vascularized bone repair. 
 While the segmental femoral defect model itself is not novel, the development of 
a stable defect that is critically-sized due to the size of the defect rather than 
compounding factors such as micromotion is new. Stabilization hardware amenable to 
mechanical testing and radiography is also novel. Many groups have employed the 
segmental defect model, but the majority have used a sub-critical defect size, where 
reported spontaneous healing rates of untreated defects range from 10-50%. The fixation 
devices typically used to stabilize the femoral defects are simplistic and sometimes fail to 
provide support to the defect, resulting in collapse of the defect space. Additionally, the 
typical design involves a plate that directly abuts the defect, precluding tissue infiltration 
from that region of the implant periphery. Although perhaps more akin to clinical defect 
fixation, hardware that directly contacts the defect site may limit tissue interaction with 
the implant.  
A review of the literature regarding bone defects indicates that experimental 
treatments rely on a variety of scaffolds or delivery vehicles. One type is a ceramic or 
cement. Although one such ceramic, hydroxyapatite/tricalcium phosphate (HA/TCP) is 
naturally found in bone, the brittleness of such scaffolds frequently leads to fracture in 
vivo [BRUDER 1998 JBJS]. Ceramic or cement scaffolds are limited by a lack of 
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porosity as well as a lack of pore interconnectivity – two factors crucial to the invasion of 
new mineralized matrix and invading vascularity. The second type of scaffold is non-
structural. These scaffolds are typically hydrogels or absorbable collagen sponges, 
providing no mechanical integrity to the healing defect. One advantage of these scaffolds 
is that they are easily manipulated to conform to the defect site. These non-structural 
implants may provide biologically active factors, but lack the integrity needed to promote 
early weight bearing of the limb. The use of an absorbable polymeric scaffold with 
structural integrity has not been widely investigated for use in large load-bearing defect 
repair.  
Relying on a single scaffold type makes it difficult to achieve both structural 
integrity and controlled release of bioactive factors in a model of clinical repair. Use of a 
two-phase implant gives the researcher an opportunity to focus on both mechanical 
stability of the implant and the release of bioactive agents. In the interest of 
accomplishing both tasks, we have selected a composite system of a structural polymer 
scaffold and hydrogel. The polymer scaffold selected for use here is poly(L-lactide-co-
D,L-lactide) (PLDL) with an oriented macroporosity and random microporosity. It is 
hoped that the orientation of the longitudinal macropores would create channels to 
enhance the directionality of bone repair in the femoral defect model. The hydrogel 
chosen for co-delivery with the PLDL scaffold is alginate. It is hypothesized that the 
similarities in structure between alginate and heparin allows proteins with heparin 
binding domains to interact with alginate hydrogels, permitting sustained release of the 
molecules as the alginate matrix degrades. Use of a sustained-release system could 
potentially enable researchers to produce results similar to high-dose fast-release systems 
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while utilizing a lower total dose of protein. The work in this thesis evaluates the use of 
such a scaffold, including its ability to deliver biologic factors and promote healing of 
critically-sized segmental defects in varying geometries and compositions. 
The hypothesis is that an 8 mm femoral defect will not heal spontaneously in rats 
and that scaffold treatment will enhance mineralization within the defect site as compared 
to non-treatment of the defects but not restore full functionality. The outcomes of this 
Specific Aim I are discussed in Chapter 3. 
 
Specific Aim #2: Evaluate the ability of co-delivered TGF-β3 and BMP-2 to promote 
mineralization within the defect site. 
 Previous work by Simmons et al. has shown a synergistic interaction between 
TGF-β3 and BMP-2 in the presence of bone marrow stromal cells in a mouse ectopic 
model of osteogenesis. This treatment has not been tested in an orthotopic model 
[SIMMONS 2004]. Typical growth factor treatments have relied on high, 
supraphysiologic doses of growth factor to induce osteogenesis. This approach is often 
successful due to the sheer quantity of protein delivered. The use of dual growth factor 
delivery, particularly a therapy based on positive growth factor interactions, may have 
potential for clinical application in lowering the total dose of protein needed to achieve 
the same results. Optimization of growth factor delivery may enable investigators to more 
efficiently utilize the potential of bioactive factors.  
The hypothesis is that functional repair of segmental bone defects will be 
improved by co-delivery of TGF-β3 and BMP-2 in a dose-dependent manner, and that 
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the growth factors will interact to enhance the repair response. The outcomes of Specific 
Aim II are discussed in Chapter 4.  
  
Specific Aim #3: Test the effects of co-delivering angiogenic and osteogenic growth 
factors on early scaffold vascularization and subsequent segmental defect repair. 
 The processes of vascular invasion and mineralized matrix formation are tightly 
linked in all aspects of bone formation and repair (endochondral ossification, 
intramembranous ossification, fracture repair, osteocyte and osteoblast survival). Mature 
bony tissue is organized discretely around vascular structures. One of the frequent causes 
of atrophic nonunion is disruption of the developing vascular supply, either by excessive 
mechanical motion or disease. Recent literature publications indicate that the co-delivery 
of osteogenic and vascular-associated factors (such as mesenchymal stem cells and 
endothelial cells) interact to more rapidly and thoroughly heal bony defects [HUANG 
2005 JBMR, KAIGLER 2006]. 
The hypothesis is that delivery of VEGF will enhance vascular invasion into the 
defect site in a dose-dependent manner and that co-delivery of both angiogenic and 
osteogenic/chondrogenic growth factors will produce interaction effects that enhance the 
quantity and functionality of mineralized repair tissue within segmental defects as 
compared to delivery of osteogenic/chondrogenic growth factors alone. Secondarily, it is 
hypothesized that scaffold macroarchitecture will affect the quantity of mineral formed 
within the defect and the ability of the host body to vascularized the defect site. The 
outcomes of Specific Aim III are discussed in Chapter 5. 
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This work is innovative because of: the use of in vivo micro-CT to accomplish 
repeated sequential images of defects over time, the combined approach of quantifying 
bone and vasculature, the use of co-delivered growth factors in an orthotopic site, and the 
evaluation of the dose-dependent effects of these co-delivered growth factors on healing. 
Additionally, the development of a robust, reproducible small animal model compatible 
with quantitative imaging strategies both in vivo and in vitro is novel. 
 
1.4 Significance 
The limitations of traditional bone repair strategies have motivated the 
development and clinical application of tissue-engineered bone repair strategies. 
Primarily, these strategies have relied on the use of a singular protein (BMP-2) delivered 
in a non-structural, absorbable biological matrix (absorbable bovine collagen sponge). 
BMP-2-based therapies have been approved by the FDA for use only at high doses of 
protein (1.5 mg/ml) [SWIONTKOWSKI 2006, BURKUS 2002]. The development of a 
lower-dose growth-factor based strategy would potentially make this therapeutic method 
more accessible to large bone defect applications, while still employing a minimally 
involved process for preparation of the implant. Additionally, treatment of large defects 
would be benefit from the use of a delivery scaffold with structural integrity – this would 
create the potential for earlier weight-bearing and/or load-sharing between support or 
fixation device and the implant.  
One of the limitations of cell-based tissue-engineered therapies for bone 
regeneration is the lack of a viable nutrient supply to the interior of the construct. A 
vascular supply is essential to cell survival; formation, maintenance, and remodeling of 
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osseous tissue require the presence of a vascular supply. Vascularization must precede or 
coincide with formation of mineralized matrix in order to produce a viable tissue. This 
work seeks to develop a challenging critically-sized segmental bone defect model, to use 
this model to explore the relationship between angiogenesis and osteogenesis within the 
framework of tissue regeneration, and to investigate the ability of growth factor 
combinations to promote both angiogenesis and osteogenesis within the defect site 
thereby producing functional repair tissue.  
This work is significant because it quantifies these two processes in a challenging 
orthotopic model and promotes understanding of the necessary components to the 
generation of an efficacious tissue-engineered construct for osseous defect repair. It 
assesses the ability of sustained growth factor co-delivery to accelerate bone repair and 
revascularization of a critically-sized segmental defect over delivery of a scaffold alone. 
This project provides an improved knowledge base regarding the link between early 
vascularization and subsequent functional bone repair. This work has produced the 
following outcomes: 1) established a rigorous and reproducible small animal model 2) 
combined the animal model with quantitative measures for assessing functional repair of 
segmental bone defects 3) employed novel in vivo and in vitro imaging techniques 4) 
determined the interactions between and dose-dependent effects of co-delivering an 
osteoinductive and chondrogenic growth factor combination and 5) evaluated the 
vascular and osteogenic responses to delivery and co-delivery of an angiogenic growth 






2.1 Bone Structure and Function 
Bone develops from three main lineages; the craniofacial skeleton develops from 
the neural crest, the axial skeleton derives itself from the sclerotome of the somite masses 
of the mesoderm (somite masses form in symmetrical pairs, arranged alongside the neural 
tube of the embryo, derived from the mesodermal tissue), and the appendicular skeleton 
is derived from the portion of the mesoderm that also contributes to formation of limb 
buds. Spinal patterning is determined by the regular arrangement of the somite masses. 
As the somite masses mature they produce sclerotomal cells, which migrate to surround 
the spinal cord, forming the bony vertebrae.  
There are two processes by which bone develops – endochondral ossification and 
intramembranous ossification. Endochondral ossification is the process by which long 
bones develop and grow. It is also the process by which simple fractures heal. Using long 
bone development as an example, a primary matrix of cartilage is laid down by 
chondrocytes in the general pattern of the limb. The diaphyseal region of the bone 
mineralizes, forming a primary ossification center. Secondary ossification centers form at 
either end of the long bone, and develop into growth plates.  
The endochondral ossification process in growth plates is patterned into several 
zones, representative of the overall process that occurs during fracture healing as well. 
First is the resting zone, where chondrocytes maintain normal morphology and are 
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relatively senescent. Second is the proliferative zone, where chondrocytes are 
proliferating and arranging themselves into columnar formations. This is followed by the 
pre-hypertrophic and then hypertrophic zones, in which chondrocytes grow in size and 
deposit a dense pericellular matrix. In the following zone, the chondrocytes die off and 
chondroclasts move in, disassembling the cartilaginous matrix to some extent. As the 
chondroclasts move in, vascular structures develop within the semi-cartilaginous zone, 
bringing osteoblasts into the tissue. Osteoblasts, or bone forming cells, then deposit 
mineralized matrix, resulting in the formation of calcified cartilage – a collagenous 
structure containing immature hydroxyapatite crystals. As the tissue around the 
osteoblasts becomes more dense and remodeled by osteoclast and osteoblast activity, it 
begins to resemble mature bone, and the osteoblasts become embedded in the mineralized 
matrix, maturing into osteocytes.  
In osteoid, or immature bone, the collagen fibrils are random and unorganized, 
and the hydroxyapatite crystal density is less than that of mature bone. As osteoid is 
remodeled into mature bone via the coupled process of bone resorption and deposition, 
the collagen fibrils align together in distinct units and hydroxyapatite crystal deposition 
becomes regular and organized. The osteocytes embedded in bone and osteoid are the 
mature, mechanosensitive bone cells responsible for the signaling required to maintain 
healthy bone structure.  
Intramembranous bone formation occurs as a direct result of the condensation of 
the mesenchyme. Progenitor cells contained within the mesenchymal tissue that patterns 
the flat bones of the body, such as the craniofacial skeleton, differentiate directly into 
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osteoblasts and osteocytes. Bone forms through appositional deposition of mineralized 
matrix by these differentiated progenitor cells. 
A highly organized tissue, bone is characterized by two distinct microstructures: 
cortical and trabecular bone. The dense cortical bone makes up structures such as the 
shafts of long bones, and laminates the surfaces of spongy trabecular bone. Cortical bone 
is composed of osteons – concentric rings of mineralized collagenous matrix embedded 
with osteocytes organized around a common Haversian canal. The Haversian canal is a 
vacuous space in the bone inhabited by a single vascular structure. The osteocytes inhabit 
lacunae within the Haversian system, and are connected by Volkmann’s canals and tiny 
canaliculi that permit vascular ingrowth (Volkmann’s canals) and fluid flow and growth 
of cellular processes (canaliculi) between the osteocytes and their lacunae. Bundling 
together osteons, the interior and exterior surfaces of the hollow cortical bone are covered 
by membranes. The endosteum, or inner membrane that abuts the marrow in the cavity of 
bones, and periosteum, or outer membrane covering the bony surface, provide a vascular 
supply and residence for bone progenitor cells. The periosteum is dense with osteoblastic 
precursor cells that are able to rapidly mobilize for repair of damaged bone.  
Trabecular bone, also known as spongy bone, is the other type of microstructure. 
It is composed of a combination of plate and rod-like elements. Each trabecular strut is 
composed of multiple trabecular packets – areas of bone that were formed at the same 
time as a result of local formation or remodeling. Like cortical bone, trabecular bone is 
composed of organized collagen fibrils and hydroxyapatite crystals. The osteocytes 
within trabecular bone are also connected by canaliculi. Spongy bone is typically found 
within flat bones and at the epiphyses and metaphyses of long bones. The plate to rod 
 15
ratio of trabecular bone, as well as the orientation of the trabecular structures, is 
modulated by the mechanical demands at that specific anatomical site. Trabecular bone 
also plays a significant role as a load distributor in the body, cushioning the mechanical 
stresses placed on the joints and skeleton by activity.  
Not only does the skeletal system serve as a structural tissue in the body, it also 
helps to keep the body biochemically balanced. Bone serves as a repository for minerals 
such as calcium, phosphorous, and magnesium. Bone provides exchangeable calcium for 
the body, a mechanism by which the body maintains its ionic homeostasis. 
Approximately 99% of the body’s calcium is stored in bones. Calcium provides structural 
integrity to the skeleton in the form of hydroxyapatite crystals. Hydroxyapatite crystals in 
bone also contain 85% of the body’s phosphorous. Magnesium, an ion that serves to link 
hydroxyapatite crystals to the fibrillar collagen network of bone, is 54% contained in 
bony tissue. Bone also contains sodium in the hydroxyapatite crystals, and plays a role in 
the maintenance of this ion as well. Bone composition is typically 60-75% mineral by 
weight, the balance being mostly organic extracellular matrix (mostly type I collagen) 
and fluid. Hematopoiesis is another critical function of bone. Marrow contained within 
the confines of the cortical bone provides the body with a constant supply of red and 
white blood cells, as well as a repository of mesenchymal progenitor cells, able to 
differentiate into multiple cell lineages.  
 Bone development, maintenance, and remodeling are processes driven by the 
mechanical forces applied to the tissue. Bone is a dynamic tissue, capable of organizing 
itself to best suit the mechanical environment to which it is exposed. Julian Wolff is 
traditionally credited with the theory that the architecture and function of bone are 
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inextricably linked, postulated in  1892. Galileo, however, had made similar observations 
in the 17th century, suggesting that the shape of a bone was related to its mechanical 
strength. In the 20th century, H.M. Frost proposed the mechanostat theory: strain 
magnitude thresholds can predict bone’s adaptive response. The mechanostat theory 
hypothesizes that in situations of disuse (bedrest, microgravity, paralysis, etc.) bone 
deteriorates, while normal physiologic use maintains the mechanical integrity of bone. 
Slight overloading can cause a shift favoring modeling over remodeling of bone, 
resulting in increased mechanical properties and quantity of mineralized tissue. Thus, 
both the physiologic and mechanical environments are critical to bone development and 
adaptation. Bone is in a constant state of damage and remodeling. Disrupting the balance 
of these two processes leads to diseases such as osteoporosis (increased bone remodeling 
and decreased bone modeling) and osteopetrosis (increased bone formation with no 
remodeling). The signaling system that correlates the activity of osteoblasts and 
osteoclasts is complex and unclear, but the intricate balance of both processes is critical 
to normal skeletal maintenance.  
 
2.2 Angiogenesis and Bone Formation and Repair 
The formation and maintenance of bone is tightly linked to the presence of a 
vascular supply. Osteoblasts and osteocytes must be within 0.1 mm of a vascular 
structure to survive and function. In fact the microstructural unit of cortical bone, the 
osteon, is organized around a vascular structure. Formation rates of trabecular bone have 
been found to have a positive correlation with blood vessel area [BAROU 2002]. 
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Vascularity and bone are tightly linked in the processes of endochondral ossification, 
callus formation, metastatic invasion, and bone regeneration [BAROU 2002].  
There are two vascular growth processes responsible for promoting new bone 
formation and repair of bone defects: angiogenesis and arteriogenesis. Angiogenesis is 
the process by which new blood vessels sprout from existing vascular structures. Various 
proteins work in concert to increase vascular permeability within an existing vessel wall. 
Following this, a tubular structure begins to develop, branching off from the existing 
vessel and extending into the adjacent hypoxic environment. This involves migration of 
endothelial cells or recruitment of circulating endothelial progenitor cells to the hypoxic 
site [RABBANY 2003]. Endothelial progenitor cells can also be derived from the bone 
marrow, and may contribute to endothelialization of a newly forming capillary.  In order 
to produce functional, non-leaky vessels, however, periendothelial cells, such as smooth 
muscle cells, must also be recruited to the growing vascular structure [CARMELIET 
2000]. During this process, mural cells stabilize the newly formed vascular structure via 
inhibition of endothelial cell migration and proliferation.  
The process of angiogenesis is followed by arteriogenesis – the maturation and 
enlargement of existing vessels. This process includes the development of a muscular 
sheath around a nascent vessel as well as increases in vessel diameter. In simple terms, 
angiogenesis is the process of vessel sprouting, while arteriogenesis is the process of 
collateral vessel growth and maturation [CARMELIET 2000]. Arteriogenesis plays a role 
in the maturation of bone repair tissue, where osteons develop around mature vascular 
structures, restoring normal morphology and functionality to the bone. The cells 
responsible for the maturation of these vessels are, unlike many of the cells involved in 
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bone repair, not derived from the bone marrow [ZIEGELHOEFFER 2004]. Rather, it 
appears that bone marrow-derived cells serve to provide paracrine signals to the 
migrating endothelial cells and pericytes, helping to create the inflammatory 
microenvironment that motivates angiogenic/arteriogenic processes [KINNAIRD 2004]. 
In the bone growth process of endochondral ossification, invasion of osteoblasts 
and deposition of mineralized matrix are facilitated by angiogenesis and arteriogenesis 
within the calcified zone of the growth plate. The newly developed vasculature permits 
migration of osteoblasts, osteoclasts, and progenitor cells to the site of the calcified 
cartilage, enabling the formation of osteoid and maturation of the woven bone into fully 
formed osteons. Fracture healing similarly relies on angiogenesis to facilitate callus 
formation and remodeling. Immediately following bony fracture, the damage to the blood 
vessels initiates the clotting cascade, and a haematoma develops. This haematoma is 
inherently angiogenic in its composition [STREET 2002]. Initially, the fracture 
haematoma suppresses endothelial cell proliferation and displays osteoblastic 
cytotoxicity, possibly by altering cell viability through a disruption in potassium channel 
function [STREET 2000 Clin Orthop Rel Res]. At later time points, however, the hypoxic 
environment and potent growth factor milieu contained within the clot encourage 
revascularization of the fracture site. Transplantation of fracture haematoma into a 
subcutaneous mouse model indicates enhanced blood vessel formation by 7 days post-
implantation. This effect is mediated by vascular-associated growth factors contained 
within the clot, and primarily by high concentrations of VEGF, with VEGF release 
peaking at 5 days post-fracture [CARANO 2003]. As the haematoma condenses and 
vascular structures develop through the interfragmentary region, the periosteal tissue 
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develops an external mineralized callus via intramembranous ossification mediated by 
progenitor cells from the marrow cavity [YU JBMR V60, GERSTENFELD 2003]. 
During this process, the fracture haematoma is resorbed and the endochondral 
ossification process begins, forming a soft internal callus. The end result of this process is 
the formation of a large, mineralized fracture callus that encompasses the fracture site 
with large quantities of disorganized woven bone [KOKUBU 2003]. With time, the 
fracture callus remodels to reveal organized, mature bone in a uniquely scar-free healing 
process. A stable fracture environment is critical to the cooperative processes of 
angiogenesis and fracture healing. Environments that are unstable in either axial or shear 
modalities will disrupt the vascular supply and delay fracture healing and callus 
remodeling, altering the tissue differentiation profile [LIENAU 2005]. Unstable fractures 
also tend more towards healing via the endochondral ossification process than stable 
fractures [FERGUSEN 1999]. Stable fractures heal by both intramembranous and 
endochondral ossification pathways. 
 
2.3 Bone Trauma and Clinical Repair 
 Bone trauma takes many forms. There are multiple modes of long bone fracture 
that can lead to a variety of defects, ranging from a simple transverse fracture caused by 
excessive tension, to a more complicated spiral fracture, caused by extreme torsional 
force. Extreme trauma can induce shattering of the bone such that traditional fracture 
reduction techniques are non-applicable. Bone loss due to traumatic injury or disease 
poses a challenge for orthopaedic treatment. Delayed union or nonunion are common 
results of traumatic bone damage in which a significant defect is created [BORRELLI 
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2003, WERNTZ 1996]. Such defects must be treated with a graft to promote union. 
Disease, such as bone tumors, can also force an osteotomy. Osteotomies of any critical 
size must be treated with grafts, typically an allograft, to ensure bony union and 
restoration of limb functionality. Osteomyelitis, or chronic bone infection, is a 
notoriously difficult condition to treat. Despite surgical intervention (osteotomy and/or 
debridement of the afflicted bones), nonunion in this case is a frequent occurrence 
[CHEN X 2006].  
 The gold standard treatment for osseous defects is the autograft. Autografts are 
not subject to rejection by the immune system since they are derived from the patient’s 
own body. The use of autografts, however, is limited due to three critical factors. First, 
there is a lack of available material for use. The only real source for autograft material is 
the iliac crest of the pelvis, which provides only a small amount of tissue. Second, there 
is no means to obtain a structural graft from this tissue source. The iliac crest can provide 
only morselized bone chips without any mechanical integrity. Use of these bone chips 
requires containment and support from an outside device, such as a titanium chamber. 
Although this treatment is successful in certain specific procedures, such as spinal 
fusions, it is unsuitable for repair of long bone defects. Third, the use of autograft 
material is subject to significant donor site morbidity and chronic pain. These are factors 
which greatly diminish patient quality of life, defeating the purpose of the treatment. 
 The facile and de facto standard treatment for substantial bony defects is the 
allograft. Allografts are derived from processed cortical cadaver bone. The processing of 
the material, designed to ensure sterility and prevent disease transmission, devitalizes the 
tissue. The resulting graft, devoid of all living material and many of the bioactive factors 
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stored in viable bony matrix, is then implanted into the defect site as a structural support. 
Although effective to some extent, the allograft is constrained by two critical factors: 
Low porosity of the allograft severely limits graft revascularization and revitalization, 
which leads to slow remodeling of the allograft by the host body. Lack of remodeling 
leads to an accumulation of microdamage within the graft, a major contributor to 
catastrophic graft failure. Together, these factors lead to the 25% clinical failure rate and 
contribute to the 30-60% complication rate associated with allografts [LUCARELLI 
2005, WHEELER, 2005]. Complications occur rapidly – within 1-2 years post-
engraftment – and frequently result in defect non-unions or delayed unions, significantly 
impacting patient quality of life [ITO 2005]. 
 One potential alternative for addressing the associated limitations of autografts 
and allografts is development of tissue-engineered bone graft replacements. Recently the 
first steps towards employing this technique have been taken with FDA approval of the 
Infuse spinal fusion system (Medtronic Sofamor Danek). Tissue engineering has been 
described as a three-fold strategy. First, there must be a matrix, substrate, delivery 
vehicle, or support for the delivery of the bioactive factors. Secondly, there must be a 
presence of bioactive factors; for example, growth factors, genes, or signaling molecules. 
Third, there must be a cellular component. This component may be delivered as a part of 
the therapy, or rely on recruitment of host cells from the treatment recipient. This tissue 
engineering strategy may combine biological factors as well as synthetics to create a 
porous, cell-friendly microenvironment that will enhance bone and vascular infiltration 
into the defect site. The work presented in this thesis represents one model strategy for a 
tissue-engineered bone replacement. We have developed a porous polymer scaffold with 
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mechanical integrity that can be co-delivered with biological agents to promote 
osseointegration of the scaffold into a bony defect site and enhance functional repair of 
the osseous defect. 
 
2.4 Bone Defect Models  
 There are many models of osseous non-union. These include the cranial defect, 
mandibular defect, radial defect, tibial or fibular defect, and femoral defect. Cranial 
defects are relatively easy to generate, and require no fixation device. The major 
limitation of these defects, however, is that they have a high rate of spontaneous healing 
[BYERS 2006]. It is difficult to achieve a true critically-sized defect in the cranial model, 
although short-term studies have been able to detect differences in early mineralization 
between treatment groups [SAKATA 2006]. This is due primarily to the proximity of 
cranial bones to the dura mater, an excellent and ready source of vascularity, and the 
large quantity of periosteum surrounding the defect – an excellent source of 
osteoprogenitors. One must note that the marrow within the cranial bones also contains 
osteoprogenitor cells. These three sources of cells and vascularity are readily available to 
the defect site. The immediate formation of a haematoma within the defect site is often 
enough to initiate spontaneous fusion of the defect. Scaffolds implanted into this model 
rapidly facilitate bony healing when acting as osteoconductive structures. 
 Mandibular defects come in a variety of geometries. The most common is the 
circular defect in the ramus of the rat mandible, which is somewhat more challenging 
than the cranial defect [SAADEH 2001]. Implantation of non-porous scaffolds has been 
known to impede wound healing in this model, while untreated defects achieve 
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spontaneous union in 11% of samples [AROSARENA 2003, SROUJI 2005, SHAH 
2003]. Like the cranial defect, the mandibular defect occurs in a flat bone formed by 
intramembranous ossification. Periosteal tissue surrounding the intact bone provides a 
reservoir of osteoprogenitor cells that may contribute to bone healing. Mandibular defects 
must be fairly large in order to be critically-sized, and the typical surgical model employs 
sub-critical defect sizes [SPECTOR 2001]. This model, like the cranial defect model, is 
suitable for evaluation of cranial-maxillofacial treatment strategies, but is not 
representative of a long bone defect. Results from these models should not be 
extrapolated to treatment of long bone defects, which tend to be more challenging. 
 Defects of the radius, ulna, or tibia are popular because the presence of the 
proximal load-sharing bone may negate the need for implantation of a fixation device, 
and the defects are partially load-bearing. A consistent size for these defects has not been 
agreed upon, and reports of what constitutes “critically-sized” vary widely, although 
ulnar defects tend to be larger than their radial counterparts (ranging from 0.5 cm to 2 
cm) [SHELLER 2004, GIARDINO 2006, KOKUBO 2003, TUOMINEN 2001]. The 
presence of the intact ulna, radius, or fibula, however, also contributes a readily available 
source of osteoprogenitor cells and vascularity, via the periosteum, to the defect site. 
Because of this, these defects tend to be less challenging than the femoral defect model. 
The presence of the intact periosteum on the ulna of a 1 cm radial defect model in rabbits 
provides a source of osteoprogenitors that readily populate the surface of implants and 
contribute to partial bridging of untreated controls [GOGOLEWSKI 2000, 
YAMAMATO 2006].  Use of intramedullary Kirshner wires to stabilize the defect and 
graft seems to inhibit part of the healing response [TUOMINEN 2000]. Adding stability 
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in the form of a bone plate partially stabilizes the defects, but also provides a site for 
excess mineralization to occur on [ITOH 1998]. The use of ulnar defect models makes 
mechanical testing of the samples difficult, due to the presence of synostosis between the 
radius and the ulna, which occurs even in untreated control defects [BOSTROM 1996]. 
Murine tibial defects heal in the presence of an unaugmented collagen sponge [ENDO 
2006].  Like radial defects, the size of tibial defects ranges considerably – 5 mm defects 
are employed in both rat and rabbit models; and mechanical fixation is required to 
achieve stabilization [ENDO 2006, KOMAKI 2006]. Tibial defects are a popular 
research model clinically as well as experimentally because the mode of fracture tends to 
be complex, requiring multiple stage clinical interventions [JONES 2006, ATTIAS 
2006]. 
 Femoral defects are perhaps the most challenging model of osteotomy available in 
the body. Beyond the cut ends of the defect site, there is no proximal periosteum to 
contribute vascularity or osteoprogenitors to the osteotomy. It is easy to achieve a 
critically-sized femoral defect due to the length of the bone. Stable fixation of these 
defects, however, is challenging. Typical fixation relies on a simple polyethylene bar that 
directly abuts the femur and implant, secured in place with four smooth pins. This 
fixation method is highly unstable, permitting excessive micromotion, and is prone to 
defect collapse. Additionally, the placement of the plate directly against the implant in 
the defect site prohibits invasion of cells from that portion of the circumference of the 
implant. This direct abutment of the plate against the defect site also predisposes the limb 
to formation of ectopic mineralized matrix along the length of the plate [KADIYALA 
1997]. In the literature the typical defect length is 5 mm. This defect, however, is not 
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critically-sized, as the untreated 5 mm defects are prone to spontaneous healing. 
Published spontaneous union rates range from 10-50%. [WERNTZ 1996, 
NOTTEBAERT 1989] Without a truly critically-sized defect, stringent evaluation of 
large bone defect treatment strategies is not possible. The robust 8 mm defect in rat 
models is critically-sized, unlike the more commonly used 5 mm defect. Pilot work for 
the studies presented here included an attempt at the 5 mm defect using the standard 
block-and-pin fixation strategy widely employed in the literature. That pilot study was 
compromised by frequent collapse of the defects and spontaneous union in multiple 
untreated defects. Given a larger defect (8 mm) and a more stable fixation system such as 
the one employed in the work presented here, however, a secure, robust, and challenging 
defect model can be established. The stable 8 mm defect is not subject to spontaneous 
healing, and fits the criteria for a critically-sized defect as established by Hollinger 
[BRUDER JOR 1998, FEIGHAN 1995, KADIYALA 1997, LIEBERMAN 1999 JBJS, 
STEVENSON 1994, HOLLINGER 1990].  
 
2.5 Experimental Treatments 
 Experimental treatments for large osseous defects are wide-ranging in their 
specific components, but consist of two fundamental elements – a delivery vehicle 
(scaffold) and a stimulus intended to evoke a biologic response (cells, growth factors, or 
genes).  
 Scaffolds may serve a variety of purposes. Some investigators choose to use 
materials with structural integrity that may provide mechanical support to the bony 
defect; others select materials with little to no mechanical strength, serving primarily as 
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delivery vehicles for biologics. The typical structural scaffold implanted into defects is 
hydroxyapatite/tricalcium phosphate (HA/TCP). This ceramic scaffold is composed of 
naturally occurring minerals in bone tissue. However, it is limited by low porosity, lack 
of interconnected porosity, and brittleness that predisposes it to fracture when exposed to 
mild loading in vivo [BRUDER 1998 JBJS]. Implantation of a plain HA scaffold in vivo 
does not promote union of an osseous defect, and results in formation of fibrous tissue 
within the defect site [BRUDER 1998 JOR, KADIYALA 1997]. The healing response to 
implantation of HA/TCP is not elevated by augmentation with bone marrow. The result 
of this treatment is minimal bone fill into the scaffolds by 8 weeks post-op. However, 
addition of mesenchymal stem cells (MSCs) to the HA/TCP scaffold substantially 
improved formation of new mineralized matrix, resulting in the formation of a periosteal 
callus around the implant [KADIYALA 1997]. This strategy has even been attempted 
clinically; in four patients ranging from 16 to 41 year of age autologous BMSCs were 
harvested and seeded onto porous HA blocks implanted in vivo. The results showed 
improved functionality of the affected limbs and incorporation of the graft into the host 
bone over the first year in vivo, but relied heavily on mechanical stabilization of the limb 
and implant [MARCACCI 2007]. Augmentation of HA scaffolds with demineralized 
bone matrix (DBM) enhances mineralization somewhat, but does not restore mechanical 
integrity. In a study involving rat femurs, samples were so brittle and grossly unstable 
that mechanical testing post mortem was impossible [FEIGHAN 1995].  
 DBM itself has also been delivered to segmental defects in varying formulations. 
In a rat model utilizing 8 mm femoral defects, human demineralized bone matrix 
(hDBM) was delivered in one of two carriers – hyaluronic acid or glycerol. While 
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delivery of the carrier alone did not encourage mineral formation, a small number of 
hDBM-treated groups achieved bony union (8/48) by 16 weeks post-op [OAKES 2003]. 
These results point to the potential osteoconductive properties of DBM, but a lack of 
osteoinductivity.  
 Although limited by a lack of mechanical integrity, a number of gel-consistency 
materials have been used as experimental treatments for bone regeneration. Collagen is a 
popular matrix due to its inherent biocompatibility. Because of its lack of bioactivity, 
collagen matrices must be combined with other biologically active factors in order to 
promote osseous union. A popular use of this delivery method is the clinically-approved 
delivery of bone morphogenetic protein-2 (BMP-2) in an absorbable bovine collagen 
sponge to produce spinal fusions. This method is also being clinically investigated as a 
means of accelerating open tibial shaft fracture repair [SWIONTKOWSKI 2006, 
BURKUS 2002]. Delivery of BMP-2 in an absorbable collagen sponge may also aid 
allograft incorporation into the host bone [ZABKA 2001]. The bovine collagen sponge 
has also been used experimentally in animal models to deliver morselized autogenous 
bone chips and cell culture extracts in an attempt to promote healing. The use of 
autogenous bone chips in a rat segmental defect model failed to heal the defect; rather, it 
resulted in formation of fibrous tissue [HUNT 1996]. Conversely, autogenous bone chip 
treatments have been used clinically to produce spinal fusions and met with success in 
producing radio-opaque mineralized tissue in a critically-sized canine femoral defect 
model [SWIONTKOWSKI 2006, KRAUS 1999]. Mechanical integrity, however, was 
not restored in the canine model by 16 weeks post-op.  
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BMPs are also a popular choice for gene therapy in a variety of delivery systems. 
Delivery of BMP-9 by intramuscular adenoviral injection induces ectopic mineralization 
in vivo and stimulates in vitro ALP production by human MSCs [LI 2003]. Direct transfer 
of adenoviral BMP-2 locally to a tibial fracture in an osteoporotic ovine model enhances 
the bending strength, callus area, and callus density over untransfected controls 
[EGERMANN 2006]. Thus, gene therapy has potential for application even in 
challenging fracture models [EGERMANN 2005]. Local injection of adenoviruses 
encoding BMP-2 to a stabilized lapine femoral defect of 1.3 cm significantly improved 
the bending strength and stiffness over treatment with adenoviral luciferase (control 
vector). Bony bridging of the defect was apparent in both treatment groups [BALTZER 
2000]. A parallel study in a 5 mm rat femoral defect model showed enhanced mineralized 
matrix in BMP-2 gene-treated defects versus luciferase cDNA treated defects. However, 
the incidence of bony union in the BMP-2 treated defects hovered around 75%, although 
50% of these defects still contained islands of cartilaginous tissue by 8 weeks post-op 
[BETZ 2006]. Mechanical integrity was not restored. Delaying the delivery of adenoviral 
BMP-2 until day 5 or 10 post-op slightly increased the incidence of bony union to 86% 
[BETZ 2007]. Delivery of condensed plasmid BMP-4 to murine cranial defects in PLGA 
enhances bone fill by 4.5 fold over delivery of a scaffold or non-condensed plasmid 
[HUANG 2005]. This study illustrates that the delivery method for gene-based therapies 
is of great importance, similar to the observations made regarding protein therapies. 
However, when the correct titre of virus is delivered, delivery of genes such as caALK2, 
VEGF, and RANKL have been shown to revitalize even cortical allografts [AWAD 
2007].  
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 Regional gene therapy for bone defects is also commonly achieved via 
implantation of pre-transfected cells [BALTZER 2004]. Local delivery of BMP-2-
transfected BMSCs in an alginate hydrogel enhances late bone formation in a rabbit 
cranial defect model [CHANG 2004]. Both delivery of BMP-2-producing BMSCs and 
delivery of BMP-2 protein (both in guanidine-extracted DBM) produce similar results in 
terms of radiographically-defined bony union in an 8 mm rat femoral defect model or a 6 
mm defect (BMP-2 transfected MSCs on a collagen scaffold) [LIEBERMAN 1999, 
TSUCHIDA 2003]. However, histomorphometric analysis showed an increase in total 
bone area in the gene therapy group over the protein delivery group. This increase in 
bone area did not correlate to an increase in mechanical though, indicating that bone 
quality may be more critical than bone quantity for restoration of limb functionality. 
Transduction of BMSCs with BMP-4 enhances mineralized tissue deposition in sub-
critical rabbit femoral defects over delivery of unaltered BMSCs [SAVARINO 2007]. 
Delivery of the BMSCs alone enhanced tissue invasion into the defect site, but did not 
impact mineralization to the degree that implantation of transfected BMSCs did. 
Transduced mesenchymal cell lines (BMP-2/β-galactosidase) have been used in vivo as a 
type of engineered periosteum to enhance incorporation of allografts into a murine 
segmental defect model [XIE 2007].  
 Gene therapy can also be used to induce osteogenic gene expression in non-
osteoblastic cells, such as fibroblasts and muscle-derived cells [KREBSBACH 2000, 
PHILLIPS 2006, SHEN 2004]. BMP-7 (OP-1)-producing fibroblasts have been shown to 
produce mineralized tissue when implanted in vivo (subcutaneous rat model) on Gelfoam 
sponges. This approach also enhances healing of murine cranial defects over delivery of 
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untransfected fibroblasts [KREBSBACH 2000]. Primary muscle-derived cells (preplate 
isolation technique) can be transfected to express BMP-4 and, upon implantation into a 
murine femoral defect, produce radiographically apparent union and partially restore limb 
functionality [SHEN 2004]. Adipose-derived MSCs modified to produce BMP-2 have 
also been shown to have osteoregenerative potential with results similar to those 
produced by high dose BMP-2 (20 µg in a 6mm rat femoral defect) [PETERSON 2005].  
However, the ability of non-osteoblastic cells transfected with gene constructs, such as 
Runx-2, to mineralize has been shown to be highly scaffold-dependent [PHILLIPS 2006].  
Cell-based therapies without genetic modification have also been investigated. In 
a canine parietal bone defect model, delivery of BMSCs has been shown to have 
osteoregeneration potential similar to delivery of autologous bone chips [UMEDA 2007, 
NIEDZWIEDZKI 1993]. Similar results were achieved in an ovine metatarsal defect 
model [VIATEAU 2007]. The reported ability of simple cellular therapies to regenerate 
large defects varies widely, but when the degradation properties of the delivery scaffold 
are adequately matched to the rate of mineralized matrix deposition, this approach can be 
successful [BENSAID 2005, BRUDER Clin Orthop Rel Res 1998, BRUDER JOR 1998]. 
Although whole bone marrow has occasionally been used in combination with ceramic 
scaffolds to attempt osseous defect regeneration, there is evidence supporting the 
hypothesis that selecting a specific population or populations of cells from the marrow 
cavity may be more advantageous [KADIYALA 1997]. Although autogenous bone 
marrow-derived cells are optimal as they do not activate the host immune system, 
allogeneic stem cell populations may by immunologically inert enough to successfully 
engraft in the recipient [LIVINGSTON 2003]. The key factor present in bone marrow 
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necessary to potentiate this regenerative capacity appears to be the living cells, not the 
inherent growth factor milieu [WERNTZ 1996].  
Combining cellular therapies with growth factor or gene therapy can also 
accelerate the process of bone regeneration. In a rat radial defect model, addition of basic 
fibroblast growth factor (bFGF or FGF-2) to BMSCs accelerated deposition of bone 
repair tissue [LISIGNOLI 2002]. Co-delivery of condensed plasmid DNA encoding 
BMP-4 and VEGF with BMSCs on a PLGA scaffold significantly improved the ability of 
the cells to induce ectopic osteogenesis and implant vascularization [HUANG 2005]. The 
role of VEGF in bone defect repair models is a complex problem, and reports on the 
efficacy of VEGF as a treatment are varied. Delivery of high-dose VEGF (10 µg) in 
protein form to a stabilized but challenged (periosteal stripped) mouse fracture model 
stimulated an increase in the percent of the callus that was calcified [STREET 2002]. 
Systemic treatment with soluble VEGF receptor of animals that had received a stabilized 
fracture resulted in dramatic impairment of new bone formation and an overall decrease 
in callus mineral content [STREET 2002]. The same results were seen in a cortical bone 
defect model of intramembranous bone healing. In a segmental defect of the radius in 
rabbits, VEGF was continuously delivered via an osmotic pump over the first 7 days 
post-op. VEGF treatment at a dose of 250 µg stimulated significant filling of the defect 
site with new bone, while non-treatment resulted in a lack of bony bridging [STREET 
2002]. In a murine cortical defect model, delivery of VEGF in gene form intramuscularly 
to the defect location resulted in a moderate increase in the bone mineral content at an 
early time point (2 weeks) [TARKKA 2003]. By week 4 the control group (LacZ-treated) 
and VEGF groups were comparable in bone mineral content and histological appearance. 
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VEGF gene therapy decreased the quantity of cartilage at 2 weeks post-op; it is unclear if 
VEGF therapy accelerated endochondral ossification or simply forced direct ossification, 
circumventing the cartilaginous period. In exercise-induced models of anabolic bone 
formation, blocking VEGF signaling attenuates the modeling response that occurs in 
untreated animals. Gene therapy using VEGF and RANKL enhances revascularization, 
resorption, and mineralization of processed cadaveric allografts in a mouse model [ITO 
2005]. Similarly, co-delivery of BMP-4 and VEGF condensed plasmid DNA along with 
BMSCs into a subcutaneous location induced local bone formation [HUANG 2005]. 
Continuous delivery of VEGF or VEGF-inhibitor to a lapine tibial segmental defect, 
however, failed to induce an osteogenic response. Delivery of VEGF in this model did 
enhance vascular invasion [ECKHARDT 2003]. Delivery of 3 µg of VEGF to a 3.5 mm 
diameter calvarial defect enhanced defect vascularization in both irradiated and non-
irradiated samples. Bony bridging was enhanced by delivery of VEGF-containing 
scaffolds in both groups [KAIGLER 2006]. Collectively, these studies point to the 
potential for a highly dose-dependent and injury-dependent efficacy of delivering VEGF 
for bone regeneration therapy.  
The therapies described above relied largely on delivery vehicles or scaffolds with 
suboptimal mechanical properties. In addition to exploiting the chemoresponsive stimuli 
to regenerate bone, one can design a treatment strategy that incorporates the 
mechanosensitive nature of the tissue. Because mechanical stimulation is known to 
potentiate increases in bone quantity and quality, it may be advantageous to design a 
tissue-engineered construct that can load-share with the mechanical stabilization 
apparatuses. Structural polymer scaffolds can be produced with sufficient elasticity and 
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integrity to achieve these goals. The use of structural polymer scaffolds as treatments for 
large load-bearing defects, however, has not been widely investigated. For segmental 
defect repair in load-bearing sites, HA/TCP is the typical scaffold delivered if structural 
stability of the implant is a factor for consideration [BRUDER 1998 JBJS, FEIGHAN 
1995, BRUDER 1998 JOR, KADIYALA 1997]. There are few instances of polymer 
implantation [OEST 2007, RAI 2007, CHU 2007]. However, this strategy has been 
explored for reconstruction of craniofacial defects [SCHANTZ 2003, ROHNER 2003, 
GOMEZ 2006, KAIGLER 2006]. The inert nature of the simple polymer scaffold 
necessitates combination with biologically active agents, such as marrow cells and/or 
growth factors. Incorporation of VEGF into a PLGA scaffold enhanced both angiogenesis 
and mineralized matrix formation in an irradiated murine calvarial defect model 
[KAIGLER 2006]. Polycaprolactone (PCL) has been investigated by several research 
groups. Combination of autologous bone marrow with a porous PCL scaffold 
significantly improved bony fill in a porcine orbital defect model over delivery of a naked 
PCL scaffold. Non-treatment of the defect resulted in fibrous tissue formation [ROHNER 
2003]. Use of a lapine calvarial defect model was applied to the investigation of marrow 
progenitor cell- and osteoblast-seeded PCL scaffold abilities to regenerate osseous tissue. 
The PCL scaffolds used here were similar to those investigated by Rohner et al.  The 
cells were seeded in a fibrin glue suspension into the PCL scaffolds with a 3 day 
preculture period prior to implantation. Incorporation of cells into the scaffold 
significantly enhanced bony fill and push-out strength within the calvarial defects (by 
approximately 60%). The type of cell delivered did not significantly impact bone 
regeneration or mechanical integrity [SCHANTZ 2003].  
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The results of the various treatment strategies reviewed here attest to the complex 
nature of the bone regeneration problem. Without a biologically active component, 
delivery of a bare scaffold is insufficient to induce osteogenesis in vivo. Although simple 
cell-based therapies meet with some success, their efficacy can be improved upon by co-
delivery with active proteins or genetic modification. Provision of grafted cells on the 
scaffold is not necessary to produce an osteogenic response, as scaffold modification with 
gene-encoding vectors or growth factors is suitable to elicit a response from the 
surrounding host cells. The current limitation of these acellular therapies is largely based 
on the sheer quantity of vector or protein that must be delivered. Transfection rates for 
viral vectors remain relatively low, and many investigators may overdose the quantity of 
growth factor in order to induce a positive response. The work presented here rigorously 
evaluates the potential to efficiently generate consistent bony union in a large femoral 
defect model using low-dose growth factor co-delivery. 
 
2.6 Growth Factor Selection 
 In order to promote vascularized bone healing within the segmental defect, three 
growth factors (osteogenic, chondrogenic, and angiogenic) have been selected for use in 
these studies.  
BMP-2 (bone morphogenetic protein-2) was selected for its potent osteoinductive 
activity both in vivo and in vitro, and is essential for fetal skeletal development (deficient 
phenotypes of BMPs -2, -4, and -7 are embryonic lethal) [SCHMITT 1999]. BMPs play 
roles not only in calcified tissue development, but also in cartilage and skeletal 
connective tissue formation [WOZNEY 1998]. BMP-2 is capable of inducing progenitor 
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cells to adopt an osteoblastic phenotype when implanted both ectopically and 
orthotopically in vivo [RILEY 1996]. Endogenous BMP-2 is heavily implicated in 
fracture healing and bone induction [REDDI 1998]. The key steps in the bone induction 
cascade -- chemotaxis, mitosis, and differentiation -- are all promoted by BMP-2 at 
varying doses, although BMP production during fracture healing seems to be restricted to 
the initial phases of healing [REDDI 1998, EINHORN 1998]. BMP-2 is known to induce 
osteoblast migration in vitro, and is involved in the differentiation of progenitor cells 
derived from both bone marrow and periosteum to the osteoblastic phenotype [MAYR-
WOLFHART 2002]. Chondrogenic differentiation of progenitor cells is also partially 
regulated by BMP-2 expression [EINHORN 1998, RILEY 1996, WOZNEY 1998]. Peak 
BMP-2 expression occurs during early stages of fracture healing, where the growth factor 
plays an important role in initiating and directing the formation of new bone by 
progenitor and osteoblastic cells in vivo. 
BMP-2 is also known to play a role in the regulation of angiogenesis in both soft 
tissues and bone [LANGENFELD 2004]. BMPs can induce production of VEGF by 
osteoblastic cells and placental growth factor (PlGF) in mesenchymal cells [DECKERS 
2002, MARRONY 2003]. Although osteoblastic differentiation occurs independently of 
VEGF production, the dual effects of BMP-2 on angiogenesis and osteogenesis suggest 
an important bifunctional role for the protein in vivo. The final connection in this circular 
regulation is the ability of endothelial cells to secrete BMP-2 and thereby attract 
osteoblasts and osteoblastic progenitor cells.  
The specific osteogenic activity of BMP-2 has prompted extensive in vivo 
evaluation of the peptide for bone regeneration. Administration of BMP-2 to segmental 
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defect sites has been shown to promote bony union in defects at extremely high 
concentrations (up to 20 micrograms per defect), but not at lower concentrations (1.4 
micrograms per defect) [ISOBE 1999, LEE 1994, YASKO 1992, PETERSON 2005]. 
BMP-2 administration has been approved for clinical use in spinal fusions, and has been 
extensively tested in bone defect models and ectopic implantations in a wide range of 
animals [WOZNEY 1998]. The proposed growth factor dose for the studies in specific 
aims II and III is significantly lower than the effective dose used by Yasko et al. and 
Peterson et al. in accordance with the hypothesis that co-delivery of BMP-2 with another 
protein may lower the concentration of BMP-2 required to promote union. 
The growth factor selected for co-delivery with BMP-2 was TGF-β3 
(transforming growth factor beta-3). TGF-βs are typically associated with 
chondrogenesis, but have been shown to act synergistically with BMP-2 to form 
mineralized matrix in an ectopic mouse model of osteogenesis, and TGF-β1 is known to 
synergize with BMP-7 to enhance angiogenesis [SIMMONS 2004, RAMOSHEBI 2000]. 
TGF-β family proteins are highly expressed during endochondral ossification and 
fracture healing, and serve to partially regulate the chondrogenic phenotype adopted by 
progenitor cells during fracture healing [LIEBERMAN 1999]. TGF-β synthesis may also 
be upregulated under hypoxic conditions such as those seen locally during fracture 
healing [BOULETREAU 2002, SAADEH 2000]. During the initial inflammatory phase 
reaction to bone fracture, TGF-β is released by platelets [EINHORN 1998]. TGF-β is 
involved in the regulation of late stage chondrocyte and osteoblast differentiation in 
fracture healing as well as osteoblast/osteoclast coupling and extracellular matrix 
production [CARANO 2003]. Delivery of TGF-β3 to an osseous defect may promote 
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formation of cartilaginous tissue which can be subsequently calcified and remodeled to 
form fully mineralized matrix. TGF-β3 expression can also increase VEGF production in 
osteoblastic cells, linking it to angiogenic responses [SAADEH 1999]. TGF-β family 
members, specifically TGF-β3, are crucial to reducing inflammation and promoting scar-
free healing. TGF-β3 is under clinical investigation as an agent to promote scar-free 
healing of a variety of tissue defects.  
VEGF (vascular endothelial growth factor) is the classic angiogenic growth factor 
that, at low doses, promotes formation of neovasculature both in vivo and in vitro while 
also acting to induce vascular permeability [PUFE 2002, DVORAK 2002]. VEGF 
production represents the crucial rate-limiting step in angiogenesis, inducing the 
proliferation, migration, and survival of endothelial cells both in vivo and in vitro 
[COSTA 2004]. VEGF is capable of inducing bone marrow-derived endothelial 
progenitor cells to enter the circulatory system and contribute to angiogenic processes in 
vivo [ASHARA 1999].  However, the vasculature formed by delivering high levels of 
VEGF alone has been shown to be leaky and immature in nature [McCOLL 2004]. 
Formation of functional, mature vascular tubes requires co-migration of pericytes and 
smooth muscle cells in addition to endothelial cells, emphasizing the fact that 
angiogenesis is a complex process regulated by multiple factors [KURZ 2000]. VEGF 
synthesis by endothelial and osteoblastic cells is upregulated under hypoxic conditions, 
such as those seen in ischemia and large tissue defects, via elevated expression of HIF-1α 
(hypoxia inducible factor 1-alpha), which in turn induces transcriptional activation of 
VEGF [BOULETREAU 2002, McCOLL 2004]. VEGF is chemotactic and mitogenic for 
endothelial cells (as well as osteoblasts and osteoclasts), and may also induce smooth 
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muscle cell migration [BUSCHMANN 2003, GERBER 1999, MAYER 2005]. The 
ability of the body to produce VEGF, stimulate angiogenesis, and heal wounds is known 
to decrease with age suggesting a potential regulatory mechanism for the observation of 
delayed tissue repair in elderly patients [SWIFT 1999]. 
VEGF, particularly slice variant 164 (murine) or 165 (human), has also been 
implicated in the process of bone formation by promoting angiogenesis and thereby 
facilitating bone and calcified cartilage remodeling [STREET 2002, PUFE 2002]. VEGF 
expression is increased during osteogenic differentiation, inhibiting apoptosis of 
osteoblasts and newly migrated endothelial cells and helping to maintain the viability of 
the neovasculature and osseous repair tissue [CARANO 2003, MAYER 2005]. In turn, 
VEGF treatment of endothelial cells increases BMP-2 expression [BOULETREAU 
2002]. VEGF expression in the fracture callus recapitulates the expression of VEGF seen 
in long bone development, where VEGF expression is critical to promoting chondrocyte 
cell death and mineralization of the cartilaginous tissue [CARANO 2003, GERBER 
1999]. Inhibition of VEGF may block BMP-induced angiogenesis as well as osteoblast 
differentiation and bone formation while addition of VEGF to segmental defects 
enhances bone formation [CARANO 2003, MAYER 2005]. VEGF activity in bone repair 
typically peaks around 5 days post-fracture and returns to basal levels by day 10 [PUFE 
2002]. The ability of VEGF delivery to promote fracture healing may, however, be highly 
dose-dependent as there are varying reports on the efficacy of this treatment 
[ECKHARDT 2003, STREET 2002]. 
 The effects of delivering these growth factors both individually and in 
combination were investigated in the work presented here. Traditionally growth factor 
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therapies have relied heavily on bulk doses of a single osteogenic peptide. The limitations 
of this simplistic approach are primarily found in 1) the associated cost of the treatment 
and 2) the potential for inducing ectopic osteogenesis or hyperossification of the 
treatment site. Using a more diversified therapy to treat the complex problem of 
functional bone regeneration may promote a more natural and controlled mechanism for 
healing of critically-sized defects. 
 
2.7 Methods of Growth Factor Delivery 
Non-structural scaffolds are the primary mode of growth factor delivery; 
hydrogels and gel-consistency polymers are popular choices. Both biologically-derived 
and synthetic hydrogels are commonly used in tissue engineering applications 
[KRETLOW 2007]. Although their consistency is more similar to that of cartilaginous 
tissues, hydrogels serve as effective delivery vehicles for growth factors, cells, genes, and 
other biologics [KASPER 2006, SIMMONS 2004]. Co-delivery of human MSCs with 
BMP-2 in a hyaluronic acid-based hydrogel was shown to enhance regenerative tissue 
formation in a rat cranial defect model over delivery of a scaffold alone, delivery of only 
BMP-2 on the scaffold, or delivery of only MSCs on the scaffold [KIM 2007]. The 
efficacy of synthetic matrices, such as PEG, is largely impacted by the degradability of 
the polymer and/or release and support of the biological component(s). Physical linkage 
of BMP-2 to a PEG (polyethylene glycol) matrix via a proteolytically degradable 
mechanism proved to be a suboptimal strategy for healing of murine cranial defects 
[RIZZI 2006, LUTOLF 2003]. It is likely that this delivery strategy was ineffective 
because 1) the hydrogel matrix was not easily degraded by the native host cells and 2) the 
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BMP-2 was not released into the surrounding tissue to chemotactically cue the 
surrounding cells to proliferate and/or migrate into the defect site. Use of a fibrin matrix 
with similarly incorporated BMP-2 also failed to regenerate cranial defects in both 
murine and lapine models suggesting that to some extent the BMP-2 must be soluble in 
order to induce osteoprogenitor cell proliferation and migration [SCHMOEKEL 2004]. In 
contrast, if a biodegradable hydrogel (in this case gelatin) is engineered to release BMP-2 
in a controlled fashion, a large lapine ulnar osseous defect can be effectively regenerated 
[YAMAMOTO 2006 Tissue Eng]. In vitro use of anti-adhesive hydrogels (such as 
hyaluronic acid and PEG) has proven challenging in terms of maintaining cell viability. 
This observation may also partially explain the limited efficacy of these treatments in 
vivo [KIM 2007].  
In addition to growth factors, complex naturally derived biologics can be 
employed for tissue engineering. One such example is platelet-rich plasma (PRP). 
Although initially investigated for use in dental and maxillofacial reconstructive 
applications, PRP has also recently been investigated as an agent for tissue engineering of 
other skeletal components [RAI 2007, ROLDAN 2004]. Augmenting gelatin hydrogels 
with PRP significantly improved mineralized matrix deposition in a lapine ulnar defect as 
compared to delivery of a naked matrix or free PRP. Formation of new bone was 
somewhat improved in the gelatin-PRP group as compared to a fibrin-PRP treatment 
group. This finding illustrates the importance of developing a proper interaction and 
release profile for biologically augmented matrices [HOKUGO 2005].  
In addition to controlling for release of biologics, the converse aspect of 
controlling the retention of these factors is also important. Although extremely high doses 
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of free, soluble growth factor (particularly BMP-2) have occasionally shown positive 
results, most studies have shown that soluble growth factor is a challenging mode of 
delivery to use [HONG 2000]. Application of gelatin hydrogels with varying water 
contents and TGF-β1 to calvarial defects in a lapine model was effective only when the 
hydrogel was able to both prevent rapid soft tissue formation in the defect (serve as a 
placeholder) and retain the growth factor long enough to stimulate mineralized matrix 
formation [YAMAMOTO 2000 J Control Release, HONG 2000]. Chimeric natural-
synthetic hydrogels are possible, although not widely used. PEGylated fibrinogen 
hydrogels can, similarly to gelatin hydrogels, serve as place holders to prevent rapid soft 
tissue invasion. When designed with a degradation rate that is roughly on par with the 
rate of appositional bone formation in a murine tibial defect model, the PEGylated 
fibrinogen hydrogel can encourage osteogenesis more effectively than if it is designed 
with a particularly rapid or slow degradation rate [PELED 2007]. Controlled release 
capsules containing BMP-2 delivered to a femoral defect site have been shown to induce 
bony bridging of the defect by 8 weeks post-op. In this case, a high dose of BMP-2 was 
used (5 mg per defect). Using PLGA particles of various sizes to deliver BMP-2, Lee et 
al. investigated the dose-dependent response of segmental defect healing [LEE 1994]. In 
terms of mechanical properties, significant differences in failure torque between defects 
treated with particles alone and particles augmented with BMP-2 were only seen at the 
highest dose (9.3 µg per defect), and not at the two lower doses (3.1 µg or 0.93 µg). High 
doses of BMP-7 (200 µg per 6 mm defect) delivered in a lyophilized collagen carrier can 
efficaciously overcome challenged (chronically infected) nonunion models when 
delivered concomitantly with antibiotics [CHEN X 2006]. What these studies point to is 
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the importance of properly managing growth factor release in order to elicit the desired 
biological response. Controlled and/or sustained release of proteins is a challenging 
problem to engineer. This situation may be further complicated by use of a two-phase 




Quantitative Assessment of Scaffold and Growth Factor-Mediated Repair of 
Critically Sized Bone Defects 
 
3.1 Abstract 
 An 8 mm rat segmental defect model was used to quantitatively evaluate the 
ability of longitudinally-oriented poly(L-lactide-co-D,L-lactide) (PLDL) scaffolds  with 
or without growth factors to promote bone healing. BMP-2 and TGF-β3 combined with 
RGD-alginate hydrogel were co-delivered to femoral defects within the polymer 
scaffolds at a dose previously shown to synergistically induce ectopic mineralization. A 
novel modular composite implant design was used to reproducibly achieve stable 
fixation, provide a window for longitudinal in vivo micro-CT monitoring of 3-D bone 
ingrowth, and allow torsional biomechanical testing of functional integration. A contrast 
agent perfusion procedure was established to enable micro-CT imaging and 
quantification of vascular structures within the defect site. Sequential in vivo micro-CT 
analysis showed that bone ingrowth increased significantly between 4 and 16 weeks for 
the scaffold-treated defects with or without growth factors, but no increase with time was 
observed in empty defect controls. Post-mortem regional micro-CT analysis revealed that 
the majority of the new bone formation occurred in the proximal half of the 8 mm defect. 
Treatment with scaffold alone improved defect stability at 16 weeks compared to non-
treatment but did not achieve bone union or restoration of mechanical function. 
Augmentation of scaffolds with BMP-2 and TGF-β3 significantly increased bone 
formation at both 4 and 16 weeks compared to non-treatment but only produced bone 
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bridging of the defect region in 2 of 6 cases. Mineralization was observed to form first at 
the periphery of the scaffolds followed by more limited mineral deposition within the 
scaffold interior, suggesting that the cells participating in the initial healing response 
were primarily periosteal-derived. This study introduces a challenging segmental defect 
model that facilitates quantitative evaluation of strategies to repair critically-sized bone 
defects. Healing of the defect region was improved by implantation of structural 
polymeric scaffolds infused with growth factors incorporated within RGD-alginate, 
however, functional integration of the constructs appeared to be limited by continued 
presence of the slow-degrading scaffolds and perhaps suboptimal dose or delivery of 
osteoinductive signals.  
 
3.2 Introduction 
Large osseous defects pose a significant treatment challenge to orthopaedic 
surgeons and nonunion is common [BORRELLI 2003, WERNTZ 1996]. Although the 
gold standard treatment is autologous bone grafting, this procedure is constrained by the 
inability to obtain large structural grafts for transplantation and significant donor site 
morbidity. As a result, the clinical use of processed cadaveric allografts continues to 
increase [LUCARELLI 2005, WHEELER 2005]. However, allografts do not repair as 
quickly or completely as autografts and carry some risk of disease transmission.  The 
destruction of live cells during tissue processing is a primary factor responsible for the 
loss of osteogenic properties, and the dense nature of cortical bone allografts impedes 
revascularization and cellular invasion from the host following implantation 
[ENNEKING 2001, ITO 2005, WHEELER 2005]. This limited ability to revascularize 
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and remodel is believed to be responsible for the 25% clinical failure rate and 30-60% 
complication rate associated with allograft implantation [LUCARELLI 2005, WHEELER 
2005].   
Tissue engineering strategies that include a porous structural scaffold with or 
without delivery of biological components provide a possible approach to the 
development of effective bone graft substitutes. The critically-sized segmental defect 
model can serve as a robust test bed for tissue-engineered bone regeneration strategies, 
even in small animals such as rats [BRAUN 1992, BRUDER 1998 Clin Orthop, CHEN 
2002, LIEBERMAN 1999 JBJS, LEE 1994, OHURA 1999, WERNTZ 1996, YASKO 
1992]. Although most segmental defect repair studies have focused on radiographic 
evaluation of healing, more quantitative measures of functional integration may provide 
an improved ability to benchmark different strategies for bone regeneration.  In addition 
to biomechanical testing to quantify functional integration of bone repair constructs, in 
vitro or in vivo microcomputed tomography (micro-CT) imaging can be applied to 
quantify the ingrowth of mineralized matrix into bone defects [CASE 2003, GULDBERG 
1997].     
The composition and architecture of biomaterial scaffolds are important variables 
that strongly affect the repair response.  Although ceramic scaffolds composed of 
hydroxyapatite or tri-calcium phosphate are by composition an attractive option, they are 
typically limited by brittleness, incomplete interconnectivity, and relatively low porosity. 
When implanted in vivo, ceramics may in fact sustain enough damage under repeated 
loading to fracture [BRUDER 1998 JBJS]. In order to achieve more desirable mechanical 
properties and more controllable architecture, polymeric or composite scaffolds may be 
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custom manufactured to meet the functional requirements at the defect site [ZEIN 2002].  
However, the ability of structural polymeric scaffolds to promote the repair of large 
critically-sized defects – alone or in combination with bioactive factors – is not well 
established.  
Growth factors, such as members of the bone morphogenetic protein (BMP) 
family, are frequently used at very high doses to treat osseous defects [YASKO 1992, 
SWIONTKOWSKI 2006, BURKUS 2002]. It has been shown previously, however, that 
delivery of two growth factors together, specifically BMP-2 and transforming growth 
factor β3 (TGF-β3), can result in a synergistic interaction that promotes bone formation 
at relatively low doses of total delivered protein in the presence of bone marrow stromal 
cells [SIMMONS 2004]. This work, however, was done in an ectopic mouse model of 
osteogenesis and the potential for co-delivered growth factors to promote functional 
repair in a critically-sized segmental bone defect model has not been previously 
investigated. 
One essential element contributing to the viability of an implanted tissue-
engineered construct is the development of a vascular supply to the implant that will 
provide nourishment and biological cues for cells migrating into or previously seeded 
onto the scaffold. In order to develop an efficacious tissue-engineered bone replacement, 
it is important to understand the process of and factors affecting vascular ingrowth into 
the defect site. Although traditional methods have relied on histological methods to 
quantify vascular structure density, recent use of micro-CT coupled with perimortem 
perfusion of a radio-opaque contrast agent provides a promising and more facile 
alternative method [DUVALL 2004]. This technique was developed and characterized in 
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a mouse model, and some adaptation would be required for application to a larger rodent 
model, such as the rat.  
 The goals of this study were to establish a segmental bone defect test bed model 
that allowed in vivo micro-CT analysis, to test the ability of structural polymer scaffolds 
to promote bone repair and restore mechanical function in the rat femur, and to establish 
the feasibility of a hindlimb vascular perfusion procedure. Polymeric scaffolds having 
longitudinally oriented porosity aligned with the direction of healing were tested with and 




3.3.1 Scaffold Production 
Poly(L-lactide-co-D,L-lactide 70:30) (PLDL) cylindrical scaffolds with 
longitudinally oriented porosity (4 mm φ x 8 mm L) were created using previously 
described methods [LIN 2003].   Briefly, 100 micron removable fibers coated with a 
mixture of PLDL and the porogen azodicarbonamide were used to create oriented 
macroporosity, while decomposition of the porogen with the addition of heat produced 
random microporosity.  Prior to implantation, the PLDL scaffolds were sterilized by 
gamma-irradiation (2.5 Mrad). The scaffolds were then wetted with 70% ethanol and 
rinsed in saline prior to vacuum coating with 25 µg/ml rat plasma fibronectin (F0635; 
Sigma-Aldrich) overnight to improve cell adhesion capability. Excess fibronectin was 





3.3.2 Addition of Growth Factor to Scaffolds 
Sterile recombinant carrier-free BMP-2 and TGF-β3 (355-BM/CF and 243-
B3/CF, R&D Systems, Minneapolis, MN) were reconstituted in 4 mM HCl immediately 
prior to use. MVG sodium alginate (Pronova Biopolymers, Norway) was gamma-
irradiated at a dose of 5 Mrad to produce a short chain length alginate powder. The short 
chain alginate was then functionalized with a G4RGDSP sequence at a density of 2 RGD 
sequences per chain using carbodiimide chemistry [SIMMONS 2004]. The RGD-alginate 
was sterile filtered and lyophilized. For use in the PLDL scaffold system, RGD-alginate 
was reconstituted to a concentration of 2%, containing either BMP-2 and TGF-β3 or no 
growth factor. Fibronectin-coated PLDL scaffolds were placed into cylindrical molds 
with a CaCl2-wetted membrane on the bottom surface. A volume of 50 µl RGD-alginate 
containing either 200 ng BMP-2 and 20 ng TGF-β3 (growth factor-treated group) or no 
growth factor (scaffold only group) was pipetted into each scaffold, and a CaCl2-wetted 
membrane was placed on top of the scaffold in the cylindrical mold. After 20 minutes, 
the scaffolds were removed from the molds and placed into a sterile CaCl2 bath for an 
additional 20 minutes to allow full cross-linking of RGD-alginate within the scaffold.  
 
3.3.3 Surgical Technique 
All surgical techniques and procedures were reviewed and approved by the 
Institutional Animal Care and Use Committee at Georgia Institute of Technology 
(Protocol #A03017). The study presented here tested the effects of implanting plain or 
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growth factor augmented PLDL scaffolds on mineralized matrix formation and 
mechanical properties within an 8 mm gap defect. Female Sasco Sprague-Dawley rats 
(Charles River Labs, Wilmington, MA) aged 13 weeks were anesthetized using 
isoflurane. Taking an anterior approach, bilateral incisions were made over the length of 
the femurs. Each limb received a custom modular fixation plate secured directly to the 
femur using four miniature screws (J.I. Morris Co, Southbridge, MA). Bilateral full-
thickness diaphyseal segmental defects 8 mm in length were created using a miniature 
oscillating saw and flushed with saline (Figure 1). Defects received one of the following 
three treatments: no scaffold (empty treatment group) (n = 7), a PLDL scaffold (n = 15), 
or a PLDL scaffold augmented with 200 ng BMP-2 and 20 ng TGF-β3 co-delivered in 
RGD-alginate (n = 6). Animals were given 0.05 mg/kg buprenorphine subcutaneously 
every 12 hours for the first 48 hours post-op. Within 2-3 days post-op, the animals 























Figure 1: Rat femur with attached fixation plate assembly and 8 mm defect.  
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3.3.4 X-ray and Micro-CT 
Two-dimensional in vivo digital X-rays (Faxitron MX-20 Digital; Faxitron X-ray 
Corporation, Wheeling, IL) were taken at five time points: 3 days post-op and 4, 8, 12, 
and 16 weeks post-op. These X-rays provided a qualitative assessment of healing and 
defect stability over time. Rates of union were assessed by two blinded observers. Union 
was considered to occur when a visible bridge of bone extended completely across the 
length of the defect site.  
Quantitative 3-D analysis of bone ingrowth in 8 mm defects was performed at 4 
and 16 weeks post-op using an in vivo micro-CT system (Viva-CT 40; Scanco Medical, 
Bassersdorf, Switzerland) at a 38.5 µm voxel resolution (in vivo scans) and 20 µm 
resolution (in vitro scans). After scanning, a constant volume of interest (VOI) centered 
over the defect site was selected for analysis of all samples. Two VOIs were analyzed; 
the in vivo VOI was 118 slices thick (approximately 4.6 mm thick) and centered over the 
defect longitudinally while the in vitro VOI was 400 slices thick (approximately 8 mm). 
A Gaussian filter (sigma = 1.2, support = 1) was used to suppress noise in the VOI prior 
to application of a consistent global threshold corresponding to 272 mg 
hydroxyapatite/cm3. The threshold was selected manually using evaluations of ten single 
tomographic slices to isolate the bone tissue and preserve its morphology while excluding 
soft tissues and polymer scaffold. The exclusion of soft tissues and polymer using this 
threshold was verified by plotting a histogram of voxel attenuation versus threshold 
values. The selected threshold of 272 mg hydroxyapatite/cm3 was consistently found to 
lie outside of the range of values corresponding to soft tissue and polymer. Applying this 
global threshold to the VOI, object (bone) volume and total volume were computed as 
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total number of voxels multiplied by voxel volume (a direct measurement that does not 
assume any particular microstructural morphology). 
For post-mortem (in vitro) micro-CT imaging only, spatial analysis of the 
mineralized matrix was conducted. Bone formation in the proximal 4 mm of the defect 
was compared to that in the distal 4 mm of the defect. The amount of mineral in the core 
2 mm of the scaffold was also compared to that in the edges of the scaffold and 
surrounding matrix (periphery). Spatial analysis wasn’t done on in vivo images due to the 
small VOI. The distribution of mineral in the proximal and distal halves of the in vivo 
VOI is generally homogeneous. Additionally, the angle at which the femur must be 
scanned in order to permit travel of the animal’s body into the bore of the Viva-CT 40 is 
such that core vs. periphery analysis is not possible – the long axis of the femur lies at a 
variable angle.  
  
3.3.5 Mechanical Testing 
After euthanasia at 16 weeks post-op, samples were harvested and wrapped in 
saline-soaked gauze for subsequent storage at -20°C. Prior to mechanical testing, the 
samples were allowed to thaw to room temperature in a saline bath before removal of the 
gauze. The samples were subjected to torsion using a servohydraulic mechanical testing 
system (858 MiniBionix II load frame; MTS, Eden Prairie, MN). The ends of the femurs 
were potted using Wood’s Metal (033218-36; Alfa Aesar, Ward Hill, MA) and pinned 
through the potting blocks. The potted femurs remained wrapped in saline-soaked gauze 
to maintain hydration of the tissues during testing. Samples were loaded into the testing 
system and the bridging components of the plates were removed along with the gauze. 
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Samples were then tested at a rate of 3°/sec to failure. Age-matched intact femurs were 
also tested for comparison.  
 
3.3.6 Vascular Perfusion 
In a small 5 mm defect pilot study, vascularization within the defect region was 
quantified at 16 weeks post-op. Animals (n=3) were anesthetized and the abdominal aorta 
was catheterized for this terminal procedure. Heparin (H0777; Sigma-Aldrich) was 
delivered via the catheter. All blood was flushed from the hindlimbs with saline and 
exited through a vent in the inferior vena cava. A 10% neutral-buffered formalin wash 
was perfused to fix the vessel walls. After a saline rinse, the vasculature was finally filled 
with a radio-opaque silicone-based contrast agent (Microfil MV122; Flowtech Inc., 
Carver MA). The contrast agent was allowed to polymerize before the femurs were 
harvested and formalin fixed.  Each femur was scanned in vitro to obtain a composite 3D 
image of mineralized matrix and vascularity.  The samples were subsequently decalcified 
and micro-CT imaged again at a 20 µm voxel size to produce a 3D reconstructed image 
of vascular ingrowth. 
 
3.3.7 Histology 
 One sample from each treatment group was selected for histological analysis. 






Analysis of variance was performed using a general linear model and Tukey 
pairwise post-hoc comparisons (Minitab).  Differences between variables measured for 
scaffold-treated and control defects were considered significant at p ≤ 0.05 and a trend at 




3.4.1 Scaffold Characterization 
The scaffolds produced were transversely isotropic with longitudinally oriented 
macropores (Figure 2). Micro-CT quantification of scaffold parameters revealed that the 
resulting scaffold porosity averaged 77%  A previously described method involving 3-D 
image inversion and discrete component labeling indicated that the porosity was over 
99% interconnected, verifying that porogen decomposition did not produce isolated 
bubbles within the polymer struts [LIN 2003]. Analysis of strut morphology showed an 
average thickness of 0.08 mm and spacing (i.e. pore size) of 0.38 mm. The mechanical 
properties of the scaffolds after irradiation included a mean elastic modulus of 63.35 ± 






Figure 2: Micro-CT and electron microscopy images of PLDL scaffolds. 
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3.4.2 X-ray Imaging 
Monthly Faxitron X-ray images beginning at week 4 were used to qualitatively 
track the progression of bone ingrowth into the defect region (Figure 3). In untreated 
(empty) control defects, the cut ends of the femurs were consistently rounded off with a 
small amount of appositional bone formation, and bridging of the defects was never 
observed.  In contrast, X-ray images showed progressive infiltration of mineralized tissue 
into scaffold-treated defects over the 16 week in vivo implantation period.  Mineral 
deposition typically initiated at the periosteal surface and the proximal end of the defect, 
forming a sheath-like structure around the ends of the scaffolds. At 16 weeks, 
mineralized tissue was observed to form within the scaffold pore space as well. However, 
PLDL treatment resulted in bridging of the defect site with mineralized tissue in only two 
cases. Augmentation of the scaffolds with 200 ng BMP-2 and 20 ng TGF-β3 resulted in 
apparently denser mineralized matrix formation within the defect site, proceeding 
similarly to PLDL only treated defects, with union occurring in 33% (2 of 6) samples as 



















Figure 3: Digital X-ray images of femurs from each of the three treatment groups. Rates 
of bony union were: 2/6 for the 200/20 dose BMP-2/TGF-β3 augmented group and 2/12 






























3.4.3 Micro-CT Analysis 
In Vivo Micro-CT Analysis of Bone Formation 
In vivo micro-CT imaging permits quantitative 3-D analysis of bone ingrowth into 
the central region of the defect within the same animal at multiple time points. Bone 
volume (BV) was therefore quantified within a consistent VOI centralized in the 8 mm 
defect region for each group and compared at 4 and 16 weeks post-op (Figure 4). There 
was a significant increase in BV overall with time. Within treatment groups, defects 
treated with PLDL scaffolds showed a significant increase in BV from 4 to 16 weeks, as 
did the growth factor augmented treatment group, while there was no increase in bone 
volume from week 4 to week 16 in the empty defect control group. Compared to empty 
defects, implantation of scaffold alone did not significantly increase BV at either time 
point, while the scaffold plus growth factor group significantly improved repair at both 4 
















Figure 4: Average bone volumes at 4 and 16 weeks post-op for the three treatment 
groups. * denotes p < 0.05 for an increase in bone volume from 4 to 16 weeks within a 
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In Vitro Micro-CT Analysis of Bone Formation 
Micro-CT imaging done post-mortem and immediately prior to mechanical testing 
yielded similar results as were seen in the week 16 in vivo micro-CT calculations in terms 
of mature bone volume (Figures 5 and 6). The difference in bone volumes between the 
growth factor augmented group and the empty defects group was statistically significant 
(p = 0.009). Spatial analysis of the defect regions demonstrated that augmenting the 
scaffold with the 200/20 dose of BMP-2/TGF-β3 significantly improved mineralized 
matrix within the core of the scaffold as compared to delivery of the scaffold alone or 
non-treatment (empty defects) (Figure 7). The amount of bone forming within the 
periphery of the scaffold and the area immediately surrounding the scaffold was 
significantly improved in the growth factor augmented group as compared to non-
treatment (Figure 7). The bone volume fraction (BVF), or percent of the VOI filled with 
mineralized tissue, was significantly elevated in the 200/20 dose growth factor treatment 
group as compared to the empty defect group for the peripheral VOI (Figure 8). 
Additionally, the delivery of low-dose growth factors significantly improved the 
formation of bone on the proximal half of the defect as compared to empty defects. Bone 












Figure 5: Post mortem bone volumes (16 weeks) for the entire defect region (5 ≤ n ≤ 10). 
While implantation of a plain PLDL scaffold did not significantly enhance mineral 
deposition over non-treatment, addition of 200 ng BMP-2 and 20 ng TGF-β3 did 










Figure 6: Micro-CT images of the defect region taken post mortem. Left, mineral in an 
empty defect shows only a small amount of appositional bone formation. Middle, some 
infiltration of mineral into the scaffold porosity is evident. Right, mineralized matrix is 









































































Figure 7: Spatial distribution of post mortem bone volumes (5 ≤ n ≤ 10). Volumes of 
interest are separated as the core (central 2 mm) and periphery (external 2 mm of scaffold 
and adjacent periphery) along the 8 mm length of the defect. The treatment group 
receiving the 200/20 dose of BMP-2/TGF-β3 had significantly improved mineral 
volumes in both the core and periphery as compared to empty (untreated) defects. 
Augmentation of the PLDL scaffold with the low dose of BMP-2/TGF-β3 significantly 










Figure 8: Spatial distribution of post mortem bone volume fractions (5 ≤ n ≤ 10). 
Volumes of interest are separated as the core (central 2 mm) and periphery (external 2 
mm of scaffold and adjacent periphery) along the 8 mm length of the defect. The 
treatment group receiving the 200/20 dose of BMP-2/TGF-β3 had a significantly 
improved peripheral bone volume fraction as compared to the empty (untreated) group. 




















core p = 0.007, periphery p = 0.015
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Figure 9: Spatial distribution of post mortem bone volumes along the long axis of the 
femur (5 ≤ n ≤ 10). There was significantly more mineral in the proximal end of the 
defect in the group treated with a scaffold and 200 ng BMP-2/20 ng TGF-β3 than in the 
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In Vitro Micro-CT Analysis of Vascular Structures 
 In the 5mm defect pilot study, in vitro micro-CT was performed on three perfused 
samples before and after decalcification to isolate the vascularity and demonstrate the 
feasibility of the technique (Figure 10). The protocol for this perfusion technique was 
adopted from previously published work using a mouse model of hindlimb ischemia, and 
is described in Appendix D [DUVALL 2004]. Micro-CT done before decalcification 
gives images and quantitative information regarding the bone and vascular structures 
together. Imaging of samples after decalcification permits quantification of vascular 
structures alone (vascular volume) (Figure 11). Using a strictly defined VOI enables 
estimation of the bone volumes that can be obtained by subtracting the vascular volumes 
from the combined object volume of the bone and vasculature together. Although the 
small sample size precluded statistical analysis, a small elevation in vascular volume was 
observed in PLDL-treated defects as compared to empty defects (20.7 mm3 for PLDL-











Figure 10: In vitro micro-CT quantification of vascular structures in decalcified samples. 
Statistical significance was not determined due to the small sample size (n = 3). The 
results served primarily to establish that perfusion of the hindlimb defect area was 











Figure 11: Images taken from in vitro micro-CT quantification of vascular structures in 
decalcified samples. There appears to be somewhat more vasculature in the PLDL-treated 
defect than in the empty defect, although the sample size was not adequate to permit 












































3.4.4 Mechanical Testing 
Torsional mechanical testing was performed on samples harvested at 16 weeks 
post-op. Even at this late time point, empty control defects were found to have negligible 
resistance to torsional deformation with both strength and stiffness below the resolution 
of the mechanical testing system.  In contrast, PLDL-treated 8 mm defects reached an 
average maximum torque of 0.0402 ± 0.019 N-m (Figure 12) and stiffness of 0.0003 ± 
0.00019 N-m/deg (Figure 13). Although most PLDL-treated samples did not achieve 
bony union across the defect, sufficient integration of the scaffold into the defect site had 
occurred to permit torsional testing of these samples. All failures occurred at the distal 
scaffold-bone interface, consistent with observation of greater bone formation at the 
proximal end.  Augmentation of the scaffolds with BMP-2 and TGF-β3 yielded a further 
increase in mechanical properties, however the differences in maximum torque and 
stiffness were not statistically significant (Figures 12 and 13, Table 1). Although scaffold 
and growth factor treatment resulted in an improvement in mechanical function over 
empty defects, maximum torque and stiffness remained approximately an order of 
magnitude lower than those measured for age-matched intact femurs (0.4932 N-m and 










Figure 12: Average maximum torque for PLDL and 200/20 dose BMP-2/TGF-β3 
augmented groups at 16 weeks (5 ≤ n ≤ 10). The difference in maximum torque between 











Figure 13: Average stiffness for PLDL and 200/20 dose BMP-2/TGF-β3 augmented 
groups at 16 weeks (5 ≤ n ≤ 10). The difference in stiffness between the two treatment 

























































































Empty 1.8538 (n=7) 2.1397 (n=6) NA NA 
PLDL 5.1639 (n=15) 17.6466 (n=12) 0.3 (n=8) 40.2 (n=8) 
PLDL + 200/20 Dose 
Growth Factors 
9.8809 (n=6) 31.6099 (n=6) 0.8 (n=5) 56.9 (n=5) 
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3.4.5 Histology 
 Staining of 8 mm defects indicated that, in empty defects, the defect site was 
filled by loosely organized fibrous tissue with no indication of bony bridge formation 
(Figure 14). PLDL-treated defects showed invasion of highly cellular tissue into the 
porosity of the scaffold, with limited mineralized tissue infiltration into the scaffold 
longitudinal macropores primarily at the proximal end of the defect (Figure 15). 
Consistent with the healing response to segmental bone grafts, most bone formation 
occurred around the periphery of the scaffold. Masson’s trichrome and von Kossa 
staining of undecalcified sections confirmed formation of mineralized matrix along the 
periphery of the implanted scaffold with some bone ingrowth into the macropores, and 
that the empty defects were filled with fibrous tissue. Residual scaffold material was 
visible in PLDL-treated defects at 16 weeks post-op. The BMP-2 and TGF-β3 treatment 
group exhibited results similar to the scaffold only treatment group – mineralized matrix 
formation along the periphery of the scaffold and to a lesser extent within the porosity of 
the scaffold (Figure 16). There were no signs of an inflammatory reaction to the scaffold 
















Figure 14: Histological sections taken from an empty defect; top row H&E, lower row 
Masson’s trichrome. In H&E stains, tissue stains varying colors of pink (with mineralized 
matrix showing as bright pink at either end of the image) and the cell nuclei stain dark 
purple. In Masson’s trichrome, muscle fibers stain red, bone and other collagenous 
tissues stain blue, and cell nuclei stain dark purple. The remains of the femur at the 
cutting interface can be seen as the blue squared-off structure at the right end of the 




















Figure 15: Histological sections taken from scaffold-treated defect; top row H&E, middle 
row Masson’s trichrome, lower row von Kossa. In H&E stains, tissue stains varying 
colors of pink (with mineralized matrix showing as bright pink at either end of the image) 
and the cell nuclei stain dark purple. A hole remains where one of the screws for the 
fixation plate was placed. In Masson’s trichrome, muscle fibers stain red, bone and other 
collagenous tissues stain blue, and cell nuclei stain dark purple. The remains of the femur 
at the cutting interface can be seen as jagged bright blue structures at the ends of the 
image. In von Kossa staining, mineral is represented by black areas with a haematoxylin 


















Figure 16: Histological sections taken from a defect augmented with 200 ng BMP-2 and 
20 ng TGF-β3; top row H&E, middle row Masson’s trichrome, lower row von Kossa. In 
H&E stains, tissue stains varying colors of pink (with mineralized matrix showing as 
bright pink at either end of the image) and the cell nuclei stain dark purple. A hole 
remains where one of the screws for the fixation plate was placed. In Masson’s trichrome, 
muscle fibers stain red, bone and other collagenous tissues stain blue, and cell nuclei stain 
dark purple. The remains of the femur at the cutting interface can be seen at the ends of 
the image. Muscle tissue is not seen in this image as the scaffold has excluded it from the 
defect region. In von Kossa staining, mineral is represented by black areas with a 
haematoxylin counterstain. The results parallel those of Masson’s trichrome. 
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3.5 Discussion 
Long-term success of clinical treatments for repair of large segmental bone 
defects relies heavily on achieving stable union and subsequent promotion of bone 
remodeling. Although increasingly used clinically because of its desirable size and 
structural properties, processed allograft bone provides a suboptimal solution due to the 
lack of living cells and low porosity, resulting in a high rate of re-fractures within one to 
two years [ITO 2005]. In these studies, a structural polymer scaffold with oriented 
porosity designed to facilitate bone ingrowth was evaluated as a bone graft substitute in a 
critically-sized rat segmental defect model.  Micro-CT based methods were established to 
quantify 3-D mineralized matrix ingrowth into the implanted scaffolds.  These 
quantitative methods in combination with biomechanical evaluation of functional 
integration provide a robust approach to evaluate and benchmark different approaches to 
segmental bone repair. 
The standard rat segmental defect model, originally used by Nottebaert et al., was 
modified to achieve highly stable fixation of a reproducible critically-sized 8 mm femoral 
segmental defects while permitting in vivo micro-CT and X-ray imaging 
[NOTTEBAERT 1989]. The custom modular fixation plates are designed with an offset 
from the bone to permit tissue infiltration from the entire periphery of the defect. The 
fixation plates are comprised of three components; two stainless steel anchor plates that 
affix directly to the bone via miniature screws and one polymer bridging plate that is 
secured to the stainless steel plates. This modular design provides a radiolucent window 
that permits in vivo micro-CT and X-ray imaging. The unique design also facilitated 
removal of the polymer bridging plate for torsional testing without causing damage to the 
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bone or repair tissue, as it was connected only to the anchor plates, which remained intact 
and fixed to the femur. The fixation plate assembly also serves as a cutting guide that 
enables the surgeon to create consistent and uniformly sized defects. The large size, 
stability, and consistency of the 8 mm defect used resulted in a highly consistent model of 
defect nonunion. The advantages of using a small animal model include the ability to use 
high-resolution in vivo imaging techniques and the potential to house larger sample sizes 
within the study than are typically used in larger animal models such as canines. Among 
the disadvantages is the possibility that certain processes, such as revascularization, may 
be less relevant and difficult to rigorously assess as the net size of the defect is 
significantly smaller than what can be achieved in larger animal models. In an attempt to 
compensate for the inherent limitations and scaling problems of a small animal model, 
the segmental femoral defect has been made as large as possible.  
The sequential imaging strategy of multiple in vivo micro-CT scans for 
quantification of bone formation facilitated direct comparisons within the same animal at 
multiple time points, reducing the number of animals required and variability within 
treatment groups. Longitudinal scanning was done at 4 and 16 weeks post-op in 8 mm 
defect samples, permitting direct study of the changes in bone volume within the same 
sample population. Although longitudinal micro-CT scanning is very useful, repeated X-
ray exposure may have an effect on the repair response.  However, the size and resolution 
of the images produced in these studies produced an estimated local dose of 0.17 Gy per 
scan. This dose is well below the dosages (4 Gy or greater) that have been shown to 
inhibit cell proliferation and growth factor production by cells in vitro [DUDZIAK 2000]. 
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Bone volume within empty defect controls was minimal and did not increase from 
4 to 16 weeks, confirming that 8 mm represents a critically-sized defect in the rat. This is 
consistent with several previous studies that have used segmental bone defects in the rat 
model ranging from 5 to 8 mm [BRAUN 1992, BRUDER 1998 Clin Orthop, BRUDER 
1998 JOR, CHEN 2002, FEIGHAN 1995, HOLLINGER 1990, ISOBE 1999, 
LIEBERMAN 1999 JBJS, NOTTEBAERT 1989, OAKES 2003, OHURA 1999, 
STEVENSON 1994, WERNTZ 1996, YASKO 1992]. Typically, 5 mm defects achieve a 
spontaneous union rate ranging from 10-50%; the 100% rate of non-union in untreated 
defects here suggests that the 8 mm defect is sufficient in size to achieve a critically-sized 
model [WERNTZ 1996, NOTTEBAERT 1989]. Bone ingrowth into PLDL scaffolds, 
with or without growth factors, increased significantly from 4 to 16 weeks. However, 
micro-CT and mechanical testing data clearly indicated that PLDL scaffold treatment was 
necessary, but alone was insufficient to consistently bridge the defect region and restore 
the functional properties of the femur. It is possible that consistent bone union could be 
achieved in this model by using different scaffold materials or architectures or by waiting 
longer than 4 months. However, in this study, Faxitron scans qualitatively suggested that 
although bone density continued to increase between 8 and 16 weeks, the extent of 
immature ingrowth was largely determined by 8 weeks. All of the defects found to be 
bridged by mineralized matrix at 16 weeks, for example, had a similar distribution of 
slightly lower density tissue ingrowth at 8 weeks. These data suggest that the presence of 
an appropriate scaffold template is necessary but not sufficient to restore long bone 
function in the 8 mm rat defect model.     
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These results were consistent with several previous studies that demonstrated the 
need for biological enhancement of porous scaffolds to repair large segmental bone 
defects. Bruder et al. implanted hydroxyapatite/tricalcium phosphate (HA/TCP) ceramic 
cylinders into defects and found healing dominated by fibrous tissue formation and 
minimal integration at the cut bone-scaffold interfaces. The addition of mesenchymal 
stem cells to the HA/TCP implants improved the bone repair response [BRUDER 1998 
JOR]. Work by Feighan et al. showed that addition of demineralized bone matrix gel to 
HA/TCP scaffolds resulted in increased bone formation as compared to the delivery of 
HA/TCP alone, with neither group achieving functional union [FEIGHAN 1995]. Isobe 
et al. treated segmental defects with PLGA capsules containing PLGA particles with or 
without BMP-2 within the defect site [ISOBE 1999]. This treatment resulted in osseous 
union only in the BMP-2 treated groups. Overall, the evidence points to the necessary 
addition of a biological component to implanted scaffolds in order to promote union of 
large bone defects [BRUDER 1998 JOR, FEIGHAN 1995, ISOBE 1999, LIEBERMAN 
1999 JBJS, LEE 1994, NOTTEBAERT 1989, OAKES 2003, OHURA 1999, 
STEVENSON 1994, YASKO 1992].  However, the optimal strategy for safe and 
effective biological enhancement of scaffolds has not yet been determined. 
The addition of low dose of co-delivered growth factors (200 ng BMP-2 and 20 
ng TGF-β3) to a scaffold induced greater mineralized matrix formation within the defect 
and a higher rate of bone bridging across the defect than non-treatment. Growth factor 
augmentation of the scaffold significantly improved bone volume within the core of the 
scaffold over core bone volumes in the other two treatment groups. Peripheral bone 
volume was significantly increased between the growth factor group and the empty 
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group, but not between the scaffold group and the growth factor group. Bone volume 
within the core 2 mm diameter of the scaffold was significantly enhanced by addition of 
BMP-2/TGF-β3 over delivery of a scaffold alone. It is possible that the scaffold provides 
a physical path down which marrow-derived osteoprogenitors can migrate, and that 
addition of physiologic doses of BMP-2 and TGF-β3 are sufficient to enhance this 
marrow cavity response. This suggests that even at very low doses, the growth factors are 
capable of encouraging more evenly-distributed mineralization than is achieved with 
scaffold delivery alone. Additionally, proximal bone volume was affected by treatment 
while distal bone volume was not. These data suggest that the periosteal response, which 
is the likely source for osteoprogenitors contributing to the peripheral bone volume, is 
stimulated by the presence of the scaffold, but that augmentation with the low dose (200 
ng BMP-2 and 20 ng TGF-β3) of growth factor is insufficient to stimulate the pre-
osteoblastic cells to regenerate a full mineralized callus around the implant. Anecdotally, 
it is known that in segmental defect models there tends to be a stronger response to 
treatment on the proximal end of the defect region. The reason for this is not known, 
although it has been hypothesized that the distal end may suffer more necrosis than the 
proximal end due to differences in the vascularity of the tissue. The reason for this 
phenomenon merits further investigation. 
The growth factor augmented constructs, however, failed to consistently produce 
bone union across the defect and did not significantly improve torsional strength relative 
to the scaffold only group. Although the low dose of co-delivered growth factors tested 
has been shown previously to induce osteogenesis in an ectopic model, this study 
suggests that a higher dose of BMP-2 and TGF-β3, or some other combination of growth 
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factors, is required to restore function to large orthotopic defects [SIMMONS 2004]. In a 
challenging environment such as the segmental defect, much higher doses of growth 
factor have traditionally been used (9-20 µg of growth factor) [YASKO 1992, 
LIEBERMAN JBJS 1999]. It is possible that requirement for these extremely high doses 
of growth factor may be decreased through combining growth factors that demonstrate 
synergistic or additive interactions or by employing sustained release strategies. The need 
to use high doses of growth factors has been one aspect of traditional investigations that 
has slowed the translation of growth factor therapy into the clinical setting. If the efficacy 
of lower doses of growth factor can be demonstrated, it may facilitate the clinical use of 
growth factor therapies for bone repair.  
The slow degradation rate of the PLDL scaffolds used in this study may have also 
impeded mineralized matrix formation into the defect region. Scaffold modifications to 
accelerate degradation such as the addition of ceramic particles that increase the surface 
area available for hydrolysis may therefore improve functional repair of segmental 
defects. Matching the degradation rate of the scaffold to the rate of mineralized matrix 
deposition is important in maintaining structural integrity of the defect while still 
promoting functional osseous union. Scaffold pore geometry may also play an important 
role. Both histological and micro-CT images showed progressive infiltration of bone into 
the longitudinal macropores of the scaffold, while radial ingrowth appeared to rely on 
scaffold degradation from the periphery inward.   
Rather than relying on histological methods, quantitative analysis of vascular 
structures was achieved using a terminal perfusion procedure coupled with 
decalcification of samples and subsequent in vitro micro-CT imaging. The sample size 
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was insufficient to conduct statistical analysis, as the pilot study was done strictly to 
demonstrate the feasibility of the technique for use in quantifying vasculature within the 
implant. Decalcification substantially improved the ability to isolate and analyze 3D 
vascular ingrowth since segmentation of mineralized bone from perfused vasculature is 
difficult (in segmenting the bone out of the image, the integrity of the continuous voxels 
representing the vascular structures is diminished). Good agreement between micro-CT 
based vessel density calculations and traditional histomorphometric measurements has 
previously been shown [DUVALL 2004]. Combining this vascular imaging method with 
in vivo micro-CT analysis of bone ingrowth allows evaluation of 3D mineralization and 
vascularization within the same defects.  However, a limitation of the combined in vivo/in 
vitro scanning technique is that the decalcification step required for vascular imaging 
precludes subsequent biomechanical testing. 
This study established a challenging rat segmental bone defect model compatible 
with in vivo micro-CT imaging to quantify longitudinal 3-D mineralized matrix ingrowth. 
Healing of the defect region was improved by implantation of structural polymeric 
scaffolds infused with growth factors incorporated within RGD-alginate, however, 
functional integration of the constructs appeared to be limited by continued presence of 
the slow-degrading scaffolds and perhaps suboptimal dose or delivery of osteoinductive 
signals. Subsequent chapters will focus on quantifying dose-dependent effects of co-
delivered growth factors on the ability of porous polymer scaffolds to restore function to 





DOSE-DEPENDENT AND INTERACTION EFFECTS OF DUAL OSTEOGENIC 




 The delivery of bioactive proteins within porous biomaterial scaffolds represents a 
potential alternative treatment strategy to bone grafting.  Given the complex temporal and 
spatial expression of multiple growth factors during bone repair, an approach involving 
sustained co-delivery of proteins may be advantageous.  In this study, an oriented 
polylactide scaffold was used to provide structural support to 8 mm rat segmental bone 
defects and combined with RGD alginate containing BMP-2 and TGF-β3.  These two 
growth factors have previously been shown to interact synergistically in an ectopic model 
of osteogenesis. A previously established critically-sized femoral defect model in rats 
was employed to assess the ability of these growth factor-infused constructs to bridge 
large bone defects and restore limb functionality. A dose-dependent increase in bone 
volume and mechanical properties was seen with co-delivery of the growth factors to the 
defect site (233% increase in bone volume, 160-200% increase in mechanical properties). 
The higher dose, 2000 ng BMP-2 and 200 ng TGF-β3, was more efficacious than the low 
dose treatment (200 ng BMP-2 and 20 ng TGF-β3), particularly at increasing bone 
volume at the early (4 week) time point. These data indicate that by exploiting growth 
factor interactions, low doses of total growth factor can successfully be used to promote 
bony union and improve functional integration of a bone graft substitute into a large 
osseous defect located at a load-bearing site. 
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4.2 Introduction 
 Bone loss due to traumatic injury, disease, or fracture complications poses a 
challenge for orthopaedic treatment. Issues such as open tibial shaft fractures and spinal 
fusions require frequent surgical intervention. Use of traditional approaches to treating 
these defects has frequently required secondary revision surgeries to address nonunions 
or pseudarthrosis at the treatment site. Delayed union and nonunion are common results 
of traumatic bone damage in which a significant defect is created [BORRELLI 2003, 
WERNTZ 1996, SWIONTKOWSKI 2006]. Although autografting is the gold standard 
treatment, this procedure is constrained by the lack of available donor material, an 
inability to obtain a structural graft, and considerable donor site morbidity. Thus, the 
allograft is the popular and facile solution to the problem of significant bone loss, 
although subject to a high rate of re-fracture and gross failure within a relatively short 
time period (2 years) post-engraftment [LUCARELLI 2005, WHEELER 2005, ITO 
2005]. This re-fracture incidence is due in large part to a lack of graft integration into the 
remaining host bone [ENNEKING 2001, ITO 2005, WHEELER 2005]. Lack of porosity 
within the allograft inhibits revascularization and revitalization of the allograft tissue, 
resulting in a propensity to accumulate microdamage that may ultimately lead to 
catastrophic graft failure (25% clinical failure rate) or contribute to the 30-60% 
complication rate associated with allografts [LUCARELLI 2005, WHEELER 2005]. 
Complications frequently result in treatment of defect nonunions or delayed unions, often 
necessitating revision surgery and significantly impacting patient quality of life. 
 Increasingly, surgeons are turning to non-host biologics to address the limitations 
of allografts and the pain concomitant with use of autografts. BMP-2 – the classic 
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osteoinductive growth factor – has been used with general success in clinical trials to 
augment mechanical fixation of open tibial fractures and as a replacement for autograft 
tissue in spinal fusions.  
The strategy of combining synthetic and biological factors to create a porous, cell-
friendly microenvironment that will enhance cellular invasion, implant vitalization, and 
bone formation in the defect site holds promise, as evidenced by the general success of 
the BMP-2/absorbable collagen sponge trials [SWIONTKOWSKI 2006, BURKUS 
2002]. To this end, we have developed a porous polymer scaffold with mechanical 
integrity that can be co-delivered with biological agents to promote osseointegration of 
the scaffold into a bony defect site and enhance functional repair of the osseous defect.  
 The 8 mm critically-sized segmental femoral rat defect model used in these 
studies provides a robust model of non-union in the absence of treatment. This defect 
model has been modified by our research group to provide several advantages over 
traditional fixation methods and simple radiological assessment of healing [OEST 2007]. 
The fixation plates in our model have been custom designed to obtain highly stable 
fixation of the defect and permit creation of uniform defects centrally located along the 
diaphysis of the femur. The plates are modular; a polymer bridging component permits in 
vivo micro-computed tomography (micro-CT) and X-ray imaging of the defect site while 
still allowing the researcher to remove the bridging plate without damaging the remaining 
bone or repair tissue for mechanical testing of samples post-mortem. The large size of the 
defect permits stringent comparison of various treatments while maintaining consistent 
non-union results in untreated (empty) defects. Smaller, more commonly used defects, (5 
mm in length) have a spontaneous union rate of 10-50% [WERNTZ 1996, 
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NOTTEBAERT 1989]. Additionally, a new strategy for quantitative evaluation of the 
healing response has been generated for the segmental defect model [OEST 2007]. This 
evaluation regime consists of quantitative micro-CT determination of bone volume within 
the defect at two time points in vivo, quantitative determination of limb functionality 
using biomechanical testing, and the traditional and qualitative measures of radiographic 
assessment of union rates and histological analysis.  
 Growth factor treatment of large osseous defects has traditionally relied on a large 
dose of a single osteoinductive growth factor – typically BMP-2 [LEE 1994, YASKO 
1992, LIEBERMAN 1999]. Experimental doses in murine models may be as high as 11-
20 µg per defect [YASKO 1992, LIEBERMAN 1999]. Although this results in 
reproducible bony union of the defect as assessed by radiography, typically in 5 mm 
defects, the equivalent amount of protein required to treat a critical human defect is 
substantial. One way to reduce the quantity of protein required is to exploit interactions 
between growth factors. Previously, BMP-2 and TGF-β3 have been shown to interact 
synergistically in the presence of bone marrow stromal cells to promote mineralized 
matrix formation in an ectopic mouse model of osteogenesis at very low (physiologic) 
doses [SIMMONS 2004]. 
 The goals of this study were to assess the interaction between BMP-2 and TGF-
β3 and dose-dependent effects of the co-delivery of these growth factors in a critically-
sized femoral defect model. The outcome measures were: radiographic assessment of rate 
of union, micro-CT measurements of bone volume within the defect, torsional testing to 





4.3.1 Scaffold Production 
Poly-(L-co-D,L-lactide 70:30) (PLDL) cylindrical scaffolds measuring 8 mm in 
length and 4 mm in diameter were produced using a fiber coating and porogen 
decomposition technique described previously [LIN 2003]. Briefly, 100 micron fibers 
were coated with a mixture of PLDL and azodicarbonamide solvated in acetone. Fibers 
were bundled, fused together, and heat treated. During heat treatment, the 
azodicarbonamide decomposes from a solid to a gaseous phase, producing random 
interconnected micropores in the scaffold. The removal of the wires revealed oriented 
longitudinal macropores with approximately 77% porosity. Scaffolds were sterilized by 
gamma irradiation (2.5 Mrad), and coated with rat plasma fibronectin (25 µg/ml, F0635; 
Sigma-Aldrich) prior to seeding with growth factor.  
 
4.3.2 Addition of Growth Factor to Scaffolds 
Sterile recombinant human BMP-2 and/or TGF-β3 (355-BM/CF and 243-B3/CF, 
R&D Systems, Minneapolis MN) were reconstituted with sterile 0.1% rat serum albumen 
in 4 mM HCl immediately prior to use. Short chain length MVG sodium alginate 
(Pronova Biopolymers, Norway) was produced by exposing the stock alginate to a 5 
Mrad dose of gamma irradiation. The short chain alginate was then functionalized with a 
G4RGDSP peptide sequence at a density of 2 RGD sequences per chain via carbodiimide 
chemistry [SIMMONS 2004]. The RGD-functionalized alginate was sterile filtered and 
lyophilized for storage at -20°C. For use in the PLDL scaffolds, the alginate was 
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reconstituted with α-MEM to a concentration of 2%, including one of the following 
growth factor doses: 200 ng BMP-2 and 20 ng TGF-β3 (200/20 dose), 2000 ng BMP-2 
and 200 ng TGF-β3 (2000/200 dose), 2000 ng BMP-2, 200 ng TGF-β3, or no growth 
factor.  Scaffold only treatment groups included a scaffold that was infiltrated with RGD-
alginate without growth factors. The 200/20 dose and 2000/200 dose groups were 
compared in one study, while the delivery of individual growth factors and dual growth 
factor delivery were compared in a second study at the 2000/200 dose. Fibronectin-
coated PLDL scaffolds were placed into molds that served to contain the alginate solution 
as it infiltrated the porosity of the scaffold. Membranes wetted with CaCl2 bounded the 
scaffold at either end, initiating crosslinking of the alginate in situ. After 20 minutes in 
the molds, the scaffolds were transferred from to a bath of CaCl2 where the crosslinking 
process was completed. As a final step, the scaffolds were rinsed and stored in α-MEM 
until implantation.  
 
4.3.3 Surgical Procedure 
 All surgical techniques were reviewed and approved by the Institutional Animal 
Care and Use Committee at Georgia Institute of Technology (Protocols A03017 and 
A05041). Female Sasco Sprague-Dawley rats aged 13 weeks were anesthetized using 
isoflurane. Bilateral anterior incisions were made over the femurs. The femurs were 
exposed using blunt dissection through the muscle. Custom modular fixation plates were 
secured directly to the bone using four miniature screws (J.I. Morris Co, Southbridge 
MA). Bilateral full-thickness 8 mm long diaphyseal defects were created using a 
miniature oscillating saw under irrigation. After flushing the defect site with sterile 
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saline, scaffolds with or without BMP-2 and/or TGF-β3 were press-fit securely into the 
defects. Incisions were closed according to anatomic layers using absorbable suture and 
wound clips. Animals were given 0.05 mg/kg buprenorphine every 8 hours 
postoperatively for the first 48 hours and 0.025 mg/kg buprenorphine every 8 hours for 
the following 24 hours. Within 2-3 days post-op, animals had resumed normal 
ambulation and did not show signs of distress or pain.  
 
4.3.4 X-ray and Micro-CT 
 Digital 2-D X-rays were taken every four weeks postoperatively until the 
termination of the studies. Rates of union were assessed by two blinded observers, with 
union qualified as formation of a continuous bony bridge across any region of the defect. 
In vivo 3-D micro-CT imaging was done at 4 and 12 weeks post-op using a 38.5 µm 
voxel resolution (Viva-CT 40; Scanco Medical, Bassersdorf, Switzerland). A consistent 
central diaphyseal volume of interest (VOI) was selected for all analyses. This VOI was 
approximately 4.6 mm thick. A Gaussian filter (sigma = 1.2, support = 1) was used to 
partially suppress noise in the VOI prior to application of a global threshold. The global 
thresholds corresponded to densities of 206.7 and 270.3 mg hydroxyapatite/cm3, and 
excluded all non-mineralized tissues and residual scaffold material, as verified by visual 
examination of individual 2-D slices. The lower threshold was used to assess total bone 
volume (mature + immature), while the upper threshold was used to quantify mature bone 
volume. Immature bone volume was calculated as the difference between total bone 
volume and mature bone volume. The upper threshold (mature bone) was determined by 
two methods; a histogram of the number of voxels attenuating vs the threshold was 
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plotted and used to select an approximate threshold value. This threshold value was then 
validated using visual inspection of 2-D slices. The threshold of 272 mg HA/cm3 
corresponds to the attenuation of mature cortical bone in a rat. The immature bone 
threshold was selected as the lowest value that could be analyzed without picking up 
image artifacts or distorting the bone structure.  
 
4.3.5 Mechanical Testing 
 Samples were harvested at 12 weeks post-op and wrapped in saline-soaked gauze 
prior to storage at -20°C. For mechanical testing, samples were thawed in a bath of room-
temperature saline, unwrapped, and imaged using in vitro micro-CT immediately prior to 
potting in end blocks using Wood’s metal. After potting and placement of a transverse 
stabilizing pin through the end blocks and proximal and distal ends of the femur, the 
bridging component of the stabilization plate was removed. To preserve tissue hydration, 
samples were wrapped with saline soaked gauze during handling and placement into the 
testing system. Samples were then tested to failure in torsion at a rate of 3°/second using 




 One sample from each treatment group was selected for histological evaluation. 
Stains used in this evaluation included haematoxylin and eosin, Masson’s trichrome, von 




 Analysis of variance was conducted using a general linear model and Tukey 
pairwise post-hoc comparisons (Minitab). Differences were considered statistically 




4.4.1 X-ray Imaging 
Faxitron 2-D X-ray images were taken every 4 weeks post-op to monitor defect 
stability and bony ingrowth. In the 200/20 dose treatment group, there was some bony fill 
within the defect site, extending from the cut ends of the femur. The rate of bony union 
for this treatment group was 29% (2/7). In the 2000/200 dose treatment group there was a 
63% (10/16) incidence of bony union; no samples from the scaffold only treatment group 

















Figure 17: Digital X-rays taken of the three treatment groups at 4, 8 and 12 weeks post-
op. Rates of bony union were as follows: scaffold only – 0/9; 200/20 ng dose of BMP-

















































In the scaffold only and TGF-β3 only treatment groups, there was a minimal 
amount of bony ingrowth, with a small amount of appositional bone formation 
dominating the healing process. None of the samples in either of these treatment groups 
achieved bony union. In the BMP-2 only treatment group there was an increase in the 
amount of bone formation within the defects, with some samples achieving bony union 
(38% or 3/8). Addition of TGF-β3 to the BMP-2 further increased the rate of union (55% 












Figure 18: Digital X-rays taken of the three treatment groups at 4, 8 and 12 weeks post-
op. Rates of bony union were as follows: scaffold only – 0/; 200 ng TGF-β3 only – 0/7, 




























4.4.2 Micro-CT Analysis 
 In vivo micro-CT analysis was conducted at 4 and 12 weeks post-op for both 
studies. In the dose response study, micro-CT analysis revealed a significant elevation in 
bone volume in the 2000/200 dose group as compared to delivery of a scaffold alone at 
both time points (p < 0.001 at week 4, p = 0.004 at week 12) (Figure 19). Additionally, at 
4 weeks post-op the 2000/200 dose group had a significantly higher bone volume than the 
200/20 dose group (p = 0.020).  Overall, treatment and time were both significant factors 
(p < 0.001, p < 0.001). Bone volume did not increase significantly between 4 and 12 
weeks in the scaffold only treatment group (p = 0.053). There was a significant increase 
in bone volume for the 2000/200 dose treatment group between 4 and 12 weeks (p = 
0.001), as well as for the 200/20 dose treatment group (p = 0.010).  
 In vitro micro-CT imaging was done on samples immediately prior to mechanical 
testing. It should be noted that in vitro micro-CT analysis is a less sensitive measure of 
defect healing, as the bone volumes are somewhat normalized by the presence of intact 
host bone at the proximal and distal edges of the defect. There was a significant increase 
in the quantity of mature bone in the 2000/200 dose group as compared to the scaffold 
only group. Similarly, there was a statistically significant increase in both total bone 
volume and immature bone volume with the addition of the 2000/200 dose of BMP-
2/TGF-β3 to the scaffold alone (Figure 20). For this group, spatial analysis of the post-
mortem samples indicated a significant increase in the quantity of bone surrounding the 
periphery of the scaffold, but not within the core of the scaffold (Figure 21). Similarly, 
the bone volume fraction in the periphery was significantly increased in the 2000/200 
dose group over the scaffold alone group. There was no significant difference between 
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the 200/20 dose and the scaffold or the 2000/200 dose and the 200/20 dose (Figure 22). 
Delivery of the 2000/200 BMP-2/TGF-β3 growth factor dose significantly improved the 
quantity of bone within the proximal half of the defect as compared to implantation of a 
scaffold alone, but did not impact the formation of bone on the distal aspect of the defect 
(Figure 23). Representative images from the in vitro micro-CT visually demonstrate the 










Figure 19: In vivo bone volume measurements taken at 4 and 12 weeks post-op (13 ≤ n ≤ 
17). * denotes a significant increase in bone volume within the treatment group from 4 to 
12 weeks post-op. The 2000/200 ng BMP-2/TGF-β3 treatment group had significantly 
improved bone volume over both the scaffold only and 200/20 ng co-delivery treatment 
group at 4 weeks post-op. At 12 weeks post-op, the 2000/200 dose treatment group still 











Figure 20: In vitro bone volume measurements taken at 12 weeks post-op (11 ≤ n ≤ 14). 
All three measurements – total bone volume (mature + immature), immature bone 
volume, and mature bone volume – were significantly greater in the 2000/200 ng co-














































































Figure 21: In vitro bone volume spatial distribution measurements segmented by core 
(central 2 mm diameter) vs. periphery (outer portion of scaffold and area around the 
scaffold) of the implant taken at 12 weeks post-op (11 ≤ n ≤ 14). The bone volume in the 
core of the scaffold was not impacted by growth factor augmentation, but the peripheral 
bone volume was significantly increased in the 2000/200 ng dose treatment group over 




















Figure 22: In vitro bone volume fraction spatial distribution measurements segmented by 
core (central 2 mm diameter) vs. periphery (outer portion of scaffold and area around the 
scaffold) of the implant taken at 12 weeks post-op (11 ≤ n ≤ 14). The bone volume 
fraction in the core of the scaffold was not impacted by growth factor augmentation, but 
the peripheral bone volume was significantly increased in the 2000/200 ng dose treatment 









































































































Figure 23: In vitro bone volume spatial distribution measurements segmented by 
proximal vs. distal regions of the defect taken at 12 weeks post-op. The bone volume in 
the proximal 4 mm of the defect was significantly increased in the group augmented with 
2000 ng BMP-2 and 200 ng TGF-β3 (2000/200 dose) as compared to the PLDL (scaffold 























































Figure 24: In vitro micro-CT images of the 8 mm long defect regions for three treatment 
groups taken post mortem at 12 weeks. The dose-dependent increase noted in quantitative 





 In the study comparing bone volumes for dual vs. single growth factor delivery, 
treatment was a significant factor for both mature and immature bone volumes at 4 and 
12 weeks post-op (Figures 25 and 26) . The co-delivery treatment group was the only 
group that experienced a significant increase in mature bone volume with time (p < 
0.050). At week 4, there was a significant increase in immature bone volume in the co-
delivery group as compared to the scaffold only group (p = 0.034). There were no other 
significant differences at week 4 in terms of mature bone volume or total bone volume. 
At week 12, a significant increase in both immature and mature bone volumes was 
quantified in the co-delivery treatment group as compared to delivery of a scaffold alone. 
There was a significant increase in mature bone volume and immature bone volume in 
the 2000/200 co-delivery group over delivery of TGF-β3 alone. Immature bone volume 
was significantly elevated in the BMP-2 only group as compared to the scaffold treatment 
group as well. Overall, treatment was a significant factor for both mature and immature 
bone volumes at 12 weeks post-op.  
 In vitro micro-CT indicated a statistically significant increase in immature, 
mature, and total bone volumes for the 2000/200 dose co-delivery treatment group over 
delivery of a scaffold alone (p < 0.022) (Figure 27). The proximal and peripheral bone 
volumes were also elevated in the co-delivery group as compared to the scaffold 
treatment group (p < 0.020) (Figures 28 and 29). Peripheral bone volume fraction was 
likewise significantly higher in the co-delivery treatment group than in the scaffold 











Figure 25: Mature bone volume measurements taken at 4 and 12 weeks post-op using in 
vivo micro-CT (8 ≤ n ≤ 10). The co-delivery group (2000 ng BMP-2/200 ng TGF-β3) 
experienced had a significantly higher bone volume at 12 weeks post-op than either the 
scaffold only (PLDL) or TGF-β3 only treatment groups. * denotes a significant increase 










Figure 26: Mature and immature bone volume measurements taken at 4 and 12 weeks 
post-op using in vivo micro-CT (8 ≤ n ≤ 10). At 4 weeks post-op, there was a 
significantly greater quantity of immature bone in the co-delivery group as compared to 
the scaffold alone group, and a strong trend towards an increase in immature bone in the 
TGF-β3 treatment group over the PLDL group. At 12 weeks post-op the quantity of 
immature and mature bone was greater in the co-delivery group than in the scaffold or 
TGF-β3 alone groups. The BMP-2 only group had significantly more immature bone at 



























































Week 4 Week 12
immature p = 0.034
immature p = 0.095
immature p = 0.001, mature p = 0.002
immature p = 0.049, mature p = 0.010





















Figure 27: Mature and immature bone volume measurements taken at 12 weeks post-op 
using in vitro micro-CT (7 ≤ n ≤ 8). There is a significant increase in both immature and 











Figure 28: Proximal and distal bone volume measurements taken at 12 weeks post-op 
using in vitro micro-CT (7 ≤ n ≤ 8). The proximal bone volume in the co-delivery 
treatment group is significantly greater than the proximal bone volume in the PLDL 
(scaffold only) treatment group. There was a trend towards an increase in proximal bone 































































proximal p = 0.103




























Figure 29: Core and peripheral bone volume measurements taken at 12 weeks post-op 
using in vitro micro-CT (7 ≤ n ≤ 8). Peripheral bone volume was elevated in the 
2000/200 ng BMP-2/TGF-β3 co-delivery treatment group as compared to delivery of a 











Figure 30: Core and peripheral bone volume fraction measurements taken at 12 weeks 
post-op using in vitro micro-CT (7 ≤ n ≤ 8). The peripheral bone volume fraction was 
increased in the co-delivery treatment group as compared to the scaffold only treatment 






















































































































Figure 31: Post mortem micro-CT images of the full defect site average responders for 
four treatment groups taken from in vitro micro-CT. The images visually confirm the 
differences in treatment determined quantitatively by micro-CT.  
scaffold TGF-β3
BMP-2 BMP-2 & TGF-β3
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4.4.3 Mechanical Testing 
 Torsional mechanical testing was done on samples harvested at 12 weeks post-op. 
In the dose dependence study, delivery of the 2000/200 dose of BMP-2 and TGF-β3 
significantly increased stiffness over delivery of a scaffold alone (p = 0.003) and resulted 
in a nearly significant increase in the 2000/200 group over the 200/20 group (p = 0.054) 
(Figure 32). The maximum torque achieved by the 2000/200 dose treatment group was 
significantly greater than the maximum torque reached by the 200/20 dose group or the 
scaffold alone group (p = 0.031, p = 0.002 respectively) (Figure 33). Work to maximum 











Figure 32: Average stiffness values for three treatment groups (11 ≤ n ≤ 14). Stiffness 
was significantly increased by the co-delivery of 2000 ng BMP-2 and 200 ng TGF-β3 to 
the PLDL scaffold, but not by addition of the 200/20 dose. There was a nearly significant 











Figure 33: Average maximum torque values for three treatment groups (11 ≤ n ≤ 14). 
Maximum torque was significantly increased in the 2000/200 ng co-delivery treatment 
group as compared to both the 200/20 ng co-delivery group and the scaffold only group. 
Delivery of the 200/20 dose did not significantly improve maximum torque over delivery 





















































































Figure 34: Average work to maximum torque values for three treatment groups (11 ≤ n ≤ 
14). Treatment of the defects with either dose of growth factor (2000 ng BMP-2/200 ng 



















































 In the study that compared single growth factor delivery to dual growth factor 
delivery, treatment was a significant factor in determining stiffness (p = 0.014) (Figure 
35). The BMP-2 and TGF-β3 co-delivery group had a significantly higher stiffness than 
the TGF-β3 only (p = 0.021) or scaffold alone (p = 0.034) groups. The co-delivery 
treatment group was not significantly different from the BMP-2 only group (p = 0.354), 
nor was the BMP-2 only group significantly different from any of the other treatment 
groups in terms of stiffness (p = 0.623 for scaffold only, p = 0.451 for TGF-β3). 
Maximum torque was also significantly affected by treatment (p = 0.005) (Figure 36). 
BMP-2 and TGF-β3 co-delivery produced an average maximum torque that was 
significantly greater than that achieved by the TGF-β3 (p = 0.009) or scaffold only (p = 
0.014) groups. The difference in maximum torque between the co-delivery group and the 
BMP-2 only group was not statistically significant (p = 0.077). The scaffold only and 
TGF-β3 only treatment groups were not significantly different (p = 0.988) in maximum 
torque, and BMP-2 only treatment was not significantly different from treatment with 
TGF-β3 alone (p = 0.728) or a growth factor-free scaffold (p = 0.878).  Calculating work 
to maximum torque did not reveal any statistically significant differences between 










Figure 35: Average stiffness measurements taken post mortem at 12 weeks post-op (6 ≤ n 
≤ 8). The stiffness of the BMP-2/TGF-β3 (2000/200 ng dose) co-delivery group was 
significantly higher than that of both the TGF-β3 monotherapy and scaffold only groups. 
The difference in stiffness between the BMP-2 only and co-delivery treatment groups 












Figure 36: Average maximum torque values obtained post mortem at 12 weeks post-op (6 
≤ n ≤ 8). Maximum torque was significantly elevated in the BMP-2/TGF-β3 (2000/200 
ng dose) co-delivery treatment group as compared to delivery of both TGF-β3 alone and 
a PLDL scaffold alone. There was a strong trend indicating an increase in maximum 


























































































Figure 37: Average work to maximum torque (6 ≤ n ≤ 8). There was a trend towards 
increased work to maximum torque in the growth factor co-delivery group as compared 






































































 Staining of 5 µm thick sections revealed minimal mineralized matrix formation in 
both the scaffold only and 200/20 dose treated samples. New bone formation was 
constrained to appositional deposition of mineral along the cut edges of the femur (Figure 
38, Figure 39). Micro-CT analysis of these samples at the terminal time point indicated 
low bone volumes. In a representative sample of a defect treated with 2000 ng BMP-2, 
there was a substantial quantity of mineralized tissue forming within the scaffold region. 
Ingrowth of the mineralized matrix appeared to occur mainly along the longitudinal 
macropores of the scaffold (Figure 40). This sample had a bone volume of approximately 
38 mm3 by 4 weeks post-op, indicating that there is a correspondence between bone 




















Figure 38: Histological sections taken from a sample treated with an unaugmented RGD-
alginate filled PLDL scaffold. Top row, von Kossa stain; lower row, Massons’ trichrome. 
Safranin-O staining did not reveal any cartilaginous tissue. The scaffold region is filled 




















Figure 39: Histological sections taken from a sample treated with 200 ng BMP-2 and 20 
ng TGF-β3. Top row, von Kossa stain; lower row, Massons’ trichrome. Safranin-O 
staining did not reveal any cartilaginous tissue. Tissue ingrowth is constrained to 



















Figure 40: Histological sections taken from a sample treated with 2000 ng BMP-2. Top 
row, von Kossa stain; lower row, Massons’ trichrome. Safranin-O staining did not reveal 
any cartilaginous tissue. Staining reveals formation of mineralized tissue throughout the 




 Treatments for osseous defects must achieve stable bony union, restore 
functionality to the limb, and promote remodeling of the repair tissue in order to 
regenerate normal bone anatomy, strength, and function long-term. Allografts are an 
easily available source of structural material with which to treat critically-sized defects, 
but are limited by the many associated complications that result from incomplete 
integration and remodeling of the graft [LUCARELLI 2005, WHEELER 1998, ITO 
2005, ENNEKING 2001]. Tissue-engineering approaches, such as those employed in the 
work presented here, may provide a viable alternative for treatment of large osseous 
defects.  
 Here, a growth factor-based tissue-engineered bone replacement construct was 
generated using a structural polymer scaffold as both a mechanical support and, 
combined with RGD-alginate, growth factor delivery vehicle. The growth factors BMP-2 
and TGF-β3 were selected based on their potent osteoinductive and chondroinductive 
properties. A dose-dependent increase in bone volume was noted particularly at the early 
(4 week) time point. Both growth factor treated groups demonstrated a significant 
increase in bone volume between weeks 4 and 12, while the scaffold only group did not. 
The delivery of the growth factors promoted accelerated and continued increases in 
mineralized matrix formation within the defect site over 12 weeks in vivo. Delivery of the 
2000/200 dose of growth factor was particularly beneficial over delivery of the 200/20 
dose of BMP-2/TGF-β3 in terms of promoting early mineralization within the central 
longitudinal region of the defect, as measured using in vivo micro-CT. Because increases 
in mineralized tissue within this volume of interest correlated to increases in stiffness and 
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maximum torque, it is possible that the increase in early mineralization also resulted in 
increased mechanical properties early in the post-operative in vivo period. This effect is 
mirrored by the dose-dependent increase in mechanical properties seen at 12 weeks post-
op. In addition to increased mechanical properties and bone volume, the increase in 
growth factor dose also corresponded to an increase in the rate of bony union across the 
defect site.  
It has been shown previously that BMP-2 and TGF-β3 interact synergistically to 
produce mineralized matrix in the presence of bone marrow stromal cells when delivered 
to a subcutaneous site in an ectopic mouse model of osteogenesis [SIMMONS 2004]. A 
synergistic interaction was not determined in these studies. It should also be noted the co-
delivery of both BMP-2 and TGF-β3 resulted in an increase in the incidence of bony 
union as assessed by blinded observation of digital 2-D X-rays. Taken as whole, these 
data demonstrate a beneficial effect of low dose growth factor co-delivery as compared to 
single delivery of either factor alone. The lack of synergistic response may be due in part 
to the traumatic nature of the injury and the absence of direct cell delivery to the defect. 
The subcutaneous model in which this treatment strategy was first investigated is far less 
traumatic than the segmental defect model, and may not provoke the same acute 
physiologic response. This acute response may in fact be masking the full potential of the 
growth factors due to the active proteases, inflammation, and presence of endogenous 
signaling molecules. Not delivering bone marrow cells directly with the implants may 
also be inhibiting the full response of the treatment, as it takes some time for the native 
bone marrow stromal cells to invade into the defect region and be activated by the 
residual growth factor.  
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The dose-dependent response was expected, and further, it indicates that although 
physiologic doses of growth factor are sufficient to induce ectopic osteogenesis, 
moderately higher doses of growth factor are required to regenerate bone in a critically-
sized orthotopic defect site. This is not an unexpected result, given that a critically-sized 
load-bearing osseous defect requires a far larger volume of mineral to be generated than a 
50 µl hydrogel does (the implant described by Simmons et al.), and the segmental defect 
described here requires a greater host of biological signals and agents to act in concert in 
order to functionally heal the wound [SIMMONS 2004]. However, the doses used in this 
study were still well below the dose of single growth factor that is generally applied to 
promote osseous healing of segmental defects. Here, a total of 2.2 µg of growth factor 
delivered to the defect consistently promoted osseous union and abundant mineralized 
matrix formation, as compared to other studies in which doses as high as 9-20 µg of 
various growth factors (BMP-2, VEGF, osteogenin, and BMP-7) have been used for 
similarly sized or smaller defects [LEE 1994, STREET 2002, CHEN 2002, YASKO 
1992, LIEBERMAN 1999, CHEN 2006]. Such supraphysiologic doses are frequently 
effective at promoting bony union, but produce varied results (particularly VEGF) and 
are often limited to experimental investigations partially because of the unknown 
physiologic effects of delivering such large quantities of a single protein. These high 
level doses of growth factor may also hold the potential to induce excessive bone 
formation around the defect site. On the lower end of reported dosages in this spectrum, 5 
mm defects have been treated with 3 µg BMP-2, but mechanical integrity of the treated 
defects was not investigated [ISOBE 1999]. Additionally, a 5 mm defect in the rat femur 
is not critically-sized, and is subject to spontaneous union even in the absence of 
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treatment [WERNTZ 1996, NOTTEBAERT 1989]. There is clinical indication for use of 
BMP-2, as an osteoinductive agent in some applications. The current approved dose by 
the FDA for human clinical trial use of BMP-2 is 1.50 mg/ml in an absorbable collagen 
(bovine) sponge (ACS) [SWIONTKOWSKI 2006].  This dose has been approved for use 
in spinal fusions and evaluated for repair of open tibial fractures. The equivalent dose 
used in the studies presented here is 0.02 mg/ml. Here, the growth factor-laden scaffold 
was delivered within the defect itself. The BMP-2/ACS treatment for tibial fractures is an 
overlay technique in which the matrix is simply placed over the fracture site after 
stabilization with an intramedullary nailing technique. This difference in delivery 
technique may result in limited efficacy, thereby requiring a higher dose of growth factor 
in the tibial fracture application. The use of BMP-2 in this manner is efficacious – 
patients on average bear weight on the injured tibia 32 days sooner than their counterparts 
who do not receive the BMP-2/ACS onlay. Additionally, delivery of BMP-2 to the tibial 
defect decreases the need for invasive surgical revisions [SWIONTKOWSKI 2006]. 
BMP-2/ACS is also used as a treatment for anterior lumbar interbody fusion (spinal 
fusion). Although local reaming is used to prepare the vertebral endplates for insertion of 
a spinal fusion cage when the graft is composed of autografted bone, local reaming is not 
typically used when the BMP-2/ACS graft is used placed within the cage [BURKUS 
2002]. Because there is no acute local injury in the BMP-2/ACS treated spinal fusions, 
the higher (1.5 mg/ml) dose of BMP-2 may be necessitated. In the critically-sized 
femoral defect model presented here, an acute injury is created, possibly priming the 
defect site for response to bioactive factors. This acute injury may be part of the reason 
that the low dose of BMP-2/TGF-β3 is efficacious.  
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 Delivering cells, specifically mesenchymal stem cells (MSCs) and bone marrow 
stromal cells (BMSCs), has been extensively investigated in the context of brittle ceramic 
graft implantation [BRUDER 1998 JBJS, BRUDER 1998 JOR, KADIYALA 1997, 
TSUCHIDA 2001].  While delivery of MSCs or BMSCs to the defect site significantly 
improves integration of hydroxyapatite scaffolds into segmental defects in both canine 
and murine models, cellular treatment of defects requires substantial lead time to isolate 
and expand the autogenous cells before delivering them via a scaffold to the defect site. 
This delay in treatment may be detrimental to the healing and restoration of full 
functionality to the defect site as the body’s natural healing responses, such as the phase 
that promotes angiogenesis, may have senesced by the time the defect can be treated. Use 
of a brittle ceramic scaffold is also not an optimal base for tissue engineered bone 
replacements, as fractures frequently develop in the ceramic implant as a function of time 
and use [BRUDER 1998 JBJS]. The use of cellular treatment in combination with an 
absorbable, structural polymeric scaffold as an approach to the treatment of load-bearing 
critically-sized defects has not been investigated to date.  
 In the vein of allograft treatment, use of demineralized bone matrix has been a 
popular alternative to treatment of segmental bone defects in animal models [BALDIK 
2002, CHAKKALAKAL 1999, CHAKKALAKAL 2001, FEIGHAN 1995 , GEBHART]. 
Demineralized bone, however, still bears the risk for potential disease transmission. 
Demineralized bone grafts are also unable to provide any structural support to the defect 
site. Providing a scaffold with structural integrity to the defect site may be important in 
promoting early weight-bearing – a potent stimulator of osteogenesis. In these studies, an 
absorbable porous synthetic scaffold was used to both deliver biologics incorporated with 
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a hydrogel and serve as a structural support. The approach taken here asserts two 
functions (delivery of biologics and mechanical support) as opposed to the single 
function (delivery of growth factors) of demineralized bone matrix. 
 Allograft treatment has been modified using gene delivery therapy to achieve 
somewhat better results than are seen with allograft treatment alone. Incorporation of 
allografted tissue typically is limited to new bone deposition along the host-graft 
interface, rather than formation of a complete callus. The angiogenic response is similarly 
constrained. Coating of allografts in murine models with BMP-2-transfected MSCs 
enhances the ability of the host to form a callus around the allograft [XIE 2007, 
LIEBERMAN 1999 JBJS]. Alternatively, a virus encoding a specific gene (such as 
caALK2) can be directly coated onto the allograft, also enhancing the mineralization 
surrounding the allograft [AWAD 2007]. However, the incorporation of the allograft is 
still limited by slow resorption and low porosity.  
 In conclusion, dual delivery of BMP-2 and TGF-β3 resulted in an increase in 
bony fill. Co-delivery of these growth factors at two levels indicated a dose-dependent 
effect on bone volume, stiffness, and maximum torque, with the 2000 ng BMP-2 and 200 
ng TGF-β3 co-delivery dose being most beneficial. This dose is low compared to the 
doses of growth factor typically used to treat critically-sized segmental defects in animal 
models and the FDA approved dose of BMP-2 monotherapy for clinical human use. The 
approach demonstrated here serves to deliver low dose bioactive factors and may 
promote early functional use of the limb. The last chapter focuses on co-delivery of 
osteogenic and angiogenic growth factors, as well as modifications to the scaffold to 




EFFECTS OF ANGIOGENIC GROWTH FACTOR DELIVERY AND 
SCAFFOLD DESIGN ON FUNCTIONAL REPAIR OF SEGMENTAL DEFECTS 
 
5.1 Abstract 
 Tissue-engineering strategies provide a potential alternative to the traditional 
large bone defect repair strategy that incorporates a poorly-remodeling allograft. In bone 
formation and repair, development and maintained presence of vascular structures is 
critical to survival of osteoprogenitors, osteocytes, and the tissue as a whole. VEGF has 
been investigated primarily as an agent to induce angiogenesis in in vivo models, 
although recent reports on its ability to promote osteogenesis have been published. Here, 
the osteogenic and angiogenic responses to three doses of VEGF (10 ng , 100 ng, and 
1000 ng) delivered to a critically-sized segmental femoral defect in rats are investigated. 
The effects of scaffold geometry and composition on mineralization and vascularization 
are also assessed. Finally, the potential for interactive effects between delivery of the 
osteogenic growth factor combination of 2000 ng BMP-2/200 ng TGF-β3 and 1000 ng 
VEGF in the segmental defect model is determined. There was no dose-dependent 
response to the delivery of VEGF alone in terms of either bone formation or vascular 
invasion into the defect site. Modifying scaffold geometry by removing a 1.5 mm 
longitudinal core from the central region of the scaffold and addition of 10% tricalcium 
phosphate (TCP) improved the rate of union of the defects, but did not significantly 
enhance bone volume or mechanical properties over any other scaffold design (traditional 
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PLDL, cored PLDL, traditional geometry PLDL/TCP). Coring of the scaffold improved 
vascularization within the defect site as compared to the study where no core was 
removed, but did not improve the lack of dose-dependent response to VEGF treatment. 
The presence of alginate used to deliver growth factors within the scaffold porosity did 
not impact revascularization within the core of the defect site. Addition of 1000 ng VEGF 
to the defects resulted in a significant increase in bone volume within the treatment group 
with time, although bone volume was not improved as compared to delivery of BMP-
2/TGF-β3 or BMP-2/TGF-β3/VEGF. Addition of VEGF to BMP-2/TGF-β3 did not 
affect bone volume over delivery of only BMP-2/TGF-β3. In vitro growth factor release 
studies indicated that approximately 25% of the growth factor loaded (for BMP-2, TGF-
β3, and VEGF) was readily released over 5 days incubation period. Extending the 
incubation to 21 days did not result in further growth factor release. The remaining 75% 
of the growth factor may have remained bound by the residual alginate matrix. This 
indicated that the delivery mechanism in this model system is one of extended controlled 
release, which may account for the lack of response seen with delivery of VEGF in terms 
of both revascularization and mineralization. 
 
5.2 Introduction 
 The problem of regenerating bone in large osseous defects and compromised 
fractures is non-trivial. While mechanical stabilization and placement of a cadaveric 
allograft remain the standard treatments for such clinical situations, this treatment is 
severely compromised in its efficacy due to the low porosity of the allograft. The low 
porosity and lack of bioactive factors are impediments to the revascularization, 
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revitalization, and remodeling of the allograft. Because the allograft does not fully 
incorporate into the recipient body it is subject to complications within as little as 1-2 
years post-operatively. The complication rate for allografting is 30-60%, with a 25% graft 
failure rate [ITO 2005, LUCARELLI 2005, WHEELER 2005] 
 Tissue engineering is emerging as a clinical therapy for large bone defects in both 
load-bearing and non-load-bearing applications. The simplistic strategy of combining one 
high-dose osteogenic growth factor (BMP-2) therapy with a biocompatible carrier 
(bovine absorbable collagen sponge)  is now FDA-approved for clinical use in spinal 
fusions and under investigation for use as treatment augmentation for complex tibial shaft 
fractures (Infuse technology, Medtronic Sofamor Danek) [SWIONTKOWSKI 2006, 
BURKUS 2002]. Tissue-engineered grafts have been widely investigated in experimental 
animal models. There are three fundamental treatment strategies, all relying on some type 
of delivery vehicle, scaffold, or substrate: cell delivery, bioactive peptide delivery, and 
gene therapy. The treatment strategy selected for investigation here is growth factor 
delivery. 
 Design of a biocompatible scaffold that not only permits, but is conducive to, 
functional, vascularized bony union is a complex problem. While ceramics – both natural 
(coral) and manufactured (hydroxyapatite/tricalcium phosphate) – are appealing due to 
their near physiologic mineral content, they are inherently limited by a lack of porosity 
and structural brittleness that tends toward failure under loading in vivo [BRUDER 1998 
JBJS]. Nonstructural matrices are a popular option because their morphology is 
conducive to use in geometrically challenging defects and they can be synthesized in 
nearly any composition the investigator desires [KRETLOW 2007]. Specific 
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modifications to polymers, such as adding metalloproteinase cleavage sites to link a 
growth factor to a hydrogel, can also be engineered [RIZZI 2006, LUTOLF 2003]. 
Biologically-derived nonstructural matrices can be either inherently inert, such as 
collagen, or bioactive like some formulations of demineralized bone matrix. The risk of 
using natural bioactive matrices, however, is that the level of their activity is prone to 
variability from one preparation to another. Structural polymers and polymer-ceramic 
hybrids have not been largely investigated to date for use in load-bearing defect sites, 
although some investigation into their use for intramembranous bone repair has been 
done [ROHNER 2003, SCHANTZ 2003].  
 Bone is a mechano-sensitive tissue. The structure and function of bone are tightly 
linked to not only the biological environment of the tissue, but the mechanical 
environment as well [FROST 1987]. In a feedback circuit, early load bearing (without 
excessive micromotion) of a fractured bone leads to more rapid bone formation and 
remodeling, while rapid bone formation also permits early load-bearing on the afflicted 
bone. Taking advantage of bone’s natural response to loading, developing a tissue-
engineered treatment for large or challenged osseous defects that maintains structural 
integrity under a load-sharing system with some type of fixation device may enhance not 
only the rate of bone mineral deposition, but lead to early and improved limb 
functionality.  
 Structural polymer scaffolds have not been widely used as delivery vehicles for 
bioactive factors, and may be suitable for treatment of large load-bearing defects [RAI 
2007, OEST 2007]. Sustained delivery of growth factors from a structural scaffold 
requires that the growth factors be either directly incorporated into the polymer during 
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fabrication, or that some sort of controlled-release matrix be delivered within the scaffold 
porosity. The latter method is selected for use in the studies that follow. Alginate is a 
biocompatible hydrogel that has been shown to control the release of certain growth 
factors, and in the case of VEGF, actually enhance the activity of the protein 
[SHERIDAN 2000].  
 The robust model selected here to test tissue-engineered bone regeneration 
strategies does not heal in the absence of treatment [OEST 2007]. Three growth factors, 
BMP-2, TGF-β3, and VEGF were selected for delivery into the defect. In previous 
chapters, the dose-dependent effects of BMP-2 and TGF-β3 on bone formation have been 
described. VEGF is known to induce angiogenesis in a variety of in vivo models, 
including the CAM assay, retinal vascularization, and subcutaneous implantation. Its 
reported effects on bone formation, however, vary widely [STREET 2002, ECKHARDT 
2003]. 
 The goals of these studies were to: quantify the dose-dependent effects of VEGF 
delivery on bone formation and vascular invasion in a critically-sized femoral defect 
model, determine an optimal scaffold geometry and composition for repair of femoral 
defects, and investigate the potential interaction effects of co-delivering VEGF with 









5.3.1 Scaffold Production 
 Structural lactic acid-based polymer scaffolds containing 10% tricalcium 
phosphate (PLDL/TCP) were generated using a fiber-coating porogen decomposition 
technique previously described [LIN 2003]. Briefly, 100 micron diameter stainless steel 
fibers were coated in seven sequential steps using a syringe with varying gage 
hypodermic needles to flow the solvated polymer and porogen onto the fibers. After 
coating, the wires were cut, bundled, and heat treated to fuse the bundled wires together. 
During a second heat treatment the porogen was decomposed from solid to gaseous 
phase, producing random micropores in the scaffold structure. Removal of the wires 
revealed longitudinal macropores in the scaffold. Scaffolds were cut to length (8 mm) and 
punched to size (4 mm diameter), then rinsed to remove degradation particles from the 
heat treatment. In some studies, a central 1.5 mm longitudinal core was removed using a 
biopsy punch. Sterilization was achieved by γ-irradiation at a dose of 2.5 Mrad. Prior to 
loading with growth factor, the scaffolds were coated for 16 hours in rat plasma 
fibronectin (25 µg/ml, F0635, Sigma Aldrich) using a vacuum-coating technique.  
 
5.3.2 Addition of Growth Factors to Scaffolds 
 Three growth factors were selected for delivery or co-delivery: recombinant 
human BMP-2, TGF-β3, and recombinant rat VEGF164 (355-BM/CF, 243-B3/CF, and 
564-RV, R&D Systems, Minneapolis, MN). Growth factors were reconstituted 
aseptically using 0.1% rat serum albumin fraction V in 4 mM HCl immediately prior to 
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use. MVG sodium alginate (Pronova Biopolymers, Norway) was converted to a short 
chain length form by exposing the stock alginate to a 5 Mrad dose of γ-irradiation. This 
short chain alginate was functionalized with a G4RGDSP (RGD motif) peptide sequence 
at a density of 2 sequences per chain using carbodiimide chemistry [SIMMONS 2004]. 
The resulting RGD-alginate was sterile filtered and lyophilized for storage at -20°C until 
use. The growth factor doses were chosen based on the success of previous experiments 
delivering BMP-2 and TGF-β3 described in Chapter 4, and values reported in the 
literature to induce angiogenesis and osteoblast cell migration [LEE 2003, EMAD 2006, 
MAYR-WOHLFHART 2002, PUFE 2002]. 
 
5.3.3 Quantification of Growth Factor Release Kinetics 
 Seven scaffolds were loaded with 2000 ng BMP-2, 200 ng TGF-β3, and 1000 ng 
VEGF each. The preparation of these scaffolds was consistent with those prepared for in 
vivo implantation. Scaffolds were maintained at 37°C for 21 days in serum-free α-MEM. 
Media was collected and entirely replaced to maintain sink conditions at the following 
time points: 20 minutes, 40 minutes, 6 hours, 12 hours, 24 hours, 2 days, 3 days, 4 days, 5 
days, 6 days, 7 days, 10 days, 14 days, and 21 days. The quantity of growth factor 
released to the media was quantified using ELISA kits obtained from R&D Systems 
(Minneapolis, MN). For TGF-β3, only the active form of the growth factor is quantified 
by this method. Likewise, the ELISA kits quantify only the mature dimerized forms of 




5.3.4 Study Designs 
 Multiple studies were run to determine the effects of several conditions in vivo.  
Study 1: Dose-Dependent Effects of VEGF Delivery on Bone and Vascular Structure 
Formation 
 Two identical studies were run with two different outcome measures. One sample 
population went towards quantification of vascular invasion into the defect site using 
contrast agent-enhanced micro-CT. The second sample population was assayed by use of 
in vivo X-rays, in vivo and in vitro micro-CT, and post-mortem mechanical testing. For 
both studies there were four treatment groups: 0 ng VEGF (PLDL only), 10 ng VEGF, 
100 ng VEGF, and 1000 ng VEGF.  
 
Study 2: Effects of Scaffold Geometry and Composition on Bone Formation and 
Vascular Invasion 
 In the interest of improving the rate and quantity of bone deposition within the 
defect area and increasing the quantity of vasculature that forms within the core of the 
scaffold, the scaffold geometry and composition was modified. Scaffold geometry was 
modified by removing a 1.5 mm longitudinal core from the center of the scaffold. 
Composition was altered by adding 10% α-tricalcium phosphate to the polymer solution 
during the production process. The effects of these parameters were quantified by 
assessing radiographic union using digital X-rays, use of in vivo and in vitro micro-CT, 
and mechanical testing. In the interest of enhancing angiogenesis within the center of the 
scaffold, cored PLDL/TCP scaffolds were augmented with growth factor using two 
different techniques: fill the scaffold with growth factor in alginate then remove the core 
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(fill then core) or core the scaffold and then fill with growth factor in alginate (core then 
fill). The purpose of employing these two different loading regimes was to determine if 
the presence of alginate was inhibiting revascularization of the defect site.  
 
Study 3: Addition of an Angiogenic Growth Factor to the Osteogenic Cocktail BMP-
2/TGF-β3 
 Triple growth factor delivery (2000 ng BMP-2 + 200 ng TGF-β3 + 1000 ng 
VEGF) was compared to dual growth factor delivery (BMP-2 + TGF-β3), single growth 
factor delivery (VEGF), and delivery of a scaffold alone. For all groups, cored 
PLDL/TCP scaffolds filled with short chain RGD-functionalized alginate (core scaffold 
then fill with alginate method) were used. The efficacy of these treatments was 
determined using 2-D digital X-rays, 3-D quantitative micro-CT done both in vivo and in 
vitro to assess bone formation, in vitro micro-CT paired with contrast agent delivery for 
assessment of vascular structure formation, and torsional mechanical testing.  
 
5.3.5 Surgical Procedure 
 All surgical procedures were reviewed and approved by the Institutional Animal 
Care and Use Committee at Georgia Institute of Technology (Protocol A05041). Female 
Sasco Sprague Dawley-rats aged 13 weeks were used. Anesthesia was induced and 
maintained using isoflurane. Bilateral incisions were made over the anterior aspect of the 
femurs. The femurs were exposed using blunt dissection of the muscle tissue. Custom 
modular fixation plates were secured directly to the bone using miniature screws. Full-
thickness 8 mm long diaphyseal defects were created bilaterally using a miniature 
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oscillating saw cutting under irrigation. Defects were flushed with sterile saline prior to 
implantation of a scaffold. PLDL scaffolds with or without growth factors (all containing 
RGD-alginate) were press-fit into the defects. The incisions were closed according to 
anatomic layers using absorbable suture and wound clips. Analgesia consisted of 0.05 
mg/kg buprenorphine every 8 hours postoperatively for the first 48 hours and 0.025 
mg/kg buprenorphine every 8 hours for the following 24 hours. Animals resumed normal 
ambulation within 2-3 days post-op and did not show signs of pain or distress.  
 
5.3.6 X-ray and Micro-CT 
 Digital 2-D X-rays were taken every 4 weeks postoperatively until the studies 
were terminated. These X-rays were used primarily to assess defect stability. In vivo 
micro-CT was done at 4 and 12 weeks post-op in all studies where bone formation was 
assessed. For in vivo micro-CT, a resolution of 38.9 microns was used (Viva-CT 40, 
Scanco Medical, Bassersdorf Switzerland). The VOI was 4.6 mm thick. A Gaussian filter 
(sigma = 1.2, support = 1) was used to partially suppress noise in the VOI prior to 
application of a global threshold. The global thresholds corresponded to densities of 
206.7 and 270.3 mg hydroxyapatite/cm3, and excluded all non-mineralized tissues and 
residual scaffold material, as verified by visual examination of individual 2-D slices. The 
lower threshold was used to quantify total bone volume (mature + immature), while the 
upper threshold was used to assess mature bone volume. Immature bone volume was 
calculated as the difference between total bone volume and mature bone volume. The 
upper threshold (mature bone) was determined by two methods; a histogram of voxels 
attenuating vs the threshold was plotted and used to select an approximate threshold 
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value. This threshold value was then validated using visual inspection of 2-D slices. The 
threshold of 270.3 mg HA/cm3 corresponds to the attenuation of mature cortical bone in a 
rat. The immature bone threshold was selected as the lowest value that could be analyzed 
without picking up image artifacts or distorting the bone structure. 
 
5.3.7 Mechanical Testing 
 Samples were harvested at the termination of each study (12 weeks post-op), 
wrapped in saline-soaked gauze and stored at -20°C. Mechanical testing was done after 
samples were thawed in a bath of room-temperature saline, unwrapped, and immediately 
scanned using in vitro micro-CT at a 20 µm resolution. After scanning, samples were 
potted in end blocks using Wood’s metal and secured by placement of a transverse pin 
that penetrated the potting blocks and the ends of the femur. Samples were wrapped in 
saline-soaked gauze to preserve tissue hydration during transport and setup. Samples 
were then tested to failure in torsion at a rate of 3°/second using a Bose ElectroForce 
(ELF) system (ElectroForce 3200, Bose Corporation, Eden Prairie, MN). 
 
5.3.8 Histology 
 One representative sample from each treatment group was selected for 
histological evaluation. Sections were taken at a 5 µm thickness and stained using 






 Analysis of variance was conducted using a general linear model and Tukey 
pairwise post-hoc comparisons (Minitab). Differences were considered statistically 




5.4.1 Quantification of Growth Factor Release Kinetics 
 Release of growth factors was quantified using ELISAs. The ELISA kits, 
purchased from R&D Systems (Minneapolis, MN), quantified only the active form of 
TGF-β3 and the mature forms of soluble BMP-2 and VEGF. Seven scaffolds were loaded 
with the triple growth factor combination delivered in RGD-alginate: 2000 ng BMP-2, 
200 ng TGF-β3, and 1000 ng VEGF. They were maintained in media at 37°C for 21 
days. Samples were collected at the following points in the incubation period: CaCl2 bath, 
CaCl2 + NaCl + HEPES bath, 6 hours post-seeding, 12 hours, 24 hours, 1 day, 2 days, 3 
days, 4 days, 5 days, 6 days, 7 days, 10 days, 14 days and 21 days. For all three growth 
factors, the majority of the release took place over the first 5 days in culture (Figures 41, 
42, 43). About 25% of the total growth factor delivered was released in active soluble 
form over 21 days in vitro. VEGF released somewhat more quickly than BMP-2 and 










Figure 41: Cumulative quantity of soluble active BMP-2 released to media over 21 days 












Figure 42: Cumulative quantity of soluble active TGF-β3 released to media over 21 days 































































































Figure 43: Cumulative quantity of soluble active VEGF  released to media over 21 days 











































5.4.3 X-ray Imaging 
Study 1: Dose-Dependent Effects of VEGF Delivery on Bone and Vascular Structure 
Formation 
 Delivery of VEGF at any of the three doses (10 ng, 100 ng, 1000 ng) did not have 
a marked effect on the rate of bony union (Figure 44). Osseous union was apparent in 
only two samples over the course of this study; one sample from the 10 ng treatment 
group (1/5) and one sample from the 1000 ng treatment group (1/7). For a scaffold alone, 
no samples achieved bony union (0/5) and likewise for the 100 ng treatment group (0/7).  
  
Study 2: Effects of Scaffold Geometry and Composition on Bone Formation and 
Vascular Invasion 
 In this study, rates of bony union were assessed for four different scaffold 
designs, each delivering 2000 ng BMP-2 and 200 ng TGF-β3. In the traditional geometry 
PLDL treatment group, 5/7 sample united. When a 1.5 mm core was removed from the 
PLDL treatment group, 9/15 samples achieved bony union. Addition of 10% TCP to a 
traditional PLDL scaffold resulted in 3/9 samples achieving union. Coring of this 
PLDL/TCP scaffold containing growth factors promoted 8/8 samples to achieve bony 





Study 3: Addition of an Angiogenic Growth Factor to the Osteogenic Cocktail BMP-
2/TGF-β3 
 Addition of 1000 ng VEGF to the osteogenic growth factor mix of 2000 ng BMP-
2 and 200 ng TGF-β3 did not affect the rate of bony union in cored PLDL/TCP scaffolds 
(Figure 46). For this study, rates of bony union were as follows: Scaffold only 2/7, 1000 











Figure 44: Digital 2-D X-rays of samples from the VEGF dose study (5 ≤ n ≤ 7). Rates of 












Figure 45: Digital 2-D X-rays of samples from the scaffold modification study (7 ≤ n ≤ 
15). In the traditional PLDL treatment group, 5/7 samples achieved union. For cored 
PLDL 9/15, 3/9 traditional PLDL/TCP, and 8/8 cored PLDL/TCP samples achieved 
union.
































































Figure 46: Digital 2-D radiographs of the samples from the triple growth factor co-
delivery study (5 ≤ n ≤ 12). Of the samples that received BMP-2, TGF-β3, and VEGF 
11/12 achieved union. Co-delivery of BMP-2 and TGF-β3 promoted 11/12 samples to 
unite. Delivery of VEGF alone did not elevate the rate of union (0/5) over that achieved 
by delivering a scaffold alone (2/7). 



















5.4.4 Micro-CT Analysis 
Study 1: Dose-Dependent Effects of VEGF Delivery on Bone and Vascular Structure 
Formation 
 Quantitative in vivo micro-CT analysis was done at weeks 4 and 12 post-op. 
There were no differences in the bone volumes of these samples at either time point 
(Figure 47). Post mortem analysis at 12 weeks post-op showed results similar to the in 
vivo analysis (Figure 48). Spatial analysis of the core and peripheral VOIs as well as the 
proximal and distal VOIs revealed no differences (Figure 49, Figure 50, Figure 51). This 
in vitro micro-CT analysis revealed more bone on the distal end of the defect than on the 
proximal end. It is possible that the samples were inverted during scanning, which would 
explain this difference.  
 Combination of a contrast agent (Microfil MV122, Flowtech, Carver, MA) with 
micro-CT enabled quantification of the vascular structures within the defect site at 2 
weeks post-op. There were no differences between VEGF treatments in any of the VOIs 










Figure 47: Bone volumes in the central 4.8 mm of the defect area as determined using in 














Figure 48: Bone volumes as determined using in vitro post mortem micro-CT at 12 weeks 



















































































Figure 49: Bone volumes as determined using in vitro post mortem micro-CT at 12 weeks 






















Figure 50: Bone volumes as determined using in vitro post mortem micro-CT at 12 weeks 












































































































Figure 51: Micro-CT images of samples from in vitro scans at 12 weeks post-op. 
0 ng VEGF 10 ng VEGF






























Figure 52: Vascular volumes as determined using contrast agent-enhanced micro-CT at 2 
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Figure 53: Micro-CT images of perfused and decalcified samples after two weeks of 
implantation in vivo.  
0 ng VEGF 10 ng VEGF
100 ng VEGF 1000 ng VEGF
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Study 2: Effects of Scaffold Geometry and Composition on Bone Formation and 
Vascular Invasion 
  Altering the geometry of the PLDL scaffold (coring) or composition (addition of 
10% TCP) did not significantly affect the formation of mineralized matrix within the 
central region of the defect, as determined by in vivo micro-CT (Figure 54). Likewise, 
post mortem assessment of the entire defect region (8 mm) did not reveal any differences 
in treatment regardless of the VOI selected (Figure 55, Figure 56, Figure 57). Micro-CT 
images mirrored the improved bridging rates seen with the addition of cored PLDL/TCP 
scaffolds to the defect and the similarities in bone volume between all treatment groups 
(Figure 58). 
 The effects of alginate on the ingrowth of vasculature into scaffolds delivering 
VEGF were assessed using contrast agent-enhanced micro-CT at 2 weeks post-op. 
Although there were no significant differences between treatment groups, there was an 
increase in vascular volume in both the total (scaffold and periphery) and peripheral 










Figure 54: In vivo micro-CT data taken from scans at weeks 4 and 16 post-op (8 ≤ n ≤ 












Figure 55: Data from post mortem micro-CT scans at 16 weeks post-op (5 ≤ n ≤ 14). 












week 4  week 16
traditional PLDL, 2000/200 dose
cored PLDL, 2000/200 dose
traditional PLDL/TCP, 2000/200 dose






































































Figure 56: Spatial analysis of the in vitro micro-CT scans from 16 weeks post-op 
revealed no significant differences in the distribution of new bone between the treatment 











Figure 57: Distribution of the mineralized matrix between proximal and distal halves of 













































































































Figure 58: Micro-CT images of the samples at 16 weeks post-op. The images showed 
union rates that paralleled those seen in the 2-D digital X-ray analysis.  
Traditional PLDL Cored PLDL
















Figure 59: There were no significant differences between doses or growth factor loading 
regimes in terms of vascular ingrowth (5 ≤ n ≤ 9). There was an increased peripheral 
vascular volume in the 1000 ng core then fill group as compared to the same dose 








0 ng VEGF fill then core 100 ng VEGF fill then core 1000 ng VEGF fill then core 1000 ng VEGF core then fill



































































Figure 60: Micro-CT images of samples from the four treatment groups at 2 weeks post-
op. No significant differences in vascularity were detectable. 
0 ng VEGF Fill then Core 100 ng VEGF Fill then Core
1000 ng VEGF Fill then Core 1000 ng VEGF Core then Fill
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Study 3: Addition of an Angiogenic Growth Factor to the Osteogenic Cocktail BMP-
2/TGF-β3 
 Addition of 2000 ng BMP-2/200 ng TGF-β3 to the cored PLDL/TCP scaffolds 
significantly improved bone formation within the defects at 4 and 12 weeks post-op as 
assessed by in vivo micro-CT. Addition of VEGF – with or without BMP-2/TGF-β3 – 
had no effect on bone volume. The groups that received BMP-2/TGF-β3 had 
significantly elevated mature, immature, and total bone volumes as compared to the 
scaffold only and VEGF only treatment groups at 4 weeks post-op. The BMP-2/TGF-β3-
receiving groups had elevated mature and total bone volume measurements at 12 weeks 
post-op as compared to the scaffold only and VEGF only treatment groups (Figure 61). 
The two groups with BMP-2/TGF-β3 incorporated into the scaffold also experienced 
significant increases in bone volume with time, while the scaffold only and VEGF only 
groups did not. 
 Post-mortem analysis of bone volume within the 8 mm defect revealed the same 
patterns (Figure 62). Bone volume in both the core and periphery of the scaffold was 
increased by the addition of BMP-2/TGF-β3, but not by addition of VEGF (Figure 63).  
Both distal and proximal bone volumes were elevated in the BMP-2/TGF-β3-treated 
groups as compared to delivery of a scaffold alone. The group that received all three 
growth factors (BMP-2/TGF-β3/VEGF) had elevated proximal and distal bone volumes 
as compared to delivery of VEGF alone as well. Co-delivery of only BMP-2 and TGF-β3 
significantly increased distal bone volume as compared to VEGF alone (Figure 64).  
 Delivering VEGF alone or with BMP-2/TGF-β3 did not have an effect on 
revascularization of the defect site (Figure 65, Figure 66). Treatment was not a significant 
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factor in determining vascularity within any of the VOIs assessed (peripheral and 









Figure 61: In vivo bone volumes determined using micro-CT at weeks 4 and 12 post-op 
(5≤ n ≤ 12). ** p < 0.001 for immature, mature, and total bone volumes. * p < 0.05 for 
mature and total bone volumes. † p < 0.05 for time. The addition of BMP-2/TGF-β3 
significantly increased mature and immature bone volumes at 4 weeks over delivery of 
VEGF or a naked scaffold. At 12 weeks post-op, addition of BMP-2/TGF-β3 
significantly increased mature and total bone volumes over delivery of a scaffold or 
VEGF alone. The VEGF, BMP-2/TGF-β3, and BMP-2/TGF-β3/VEGF groups all 










Figure 62: Bone volumes determined using in vitro micro-CT (4 ≤ n ≤ 12). ** p < 0.030 
for immature, mature, and total bone volumes. The groups that received BMP-2/TGF-β3 
in the treatment, with or without VEGF, demonstrated a significant increase in immature, 




























































































































Figure 63: Core and peripheral VOIs were evaluated in the in vitro scans at 12 weeks 
post-op (4 ≤ n ≤ 12). ** denotes p < 0.050 for core and periphery VOIs. Co-delivery of 
BMP-2/TGF-β3 with or without VEGF significantly increased bone volumes in the core 










Figure 64: Proximal and distal halves of the 8 mm defect region were analyzed using in 
vitro micro-CT (4 ≤ n ≤ 12). ** denotes p ≤ 0.042 for proximal and distal VOIs. Addition 
of BMP-2/TGF-β3 to the defects significantly increased bone volume in both the 



































































distal p = 0.001




































Figure 65: Vascular volumes quantified within the defect site at 2 weeks post-op (n = 8). 
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Figure 66: Micro-CT images of perfused, decalcified samples at 2 weeks post-op. No 


























































































5.4.5 Mechanical Testing 
 
Study 1: Dose-Dependent Effects of VEGF Delivery on Bone and Vascular Structure 
Formation 
 The delivery of VEGF at any dose did not significantly impact mechanical 
properties. Stiffness and maximum torque were unaffected by delivery of VEGF (Figure 











Figure 67: Stiffness measured at 12 weeks post-op (4 ≤ n ≤ 7). VEGF delivery had no 










Figure 68: Maximum torque values at 12 weeks post-op (4 ≤ n ≤ 7). Delivery of VEGF at 




































































Study 2: Effects of Scaffold Geometry and Composition on Bone Formation and 
Vascular Invasion 
 Modification of the scaffold geometry (removal of a 1.5 mm longitudinal core) 
and composition (addition of 10% TCP) did not significantly impact stiffness or 






















Figure 70: Maximum torque was not significantly impacted by scaffold modification (7 ≤ 






































































Study 3: Addition of an Angiogenic Growth Factor to the Osteogenic Cocktail BMP-
2/TGF-β3 
 Delivery of BMP-2/TGF-β3 significantly increased stiffness (p = 0.004). Taken 
individually, there were no significant differences between treatment groups, although 
treatment was a significant factor (p = 0.004) (Figure 71). Similarly, treatment was a 
significant factor in determining maximum torque (p = 0.041); delivery of BMP-2/TGF-










Figure 71: Stiffness measurements taken at 12 weeks post-op (5 ≤ n ≤ 12). 
Treatment was a significant factor (p = 0.040). Collectively, delivery of 2000 ng 
BMP-2/200 ng TGF-β3 significantly increased stiffness over defects that did not 










Figure 72: Maximum torque measured at 12 weeks post-op (5 ≤ n ≤ 12). 
Treatment was a significant factor (p = 0.041). Collectively, delivery of 2000 ng 
BMP-2/200 ng TGF-β3 significantly increased maximum torque over defects that 






































































 Staining of samples with Masson’s trichome and von Kossa methods revealed 
minimal ingrowth of mineralized tissue into the porosity of a traditional geometry 
PLDL/TCP construct augmented with 2000 ng BMP-2 and 200 ng TGF-β3 (Figure 73). 
Micro-CT analysis of this group also indicated a somewhat decreased bone volume as 
well. The cored PLDL/TCP growth factor augmented scaffold showed mineral deposition 
throughout the longitudinal macropores of the scaffold (Figure 74). Similarly, a 
representative cored PLDL/TCP scaffold augmented with BMP-2, TGF-β3, and VEGF 
demonstrated mineralized matrix formation throughout the scaffold pores (Figure 75). 
Higher magnification images of H&E stained sections showed that the mineralized tissue 
was cellular in nature. Multinucleated cells resembling osteoclasts were visible on the 
surfaces of the newly deposited bone (Figure 76). Cells with single nuclei were also 






















Figure 73: Histological sections taken from a sample treated with a traditional geometry 
PLDL/TCP construct augmented with 2000 ng BMP-2 and 200 ng TGF-β3. Consistent 
with micro-CT quantification of bone volumes, this sample shows little mineralized 



















Figure 74: Histological sections taken from a sample treated with a cored PLDL/TCP 
construct augmented with 2000 ng BMP-2 and 200 ng TGF-β3. Consistent with micro-
CT quantification of bone volumes, this sample shows invasion of mineralized tissue into 
























Figure 75: Histological sections taken from a sample treated with a cored PLDL/TCP 
construct augmented with 2000 ng BMP-2, 200 ng TGF-β3, and 1000 ng VEGF. 
Consistent with micro-CT quantification of bone volumes, this sample shows significant 
invasion of mineralized tissue into the construct. Upper row, von Kossa staining; lower 




















Figure 76: Histological sections stained with H&E indicate that the mineralized matrix 
formed in the tissue-engineered constructs is cellular in nature, and undergoing active 
remodeling. Up arrows indicate osteocytes embedded in the mineralized matrix. 





































Figure 77: Histological sections stained with H&E indicate that the mineralized matrix 
formed in the tissue-engineered constructs is cellular in nature, and undergoing active 






Although the potency of VEGF as an angiogenic growth factor is well 
documented, its effects on bone formation are widely varied and may be highly dose-
dependent [STREET 2002, ECKHARDT 2003]. Use of VEGF in a large segmental 
defect has only been investigated in one other study; a rabbit radial defect model was 
treated with 0-1000 µg of VEGF. Delivery of high dose VEGF did enhance the callus 
volume of these defects [STREET 2002]. Delivery of VEGF protein has also been 
reported to enhance bone formation in irradiated calvarial defects [KAIGLER 2006]. The 
studies presented here noted two things; delivery of VEGF at doses that may cause 
angiogenic responses in various in vivo models are ineffective at promoting new bone 
formation in this model, and elevation of early vascular structure development was not 
enhanced by the delivery method of VEGF used in this model. Delivery of as little as 10 
ng/ml of VEGF has been shown to induce chemotaxis of osteoblastic cells [MAYR-
WOHLFHART 2002]. VEGF concentrations in a standard rat tibial fracture model peak 
at 5 days post-fracture at a concentration of approximately 100 pg/ml [PUFE 2002]. The 
equivalent doses delivered in the studies here range from 1-10 µg/ml, well above the 
threshold of physiologic values. Application of 1.25 µg of VEGF to a 10 x 5 mm cranial 
defect in conjunction with demineralized bone matrix grafts enhanced bone regeneration 
over control samples [EMAD 2006]. Delivery of 20-50 µg VEGF per gram of alginate 
(50 ug/g equates to 36 ng VEGF per implant) to a subcutaneous model of angiogenesis 
resulted in a significant increase in the number of blood vessels formed [LEE 2003]. 
Implants used here contained 10-1000 ng VEGF each. Delivery of 2-4 µg of VEGF has 
been shown to induce extensive angiogenesis in an in vivo model as well [ELCIN 2001]. 
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The dose-dependence of VEGF’s effects on angiogenesis vary widely in reports 
[STREET 2002]. The quantity of growth factor actually delivered to these defects was 
significantly less than that which was intended. In a similar alginate system, VEGF 
release was reported to reach 40% of the growth factor incorporated by 21 days of in 
vitro incubation [SILVA 2007]. The release of only ~25% here suggests that perhaps the 
PLDL scaffold is binding up some of the growth factors as the alginate releases them, 
resulting in inefficient delivery of the intended dose. One other probable explanation for 
these results is that the dose of VEGF used in this model is simply too low to accelerate 
the bone repair process or further stimulate angiogenesis in the model. Clearly, based on 
the growth factor release kinetics, the dose of VEGF that was actually released is far 
lower than that which was intended to be delivered. Recently published studies indicate 
that the dose of VEGF required to enhance mineral formation in certain models may be 
around 3 µg [HUANG 2005, HAO 2007, KAIGLER 2006, STREET 2002]. The quantity 
of bioavailable growth factor may also be lower due to the complex signaling and activity 
that takes place in traumatic injury. Removal of a large section of tissue activates 
proteases, which may be degrading the growth factors as they are released from the 
implant. Sequestering the growth factors in the alginate may also prevent some 
percentage of the protein from being released in active form; it is possible that the growth 
factors are not in an active conformation or orientation when contained in the alginate.  
It is, however, also possible that the animal’s angiogenic response is already at its 
maximum capacity to respond due to the acute injury; this would leave no room for 
elevation of vascular structure development to improve. It is also possible that in such a 
small total defect size (8 mm), that revascularization is not the rate-limiting step. Without 
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delivery of VEGF, scaffolds become vascularized throughout. Work by Rai et al. 
indicates that there is a potential to enhance vascularity within the defect site at 3 weeks 
post-op in this model; delivery of platelet-rich plasma resulted in a trend towards elevated 
vascular volume at 3 weeks post-op as compared to delivery of a scaffold alone [RAI 
2007]. The delivery of PRP was shown to enhance mineralization over delivery of a 
scaffold alone at 12 weeks, but not at 4 weeks post-op. The timing of VEGF release in 
the model system presented here may be suboptimal. Delivery at a later time point when 
the acute physiologic reactions have subsided may be more effective at generating an 
angiogenic response.  
Alternatively, the alginate matrix may be binding the VEGF, inhibiting release of 
the protein into the surrounding tissue. Residual alginate matrix within the scaffold, as 
well as chains that have been freed from the matrix due to crosslink degradation, may be 
bound to VEGF, inhibiting detection of the molecule. Delivery of VEGF from an alginate 
matrix has been shown to enhance the bioactivity of the growth factor [SHERIDAN 
2000]. Sustained release of VEGF has been shown to enhance angiogenesis over a longer 
period of time (8 weeks), while damping the initial response [ELCIN 2001]. If the release 
of VEGF is delayed in the PLDL/alginate system used here, it may be that the 
angiogenesis was quantified at a time point (2 weeks) too early to capture the physiologic 
response. Yet another possible explanation is that the VEGF is bound by the scaffold in 
an inactive form as the alginate degrades, resulting in delivery of a far lower dose of 
VEGF than was intended.  
The in vitro experiment quantifying growth factor release from the scaffolds put 
the cumulative release of growth factors at about 25% of the quantity loaded, with the 
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majority of the release occurring over the first 2-5 days in culture. There are a variety of 
possible explanations for the fate of the remaining ~75% of growth factor. The simplest 
explanation is that the remainder of the growth factor is bound up in the residual alginate 
matrix. Because of the large osteogenic response seen with implantation of the BMP-
2/TGF-β3-containing constructs, it is probable that the bound growth factor is released or 
exerts its effect as cells invade the construct. Another possibility is that the remainder of 
the growth factor is actually released from the matrix, but in denatured or inactive form. 
Although this may be the case, it might be unlikely; the delivery of low doses of BMP-2 
in other segmental bone defect repair models does not stimulate osseous union [LEE]. 
Alternatively, the growth factors could be released still bound to the alginate fragments, 
or be binding to the PLDL scaffold itself as they are released from the alginate. If the 
growth factors are still bound to alginate fragments, they may be active, but unable to be 
detected by the antibodies used in the ELISAs as the alginate could be blocking the 
detection epitopes. The PLDL scaffolds were pre-coated with fibronectin prior to growth 
factor seeding. Although the stability of fibronectin may have occluded open binding 
sites for the growth factors, inhibiting their adhesion to the scaffold, fibronectin itself has 
been known to bind proteins.  
It is difficult to determine how well the sustained delivery mechanism selected for 
use here correlates properly to the physiologic response to fracture repair. Expression of 
TGF-β3 typically peaks during the endochondral bone formation/periosteal response 
phase, and is sustained through primary bone formation during fracture healing. 
Histological evaluation of samples did not show evidence of endochondral bone 
formation, although a periosteal response to the injury was activated sometime during the 
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first four weeks in vivo. BMP-2 expression during fracture healing peaks in the early 
stages of injury and inflammation, with continued lower level expression throughout 
fracture healing [GERSTENFELD 2003]. It may be that the efficacy of BMP-2 in this 
model is due in part to early delivery of soluble active growth factor with sustained low-
level delivery through later time points, somewhat paralleling the natural fracture healing 
response. VEGF expression during fracture healing is not as great in magnitude as that of 
BMP-2, but appears to be more active during the primary bone formation stage of 
fracture healing. This suggests that evaluating vasculature at a later time point may 
enable differences between treatment groups to be determined.  
Scaffold architecture and composition plays an important role in the vitalization 
of the implant. This is apparent as the lack of porosity in allografts and many ceramic 
implants impedes tissue ingrowth. Although treatment differences between sample 
groups were not apparent in terms of bone volume or mechanical properties, the union 
rate of the cored PLDL/TCP constructs was higher than that of any other group. For this 
reason, the cored PLDL/TCP scaffolds were selected for investigation in the studies that 
followed. Despite the lack of significant differences between treatment groups in the 
study assessing the growth factor loading regimes, it should be noted that between studies 
1 and 2, there was a 2-fold increase in the vascularity. This may be due to the removal of 
the core from the center of the scaffold (the perfusion and imaging techniques remained 
constant between the two studies). The addition of 10% TCP to the scaffold was done 
under the hypothesis that accelerating the scaffold degradation process in vivo such that it 
would more closely match the rate of bone ingrowth. The long residence time of the 
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scaffold in the host body, however, means that 12 weeks may be too short of a time 
period to determine the effects of adding a ceramic on degradation of the PLDL scaffold.  
 The addition of VEGF to the osteogenic growth factor cocktail of BMP-2/TGF-β3 
had no beneficial effect on bone formation or vascular invasion. It has been previously 
reported that co-delivery of DNA encoding BMP-4 and VEGF enhances bone formation 
in a synergistic manner when delivered subcutaneously in the presence of bone marrow 
stromal cells [HUANG 2005]. Data presented in the work described here does not show 
an interactive effect with co-delivery of BMP-2 and VEGF protein. This may be due to 
the low doses of total protein used, the rate of growth factor release from the alginate 
matrix within the scaffold, or a combination of both factors. The work by Huang et al. 
describes the synergistic interaction between BMP-4 and VEGF gene delivery to occur 
only when BMSCs were co-delivered in the scaffold as well. The time required for 
osteoprogenitor cells to infiltrate the alginate-filled PLDL scaffolds may be such that the 
majority of the freely diffusible growth factor is gone by the time the cells populate the 
defect region. The remainder of the VEGF and BMP-2 protein, bound to the residual 
alginate and/or PLDL, could be sequestered in manner that prevents a single cell from 
interacting with both growth factors in the means necessary to induce a synergistic 
response.  
 The rate of delivery and mechanism of growth factor delivery may be critical to 
the success of the therapy. Scaffold geometry also plays an important role in enabling the 
invasion of vascular structures into the defect site, particularly within the bounds of the 
scaffold itself. Co-delivery of VEGF with BMP-2 and TGF-β3 provided no additional 
benefit over delivery of the two osteogenic growth factors alone in terms of 
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revascularization of the defect site or regeneration of functional bone. Delivery of VEGF 
at doses that may induce neovascularization in a variety of models was unsuccessful in 
elevating the angiogenesis over the innate, unaugmented response of the host body to 
creation of the defect. These doses of VEGF were also unsuccessful in promoting new 
bone formation. In the third study, however, it should be noted that the VEGF-treated 
defects did experience a significant increase in bone volume between weeks 4 and 12 
post-op. 
 The co-delivery of 2000 ng BMP-2 and 200 ng TGF-β3 demonstrated continued 
bone formation over 12 weeks in vivo and resulted in significantly improved mechanical 
properties over groups that did not receive BMP-2/TGF-β3 as a treatment (VEGF only or 
scaffold only). The maximum torque of the BMP-2/TGF-β3-treated samples approached, 
and in some cases reached, that of intact age-matched femurs. Studies described in 
previous chapters met with similar success in terms of bone volume and rate of bony 
union, but had marginally less success in reaching intact femur mechanical properties. 
The third study done in the chapter presented here used a new batch of fixation plates that 
turned out to be structurally compromised; approximately 50% of the plates in the VEGF 
only and scaffold only treatment groups fractured between weeks 8 and 12 in vivo. This 
reduction in mechanical integrity of the fixation plates might have resulted in increased 
load-sharing with the scaffold in the defect site. In defects without BMP-2/TGF-β3, there 
was inadequate mineralized matrix invasion to support load. Defects that did receive 
BMP-2/TGF-β3 had adequate integration with the host bone and mineralization within 
the central region of the implant to support this load. The increase in bone volume could 
also be due to delivery of a more potent lot of growth factor.   
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 In conclusion, addition of VEGF at any of the three purportedly angiogenic doses 
– 10 ng, 100 ng, and 1000 ng – did not improve mineralization or revascularization of the 
defect site over delivery of a PLDL scaffold alone. Although scaffold geometry did not 
affect the bone volume or mechanical properties for defects treated with BMP-2/TGF-β3-
augmented PLDL scaffolds with cored geometries and/or 10% TCP added. The rate of 
bony union was higher, however, in the cored PLDL/TCP group. Based on this 
observation, the cored PLDL/TCP scaffold was selected for use in the remaining studies. 
The manner in which the growth factors were added and the longitudinal core of the 
scaffold removed did not significantly affect vascular volume, although there was a 
strong trend towards increased peripheral vascular volume in the group treated with 1000 
ng VEGF delivered in PLDL/TCP scaffolds that were pre-cored and then loaded with 
growth factor-containing alginate. This observation, along with ease of use for the 
surgeon, prompted the use of pre-cored PLDL/TCP scaffolds for the triple growth factor 
study. Delivery of VEGF alone or with BMP-2/TGF-β3 did not significantly enhance 
mineralization or mechanical properties of the samples over co-delivery of only BMP-2 
and TGF-β3. The VEGF-treated group did experience a significant increase in bone 
volume with time though, suggesting that controlled release of VEGF may enhance bone 
formation long-term (beyond the 12 week scope of these studies). The complex problem 
of the release of the BMP-2, TGF-β3, and VEGF from the scaffolds merits further 
investigation. The simplest explanation for the fate of the unreleased growth factors is 
that they are sequestered in the remaining alginate, and exert their bioactivity only when 
cellular invasion forces degradation of the alginate structure and the progenitor cells take 




CONCLUSIONS AND FUTURE DIRECTIONS 
 
6.1 Segmental Defect Model and Analysis Techniques 
  The development of a reproducible and robust critically-sized defect model 
described in Aim I was central to the work in this thesis. The hardware and techniques 
used to stabilize and create these defects improves upon that of other researchers in 
several ways. Firstly, the hardware enables stable fixation of the defects, limiting 
confounding factors such as micromotion. Micromotion in a defect site compromises the 
body’s ability to heal and may make subcritically sized defects appear critical in nature. 
Stabilization of bone defects is critical to healing. Early experimentation with 5 mm 
defects (data not included in this thesis) revealed that 5 mm segmental defects were 
subcritical in size; they healed randomly and spontaneously in the absence of treatment. 
Attempts at defect fixation using the standard polyethylene block and four Kirshner wires 
method revealed gross instabilities in the defects. Many of the defects treated with this 
fixation technique collapsed over the duration of a 12 week study. The novel hardware 
developed here not only provides stability to the defect, but also serves as a guide for the 
surgeon. Two notches designed into the underside of the plate serve as guides for 
placement of the miniature oscillating saw, enabling the surgeon to reproducibly generate 
8 mm long defects. The stainless steel anchor plates secure directly to the bone using four 
miniature screws, providing a solid base to which the polysulfone bridging plate is 
affixed. This polymer plate allows in vivo X-ray and micro-CT imaging of the defect site, 
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enabling the researcher to do longitudinal studies and thereby reducing the number of 
animals and variability within each study. Removal of the plate is easy and can be 
achieved without damaging the bone or repair tissue, as the polymer plate is affixed to the 
stainless steel anchor plates, not the bone itself. Facile removal of the bridging plate is 
critical to maintaining the integrity of the repair tissue for mechanical testing post 
mortem.   
  The image analysis techniques used in the work described here have been shown 
to match histomorphometric techniques for quantifying vasculature, and exceed 
conventional techniques in reproducibility [DUVALL 2004]. One aspect of the vascular 
perfusion/micro-CT method that would benefit from further analysis is the determination 
of the proper resolution at which samples should be scanned. A resolution of 20 µm was 
most reasonable in terms of the scan time and computational power required to analyze 
the data. Analysis of samples at a higher resolution (10 µm) does not significantly alter 
the vascular volume, but does impact other parameters such as connectivity (see 
Appendix A). The increase in image detail obtained with higher resolution comes at the 
cost of time, data storage capacity, and computational power. Another aspect of this 
imaging technique that would benefit from improvement is the contrast agent used. Use 
of the Microfil silicone-based contrast agent requires termination of the animal. If a high-
contrast agent suitable for delivery in vivo that is also capable of being segmented from 
the bone could be developed, longitudinal studies of vascular development in defects 
would be possible.  
 It was hoped that by correlating mechanical properties with bone volume data 
through the studies presented here, a means of estimating stiffness and maximum torque 
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form in vivo or in vitro micro-CT scans would be developed. Several VOIs were analyzed 
in an attempt to establish this correlation – the central 4.5 mm long region of the defect, 
the entire defect (8 mm), the proximal half of the defect, and the distal half of the defect. 
Although statistically significant correlations between stiffness and all VOIs and 
maximum torque and all VOIs emerged, the R-squared value ranged form 41.6% to 65%. 
The distal, proximal, and central VOIs did not correlate with maximum torque or 
stiffness in an increasing linear manner for bone volumes of less than approximately 50 
mm3. Similarly, use of the entire 8 mm VOI did not result in a positive linear correlation 
for bone volumes of less than 100 mm3. These findings indicate that there may be some 
critical bone volume that must be achieved before increases in maximum torque or 
stiffness occur. Further work into establishing this threshold value would be of interest in 
attempting to use in vivo scans to assess mechanical integrity of the defects. 
 
6.2 Growth Factor Delivery and Release 
 The delivery mechanism for VEGF, BMP-2, and TGF-β3 used in these studies is 
simple in conception and implementation, but challenging to characterize. Based on 
findings in the literature and the data obtained from the in vivo studies here, it is clear that 
the alginate-filled PLDL scaffold results in controlled release of the growth factors over 
an 2-5 day period of time. In vitro characterization of the growth factor release kinetics 
indicated that only a quarter of the total protein delivered is freely diffusible from the 
scaffold in its active form. Studies investigating delivery of VEGF from an alginate 
hydrogel system have put the total release of growth factor at about 40% of the quantity 
incorporated into the alginate over 21 days in vitro [SILVA 2007]. Comparison of the 
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studies presented here and those in the literature suggest that remainder of this growth 
factor might be bound within the remaining alginate and PLDL scaffold, exerting its 
effect only as cells migrate through the construct. The ability of the implant to release 
bioactive factors to the host tissue may be critical to the success of the tissue-engineered 
treatment strategy. If the growth factor is delivered exclusively as a molecule tethered to 
the scaffold, there is no diffusible signal to the surrounding host cells that would 
potentitate cellular proliferation and/or migration to the implant site [RIZZI 2006, 
LUTOLF 2003]. On the other hand, if the growth factor is too readily diffusible, there is 
inadequate sustainment of the signal to achieve a substantial biological response unless a 
large quantity of bioactive agent is delivered [OHURA 1999, HONG 2000]. Further 
investigation of the growth factor release from the alginate-PLDL system could be 
accomplished by dissolving the residual alginate matrix as a means of releasing bound 
growth factor, although it is possible that the growth factors remain secured to the 
alginate polymer chains themselves. Radiolabeling the growth factors and tracing their 
release from the matrix would provide a more accurate description of the location of the 
growth factors with time. Engineering a well-controlled release strategy for growth 
factors is difficult. In most hydrogel and polymer systems, the microstructure of the 
delivery vehicle changes with time as the growth factor is released and the matrix of the 
delivery system degrades, gains water content, or becomes more porous. Use of 
controlled-release microspheres with varying degradation rates delivered in a stable 
hydrogel would be one option for controlling growth factor release in a minimally 
changing matrix.  
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6.3 Growth Factor Co-Delivery and Interactions 
 While co-delivery of BMP-2 and TGF-β3 significantly improved bone formation 
in a dose-dependent manner and improved the mechanical properties of the repair tissue 
over delivery of a scaffold alone, there was a marked absence of synergistic interaction. 
Co-delivery of physiologic doses of BMP-2 and TGF-β3 with BMSCs in an ectopic 
mouse model has been shown to produce a synergistic interaction that enhances 
osteogenesis by 6 weeks post-implantation [SIMMONS]. In the segmental defect model, 
delivery of the same physiologic dose of growth factor elicits no response above that seen 
with delivery of a scaffold alone. Co-delivery of the two growth factors at a dose one 
order of magnitude greater did, however, induce a significant increase in both early (4 
weeks) and late (12 weeks) bone formation. The delicate balance of BMP-2 and TGF−β3 
that produces the synergistic effect seen ectopically may be altered by scaling up the 
dosage in a linear manner, or by the presence of the growth factor milieu released by the 
resorption of the fracture haematoma, influencing the interactions between the proteins. 
The acute and traumatic nature of the segmental defect model may activate a significant 
early inflammatory response and produce active proteases within the injury site. This, 
combined with the many endogenous signaling molecules, may result in decreased or 
altered signaling as compared to the less acute subcutaneous model. Additionally, the 
segmental defect model used here relied on the proliferation and migration of endogenous 
osteoblastic cells to vitalize the implanted scaffold, whereas the subcutaneous study 
directly co-delivered the BMSCs with the growth factors. This delay in the presence of 
cells within the matrix may be partially responsible for the lack of a synergistic response, 
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as some of the freely diffusible growth factor had dissipated from the implant or lost its 
bioactivity by the time cells populated the scaffold.  
 Similarly, co-delivery of BMP-4 and VEGF in gene form has been shown to 
produce synergistic interactions in the presence of BMSCs in the murine subcutaneous 
implantation model [HUANG]. In the studies presented here, BMP-2 rather than BMP-4 
was selected, and the BMP/VEGF combination was delivered in protein form. Because of 
this, one would not necessarily assume that a synergistic interaction between BMP-2 and 
VEGF would result, although it does make a reasonable hypothesis. Although the same 
potential explanations for the lack of positive interaction between the BMP-2 and VEGF 
as were delineated previously for the BMP-2/TGF-β3 system, there is also the strong 
possibility that not enough VEGF was released to interact properly with the BMP-2. 
Alginate is known to bind VEGF when used as a hydrogel delivery system, although this 
interaction has been reported to enhance the bioactivity of the protein when it is released 
[SILVA 2007].  
 One future direction for consideration if the growth factor delivery system is 
selected for further use would be the determination of growth factor interactions in a 
more controlled model, such as in vitro tissue culture or subcutaneous or intramuscular 
implantations. A model system with fewer confounding factors – here the complex 
microenvironment created by induction of a severe defect – could potentially make it 
easier to tease out interactions between the growth factors. However, this approach is 
limited in its relevancy; the initial motivation for the use of growth factor co-delivery in 
the critically sized segmental femur defect model came from the finding that BMP-2 and 
TGF−β3 interacted synergistically in the subcutaneous implantation model.  
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 In most animal models of osteogenesis, the results of treatments are highly 
dependent on the type of scaffold used. It is possible that the PLDL scaffolds selected for 
use in these studies limited bone formation due to the small diameter of the macropores 
and relatively slow degradation rate. Use of a collagen sponge in this model would 
provide a means of assessing the effects of delivering slow vs. fast-degrading implants. It 
would also provide some comparison to the clinical BMP-2/ACS spinal fusion treatment. 
Another control group that is important in evaluating the efficacy of the growth factor 
treatment is the allograft. This is the clinical standard treatment, and direct comparison of 
the growth factor strategy tested here with the traditional allograft treatment would 
provide a measure to assess the potential advantages to using a tissue-engineered implant 
for functional bone repair.  
The use of BMSCs or MSCs delivered with or without angiogenic and/or 
osteogenic growth factors is also an interesting direction for research to expand using the 
model system established here. Although the host’s body provides adequate quantities of 
progenitor cells to regenerate the mineralized matrix and restore a certain level of 
mechanical integrity, augmentation of the implant with autogenous or syngeneic marrow 
progenitor cells may provide a means of accelerating the repair process. This approach 
has been widely investigated, but the survival of the delivered cells after implantation is 
sometimes compromised by the lack of a functional vascular supply to the defect site 
[KADIYALA, MARCACCI 2007]. Augmentation of a cellularized scaffold with 
bioactive factors that promote a rapid autogenous vascular and mineral deposition 
response could provide a means of maintaining the graft viability. In a similar vein of 
thought, modification of grafted cells to produce specific osteogenic genes has enhanced 
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the healing response [SAVARINO 2007, XIE 2007]. Although bone marrow progenitor 
cells have been the typical choice for these cell-based therapies, alternative cell sources 
have been investigated for use after genetic modification, including muscle-derived cells 
and fibroblasts [KREBSBACH 2000, PHILLIPS 2006, SHEN 2004]].  
Regeneration of bone in a segmental defect model requires the presence of cells, a 
scaffold or delivery vehicle, and a bioactive agent (such as a protein or gene). There is an 
unknown critical balance that must be achieved between these three components. The 
response described in the previous chapters may be limited by the availability of host 
cells as well as the delivery mechanism chosen for the growth factors. Conversely, 
delivery of cells alone has been somewhat limited by the lack of a biological stimulus 
that invokes a host response that will promote development of a nutrient supply to the 
engrafted tissue.  
 
6.4 Potential Modifications to the Model 
The use of the critically-sized femoral defect model described in the previous 
chapters has been constrained to immediate treatment after creation of the defect. 
Clinically, this aspect of the model may be irrelevant. In treatment of bone trauma, the 
ability of the host body is frequently compromised due to a variety of factors, including 
delayed treatment, radiation, infection, chronic nonunion, and smoking. A research model 
that mimics these confounding factors inherent to clinical treatment could potentially 
provide the opportunity to evaluate the full potential of delivered cytokines to augment 
the healing process. Induced chronic infection in a rat segmental defect model has 
indicated that, in conjunction with antibiotic therapy, delivery of only high doses (200 
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µg) of BMP-7 can induce bony repair [CHEN 2006]. Similarly, irradiation of bony 
defects has been shown to compromise the body’s ability to heal the defect. Radiation 
treatment provides a more relevant model for developing treatments for osteosarcoma. 
Patients who smoke tend to have longer bone healing times as well, although the reasons 
for this are not fully understood. Chronic nonunions may be more difficult to heal than an 
acute injury because the body’s natural sequence of healing reactions may have senesced. 
Reactivating these inherent phases of healing, such as haematoma formation, 
angiogenesis, and cartilaginous callus formation, may prove difficult. All of these 
modifications to the segmental defect model would provide a scenario more relevant to 
certain clinical conditions and possibly a more challenging defect to heal. 
 
6.5 Conclusions 
 In starting this work it was hypothesized that by exploiting growth factor 
interactions, osseous repair of segmental bone defects could be generated more quickly 
and with greater functionality than could be achieved by delivery of a single growth 
factor at the same dose. The data presented here does not support that hypothesis. 
Although a dose-dependent increase in bone formation and mechanical properties was 
seen with co-delivery of BMP-2 and TGF-β3, co-delivery of these growth factors at the 
higher dose did not provide significant benefit over delivery of BMP-2 alone. Addition of 
VEGF to the osteogenic combination of BMP-2 and TGF-β3 provided no benefit over 
delivery of these two factors alone.  
 The work presented here has established a revised and improved model for large 
bone defect repair and quantitatively analyzed the biological response to co-delivered 
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growth factor therapies in terms of angiogenesis, osteogenesis, and functionality of the 
repair tissue. The effects of scaffold geometry and composition on bone and vascular 
ingrowth were also investigated. Comparison of BMP-2 and TGF-β3 co-delivered at two 
doses indicated a positive dose-dependent response. The hypothesized benefit of adding 
TGF-β3 to BMP-2 was not supported. Altering the scaffold geometry by removing a 1.5 
mm diameter core and composition by addition of 10% TCP improved the rate of bony 
union and enabled more extensive revascularization of the defect site than was achieved 
with un-cored scaffolds. Delivery of VEGF alone to the defect site had no impact on bone 
formation or vascular invasion. Addition of VEGF to the BMP-2/TGF-β3 osteogenic 
cocktail had no beneficial effect over co-delivery of the osteogenic growth factors alone. 
The groups that received VEGF, BMP-2/TGF-β3, or BMP-2/TGF-β3/VEGF 
demonstrated a significant increase in bone volume between weeks 4 and 12 post-op, 
suggesting possible sustained release of the growth factors. The sustained release 
hypothesis could be supported by the only partial release of the growth factors in an in 
vitro protein release kinetics study. 
The acute injury caused by creating a critically-sized segmental defect activates a 
complex biological response beginning with haematoma formation and the angiogenic 
reaction. This immediate response is believed to be critical for inducing revascularization 
of the defect site. In many trauma situations, segmental defects are not immediately 
treated via surgical intervention. In these cases, delivery of VEGF might be more 
efficacious as the body’s natural angiogenic response may have senesced, giving room 
for a pro-angiogenic cytokine to exert its influence.   
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 This work sheds light on some of the critical factors for repair of large bone 
defects, motivates further investigation and modification of existing growth factor-based 
therapies, and opens the door for investigation of cellular-based tissue-engineered 
therapies in a robust osseous defect model. Further investigation into both combining 
growth factor and cell-based or growth factor and mechanically-oriented therapies would 





EFFECTS OF VOXEL RESOLUTION ON MICRO-COMPUTED 




 The utility of micro-CT as a quantitative imaging tool is limited by two 
incompatible factors: time and resolution. A high-resolution image requires significantly 
more time to generate and analyze, as well as more storage space, than a medium- or low-
resolution image does. In certain applications, however, the improved resolution of the 
image merits the use of more costly imaging. For the studies described here, a medium 
resolution of 20 µm was selected. This voxel size permitted timely analysis of a large 
quantity of specimens while still providing the capacity to detect quantitative differences 
in vasculature. A subset of perfused decalcified samples was analyzed at high resolution 
(voxel size of 10 µm) for purposes of comparison. The changes in quantitative 
parameters were generally consistent with what one would expect to occur by increasing 
the resolution of the image: connectivity and vessel number drastically increased, while 
the average vessel thickness and spacing decreased. Vascular volume experienced a 
moderate increase in switching to high resolution (Table 3). These changes in parameters 
suggest that at a higher resolution, the micro-CT imaging technique is better able to 
separate and detect small vascular structures that blended together or were undetectable at 









Table 2: Micro-CT parameters obtained at high and medium resolution in the VOI 
containing only the implanted scaffold for perfused hindlimbs in the rat segmental defect 


















































































Table 3: Micro-CT parameters obtained at high and medium resolution in the VOI 
containing only the core 2 mm of the implanted scaffold for perfused hindlimbs in the rat 
segmental defect model treated with VEGF. 
 
















































































Table 4: Micro-CT parameters obtained at high and medium resolution in the VOI 
containing the implanted scaffold and periphery for perfused hindlimbs in the rat 
segmental defect model treated with VEGF. 
 












































































 The pattern in relative change between parameters was slightly different for the 
scaffold core VOI. In this VOI, the vascular volume increased, connectivity, vessel 
number, and vessel thickness increased, and vessel spacing decreased by only about 50% 
with increasing resolution. The percent decrease in vessel spacing was dramatically less 
for the core VOI than for the scaffold or scaffold and periphery VOIs. This can be 
explained by the relatively sparse distribution of vascular structures within the core of the 
scaffold as compared to the abundance of vascular structures surrounding the scaffold. 
 The increase in resolution improved the ability of micro-CT to isolate vascular 
structures. One phenomenon that was not affected by the increase in resolution is the 
presence of mysterious “blobs” in the images (Figure 78). These rounded blob structures 
appeared in both medium- and high-resolution images. It is unclear if the structures are 
simply very dense beds of small capillaries that appear as a single globular structure due 
to the limited ability of the micro-CT to distinguish between extremely small structures, 
or if they are in fact pools of contrast agent that occur due to the inherent leakiness of 
immature vessels. If it were manageable to do histology on the perfused samples, it is 
theoretically possible that the blobs could be isolated and identified using 



















Figure 78: Micro-CT images of the same sample at medium and high resolutions. Note 



















• Polymer (PLDL, PLGA, PTMC, P(TMC-L-DL), etc.) (PLDL = Resomer LR 706, 
Boehringer Ingelheim) 
• Azodicarbonamide (Aldrich, cat # 123-77-3) 
• α-Tricalcium phosphate, ground to a fine powder 
• Media bottle, 100ml size 
• 316 stainless steel wire (0.004” diameter stress relieved wire, California Fine 
Wire) 
• Syringes -- 5ml and 1ml 
• Syringe needles – ga sizes 22, 20, and 16 (grey, yellow, and purple respectively) 
• Heat shrinkable tubing (1/8” – 3/16”, GB electrical from Home Depot) 
• Beakers 
• Acetone (Aldrich) 
• Hexanes (Aldrich) 
• Peanut oil 
• Scotch or autoclave tape 
• Ruler 
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• Razor blades 
• Biopsy punches (4mm diameter for rat seg gap scaffolds) 
• Oven 
• Long-handled hemostats. 
• Resin reaction flask, power controller, heating mantle, heat/stir plate, 
thermometer setup in fume hood. 
 
Procedure: 
Polymer solution preparation 
1. Combine dry polymer and azo compound powder in desired concentration in the 
media bottle 
30% azo = 5.6 g PLDL, 100 ml acetone, 2.4 g azo 
To make 10% TCP, add 1 g TCP to 100 ml PLDL/azo solution. 
2. Add approximately 10x by weight acetone (density ~ 0.79 g/ml) 
3. Allow the polymer to dissolve and reach a uniform solution. This step may take a 
few days, and may require addition of extra solvent or heat (37ºC water bath for a 
few minutes is ok). 
4. Solution should be viscous but still flow and maintain a single phase. 
 
Wire coating procedure 
1. String up lengths of wire (10 to 15 feet long) across the room, securing the ends 
with tape. 
2. Partially fill a 5 ml syringe with polymer solution. 
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3. Thread the wire into the 1 ml syringe (from the back so the wire tip comes out the 
small end of the syringe). If this is difficult, thread the wire through a sewing 
needle and bend the wire, then drop the needle through the syringe, or slightly 
bend the wire to eliminate its natural curvature. 
4. Thread the end of the wire through the 22 ga syringe needle, attach the needle to 
the syringe, and retape the wire to the wall or shelf. 
5. With the 1 ml syringe tilted slightly upwards, inject the solution from the 5 ml 
syringe into the 1 ml syringe. 
6. Pull the 1 ml syringe along the wire slowly so that a coating of solution is 
deposited on the wire. Remove any blobs of polymer solution with the tip of the 5 
ml syringe (or your finger) carefully. 
7. To begin the next wire, either rethread the wire on a new syringe or needle or 
rethread the ones you used for the first wire.  
8. You only coat once with the 22 ga needle.  
9. Allow this coating to dry for approximately 30 minutes, or until dry to the touch. 
10. Repeat this coating step twice more on each wire using the 20 ga needles. Allow 
these coats to dry 2 hours each or until dry to the touch. 
11. Repeat this coating four times with the 16 ga needle. For these coatings, you may 
need to refill the 1 ml applicator syringe with solution from the 5 ml syringe as 
you move along the wire. To do this, drip a little solution at a time in the 
applicator syringe as you continue to pull it along the wire. This allows the wire 
motion to carry the solution to the tip without producing backpressure and making 
too much of a mess. Allow these coats to dry 2 hours or overnight. 
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12. The next day, cut the wires into 8 cm lengths using a ruler and a razor blade. 
 
Preparing scaffold equipment 
1. Turn the oven on and heat to 125ºC. 
2. Resin reaction flask should sit on the heating mantle, which should sit on top of a 
stir plate. The heating mantle is controlled with a power controller. A 
thermometer should be clamped and suspended in the flask.  
3. Fill the flask ~half way with peanut oil. Remember – oil expands when it is 
heated. Make sure the thermometer tip is in the oil and you can read the 
graduations. 
4. Turn the stir bar on 
5. Turn the power controller that controls the heating mantle on. It should be set at 
the 82 rating so that the oil heats quickly without overheating. The maintenance of 
proper temperature will also depend on the flow rate of the fume hood. It will take 
about 45-60 minutes to heat to 260ºC. 
6. Fill the 250 ml beaker with water and place it near the stir plate. 
 
Heat treating the coated wires 
1. Count out wires to bundle them. This can be done one of two ways: 
a. Either by weighing out 10 wires, and subtracting 65.5 mg (for the bare 
wire) to determine how much polymer coating per meter of wire there is. 
Then calculate the polymer coating mass per 1 wire. Divide 424.4 mg by 
the mass of polymer per one wire (mg/wire) to get the number of wires 
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you need – this produces the scaffold size that Angela used to test the 
mechanical properties. This typically enbds up being 55-65 wires. 
b. Usually, i bundle 110 wires together, and measure them out by counting 
the number of wires. This provides a large enough diameter scaffold to 
punch out 4 mm scaffolds later. 
2. Pile the wires together and push them into the heat shrink tubing. You may have 
to cut the tubing. 
3. Pull out one wire on each end longer than the others – this will give you 
something to hold on to while frying the scaffolds. 
4. Place the heat shrink bundles in the oven on a piece of foil for 25 minutes at 
125ºC. 
5. Remove the bundles from the oven and cut in half using wire cutters. 
6. Unsheath the heat shrink tubing using a razor blade. The individual coated wires 
should not be clearly distinguishable at this time. 
 
Azodicarbonamide decomposition 
1. Verify that the peanut oil is at 260ºC. 
2. Clamp onto the one wire that’s sticking out of the uncut end of the coated wire 
bundle with the long-handled hemostats. 
3. Quickly dip the sample into the peanut oil such that it is completely covered. 
4. Gas will begin to escape the structure.  
5. When the gas effervescence stops (20-30 seconds), quickly remove the sample 
and submerge it in a beaker full of water to quench it. Sometimes the wires will 
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start to separate from each other during the procedure. If this occurs, you may lose 
your sample, so remove it quickly before full decomposition and quench in water. 
I find that for bundles of 110 wires, the scaffolds puff up and are on the verge of 
coming apart when the effervescence ceases. 
6. Repeat for the second half of the fused scaffolds. 
 
Final steps 
1. Blot the fried scaffolds with a paper towel. 
2. Dip the fried scaffolds in hexane to remove any excess oil. You should be able to 
see the oil perfuse out of the pores. 
3. Remove the wires with hemostats. Hold on to any wires you can find without 
damaging the ends and pull along the long axis of the scaffold. The wires should 
come out with a little resistance. 
4. Cut the scaffolds to size. The diameter can be sized using a biopsy punch. 
5. Wash the scaffolds again in new hexane to remove any remaining oil. 
6. Soak the scaffolds in water for a few hours to ensure any degradation products are 
leached out (the degradation compounds are water soluble). 
 
Sterilization 
1. Wash the scaffolds in 70% ethanol, then DI water, three times each, ending with a 
water wash. I usually do this by putting all of the scaffolds into a 50 ml conical 
and shaking them with the liquid. Then place them (using forceps) into eppendorf 
tubes and allow them to dry with the lids open overnight. Then close the tubes and 
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number the scaffolds (best = 1, worst = highest #), place 2 scaffolds per 
sterilization pouch, and place in a box to be shipped to the γ-irradiation facility. 
2. The dose for sterilization is 25 kGy (or 2.5 Mrad) at a standard dose rate. This 









Autoclave on trays, duplicate for two-table setup 
Tray 1 
 surgery drill 
 surgery saw 
 saw hex tool 
 jacobs chuck attachment and chuck keys 
 # 65 uncoated drill bits (1 per rat + extra = ___________) 
 5.5 x 12 x 0.4 mm micro oscillator saw blade (1 per rat + extra  = ____________) 
Tray 2 (double this for 2 table surgeries) 
 scalpel handles (2) 
 hemostats (2 curved mosquito) 
 needle holders/suture cutters (2) 
 small sharp scissors (1) 
 blunt scissors to cut drapes (1) 
 pickups (brown-adson forceps) (2) 
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 small pointed forceps (2 curved, 2 straight) 
 hex wrench for bone clamp (1) 
 russian forceps (2) 
 wound clip applicator (1) 
 wound clip remover (1) 
 retractors (3) 
 plate and bone holding clamp (1) 
 miniature screws, #00-90, ¼” length (eight per animal + extra = ________) 
 miniature screws, #000-120, 3/32” length (eight per animal + extra = ________) 
 bone plate assemblies, 1 polysulfone and 2 steel components per animal = 
___________ps & ___________ss) 
 small screw drivers – 2 of each size, larger and smaller tips (4) 
Tray 3 
 sterile surgery towels for draping over animal and on table 
Ethylene oxide- or gas plasma-sterilized materials 
 ioban film (1 small size per table) 
Gamma-irradiation sterilized materials 
 polymer scaffolds for implantation (quantity = _________) 
Autoclave separately in pouches 
 sterile bowls (2) (double for 2 table surgeries) 
 blunt square-ended bovie tips (2) 
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 white bovie cords (2) 
 hoses for surgery drill (2) and surgery saw (1) 
 extra wound clips 
 surgery lamp handles (2 sets) 
Other materials 
 4-0 vicryl suture (1 per rat = _______) 
 #10 scalpel blades (2 per rat + extra = _______) 
 sterile 4x4 gauze (1 package per rat = _______) 
 small sterile drapes (at least one package of 2 per rat, + extra = ________) 
 half-drapes for surgery table (1 per table = ________) 
 table drape for table with tools (1 per table) 
 surgical gowns for each sterile person 
 sterile gloves (one pair per person per rat) 
 glass bead sterilizer (1 per table) 
 sterile water for rinsing tools, and sterile water for irrigation (in bottle, 500 ml per 
table) 
 sterile needles for irrigation (gavage or 16g, 1 per table = ________) 
 sterile 10 ml syringes for irrigation (1 per table= ________) 
 extra nitrogen tank for second power saw 
 
Procedure 
• Turn on glass bead sterilizer 
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• Prewarm the surgery table and cover with a drape.  
• Clip hair from around the entire leg and hip area on the dorsal and ventral sides, 
including the lower abdomen (above where the rat’s waist would be if it had one) 
and down to the ankles. 
• Sterilize the entire shaved area, including the foot (the foot cannot be completely 
sterilized). 
• Transfer the rat to the surgery table, insert the rat’s nose into the nose cone, and 
elevate the feet so that they do not contact the tail. Secure the rat to the table with 
Ioban or a loop of suture running over the animal’s incisors and through the 
isoflurane face mask. 
• Holding the ankles with forceps, wrap Ioban around the animal’s feet. Cut a hole 
into the sterile drape for each foot and pull the feet through the hole. Or 
alternately arrange drapes around the leg to leave only one leg at a time exposed. 
• Place another sterile drape over the nonsterile areas of the rat’s torso and 
anesthesia nose cone. 
• Assemble the plate components on the instrument table. Secure the blade into the 
oscillating saw. Prepare the drill as well. 
• Make a long incision from the knee to above the hip on the anterior side of the 
femur. Retract the skin away. 
• Using blunt dissection, separate the quadriceps muscles on the anterior side of the 
femur, slightly lateral of the femur midline (at the first lateral muscle bundle). 
There should be a visible split in the muscle bundles that can serve as a guide. be 
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careful to avoid the femoral artery and the large cutaneous vein to the medial side 
of the quadriceps. 
• Loosen and retract the soft tissues from around the femur. Muscle tissue must be 
separated from the defect area to allow the plate & bone holding clamp to grip 
around the femur. 
• Place the fixation plate on the anterior side of the femur and hold in place with the 
plate & bone holding clamp. Drill through the bone using the screw holes on the 
plate as a guide. Start on the distal end and insert a threaded screw. Then place a 
proximal screw in the same manner. 
• Place the remaining two screws.  
• Using the oscillating saw, cut through the middle section of the diaphysis as 
indicated by the notches on the fixation plate, removing the central 8 mm of the 
femur. These cuts should be made perpendicular to the long axis of the femur and 
parallel to each other. Cool the site while cutting by irrigating with sterile water. 
Flush out the site after cutting to remove any debris and resdiual bone chips. 
• If a scaffold is being placed, press-fit it into the defect site using a lateral 
approach. If necessary, snip off excess lengths on the screws. 
• Close the soft tissues with 4-0 vicryl suture. 
• Close the skin incision using 4-0 vicryl suture and then apply wound clips. 
• Paint new-skin mixed with finely ground metronidazol over the incisions to 
discourage the animals from chewing on the sutures. 
• Remove the Ioban from the animal’s feet and body, and cradle the rat in a dark 
washcloth until it begins to move and regains sternal recumbency. 
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• Administer analgesics (buprenorphine) and return the animal to its cage. Begin 
observations. An Elizabethan collar may be placed if necessary to prevent the 
animal from chewing at its incisions. If possible, however, this should be avoided 
as the collar causes the animal additional stress. 
 
• Observations: each animal must be observed daily for ambulation. 
typical notes on ambulation: 
 1) the animal is walking normally. 
 2) the animal is weight-bearing on the operated leg(s), but lame. 
 3) the animal is not bearing weight on the operated leg(s). 
 4) the animal is dragging the operated leg(s).  
If an animal is not bearing weight on the operated leg(s), or is dragging the 
operated leg(s) for three consecutive days, consult the staff veterinarian. The 





RAT VASCULAR PERFUSION PROTOCOL 
 
Materials: 
• 0.9% normal saline 
• 1000 u/ml heparin 
• Microfil MV-122 (yellow color lead chromate compound) (http://www.flowtech-
inc.com) 
• 10% neutral buffered formalin  
• properly labeled waste bottles for formalin waste 
• 1 pair small surgical scissors, 1 pair large scissors, 2 hemostats, 1 small curved 
pair of forceps 
• 22 gage (blue) 1” long catheters 
• needles 
• pipettes and pipette aid 
• 1ml and 20ml syringes  
• peristaltic pump set at 15 ml/min flowrate 
• luer lock connectors as needed 
• diapers/chucks/absorbent plastic-backed workbench pads 
• 50 ml conicals for storage of femurs 
• gauze and cotton swabs 
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• 0.9% normal saline (~450 ml/rat) 
9 g sodium chloride 
1000 ml DI water 
• contrast agent (make 18 ml/rat) 
do not add catalyst until immediately before perfusing animal 
mix 5% catalyst, 95% MV (yellow) compound:   
do not add diluent 
do not heat MV compound  
• 10% neutral buffered formalin (~300 ml/rat) 
 
Perfusion 
1. Set up the peristaltic pump, check the flow, and bleed all air out of the line using 
the saline solution. You may have to start flow by siphoning the saline through 
the tubing using a syringe. 
2. Induce anesthesia at 5% isoflurane in an induction chamber. 
3. Switch animal over to the face mask at 2% isoflurane. 
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4. Check for pedal withdrawal reflex using the toe pinch.  When this reflex is not 
seen, the animal has reached a deep surgical plane and the procedure can begin. 
5. Using scissors, cut through the skin on the lower abdomen above the junction of 
the legs with the body. Then elevate the muscle tissue and cut through the muscle 
wall, exposing the internal organs. 
6. Move the internal organs aside and out of the abdominal cavity (to the animal’s 
left). 
7. Locate the abdominal aorta and inferior vena cava by feeling for a pulse. The 
aorta is the smaller vessel to the animal’s left side. The vena cava is the larger, 
darker vessel to the right side. 
8. Using a cotton swab, carefully rub away the fatty tissue covering the aorta and 
vena cava. 
9. Clamp off one of the renal veins if you can see it (on the animal’s left side, 
running towards the vena cava).  
10. Tunnel under the aorta and vena cava using a pair of curved forceps. Then spread 
the tips of the forceps and route a pair of curved hemostats through the tunnel. Do 
not clamp down yet with the hemostats. 
11. Place a 22g (blue) 1” long catheter into the abdominal aorta going towards the 
hindlimbs. The aorta is the smaller, whitish-looking vessel that is left of the 
animal’s midline. The insertion point should be just above the point where the 
animal’s left renal vein joins the vena cava. The catheter should be inserted with 
the needle bevel facing up. When the catheter is placed correctly, blood will be 
drawn up into the hub of the catheter. 
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12. Administer 250 units (0.25 ml of 1000u/ml) heparin through the catheter and 
allow it to circulate for approximately one minute. 
13. Clamp down across the vena cava and aorta with the curved hemostats. 
14. Verify that the catheter has not descended down one of the branches of the aorta 
that lead to the legs. The bifurcation point is located just below the junction of the 
renal veins with the inferior vena cava. If the catheter has moved preferentially 
down one branch, back it out until the end is above the branching point. 
15. Attach the tubing from the peristaltic pump. 
16. Cut  a vent in the vena cava to allow fluid to exit 
17. Optional step -- tie the catheter in place using a single loop of suture. 
18. Start the pump and deliver saline. 
19. Carefully expose and examine the femoral arteries and veins to see if the blood is 
clearing out. 
20. When ~200 ml of saline has been delivered, move the animal to 5% isoflurane 
and cut the diaphragm and aortic arch to euthanize the animal.  
21. After the animal is dead and ~300 ml of saline has been delivered, switch off the 
pump and move the tubing to the formalin reservoir. 
22. Perfuse the animal with approximately 300 ml of formalin, until the feet and tail 
become stiff. The limbs may appear to dance as the formalin moves through. Hold 
the legs in an outstretched position while the fixing step occurs. 
23. Stop the pump and rinse through the vasculature again with ~100 ml saline. 
24. Stop the pump and place a diaper under the animal. 
25. Prepare the Microfil (17.1 ml contrast agent, 0.9 ml catalyst). 
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26. Using a syringe connected to the catheter hub, deliver 15 mls of Microfil into the 
vasculature. You should see the femoral veins and arteries fill with yellow, and 
the feet should yellow as well. 
27. Allow the Microfil to polymerize for about an hour. 
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